0001389545 NOVABAY PHARMACEUTICALS, INC. false --12-31 FY 2021 0 0 641 236 0.01 0.01 5,000 5,000 14 14 0 0 0.01 0.01 100,000 75,000 47,766 47,766 41,782 41,782 0 5 7 3 5 5 7 0 1 0 0 0 0 5.5 5 10 10 5 4 0 0 0 0.2 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 1 0 0001389545 2021-01-01 2021-12-31 iso4217:USD 0001389545 2021-06-30 xbrli:shares 0001389545 2022-03-24 thunderdome:item 0001389545 2021-12-31 0001389545 2020-12-31 iso4217:USD xbrli:shares 0001389545 us-gaap:ProductMember 2021-01-01 2021-12-31 0001389545 us-gaap:ProductMember 2020-01-01 2020-12-31 0001389545 us-gaap:ProductMember 2019-01-01 2019-12-31 0001389545 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0001389545 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-12-31 0001389545 us-gaap:ProductAndServiceOtherMember 2019-01-01 2019-12-31 0001389545 2020-01-01 2020-12-31 0001389545 2019-01-01 2019-12-31 0001389545 us-gaap:PreferredStockMember 2018-12-31 0001389545 us-gaap:CommonStockMember 2018-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001389545 us-gaap:RetainedEarningsMember 2018-12-31 0001389545 2018-12-31 0001389545 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001389545 us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001389545 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001389545 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001389545 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001389545 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-12-31 0001389545 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001389545 us-gaap:CommonStockMember nby:NonemployeesMember 2019-01-01 2019-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember nby:NonemployeesMember 2019-01-01 2019-12-31 0001389545 nby:NonemployeesMember 2019-01-01 2019-12-31 0001389545 us-gaap:CommonStockMember nby:EmployeeMember 2019-01-01 2019-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember nby:EmployeeMember 2019-01-01 2019-12-31 0001389545 nby:EmployeeMember 2019-01-01 2019-12-31 0001389545 us-gaap:PreferredStockMember 2019-12-31 0001389545 us-gaap:CommonStockMember 2019-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001389545 us-gaap:RetainedEarningsMember 2019-12-31 0001389545 2019-12-31 0001389545 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001389545 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001389545 us-gaap:CommonStockMember nby:NonemployeesMember 2020-01-01 2020-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember nby:NonemployeesMember 2020-01-01 2020-12-31 0001389545 nby:NonemployeesMember 2020-01-01 2020-12-31 0001389545 us-gaap:CommonStockMember nby:EmployeeMember 2020-01-01 2020-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember nby:EmployeeMember 2020-01-01 2020-12-31 0001389545 nby:EmployeeMember 2020-01-01 2020-12-31 0001389545 us-gaap:PreferredStockMember 2020-12-31 0001389545 us-gaap:CommonStockMember 2020-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001389545 us-gaap:RetainedEarningsMember 2020-12-31 0001389545 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001389545 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001389545 us-gaap:CommonStockMember nby:NonemployeesMember 2021-01-01 2021-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember nby:NonemployeesMember 2021-01-01 2021-12-31 0001389545 nby:NonemployeesMember 2021-01-01 2021-12-31 0001389545 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001389545 us-gaap:PreferredStockMember 2021-12-31 0001389545 us-gaap:CommonStockMember 2021-12-31 0001389545 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001389545 us-gaap:RetainedEarningsMember 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:EmployeesAndDirectorsMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:EmployeesAndDirectorsMember 2020-01-01 2020-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:EmployeesAndDirectorsMember 2019-01-01 2019-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:NonemployeesMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:NonemployeesMember 2020-01-01 2020-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:NonemployeesMember 2019-01-01 2019-12-31 0001389545 nby:EmployeeMember 2021-01-01 2021-12-31 0001389545 nby:FormerEmployeeMember 2021-01-01 2021-12-31 0001389545 nby:FormerEmployeeMember 2020-01-01 2020-12-31 0001389545 nby:FormerEmployeeMember 2019-01-01 2019-12-31 0001389545 nby:The2019LadenburgWarrantsMember 2021-01-01 2021-12-31 0001389545 nby:The2019LadenburgWarrantsMember 2020-01-01 2020-12-31 0001389545 nby:The2019LadenburgWarrantsMember 2019-01-01 2019-12-31 0001389545 nby:The2019PreferredWarrantAnd2019CommonWarrantLiabilityMember 2021-01-01 2021-12-31 0001389545 nby:The2019PreferredWarrantAnd2019CommonWarrantLiabilityMember 2020-01-01 2020-12-31 0001389545 nby:The2019PreferredWarrantAnd2019CommonWarrantLiabilityMember 2019-01-01 2019-12-31 0001389545 us-gaap:AccountingStandardsUpdate201711Member 2021-01-01 2021-12-31 0001389545 us-gaap:AccountingStandardsUpdate201711Member 2020-01-01 2020-12-31 0001389545 us-gaap:AccountingStandardsUpdate201711Member 2019-01-01 2019-12-31 0001389545 nby:AvenovaSprayMember 2021-01-01 2021-12-31 0001389545 nby:AvenovaSprayMember 2020-01-01 2020-12-31 0001389545 nby:AvenovaSprayMember 2019-01-01 2019-12-31 0001389545 nby:DermadoctorMember 2021-01-01 2021-12-31 0001389545 nby:DermadoctorMember 2020-01-01 2020-12-31 0001389545 nby:DermadoctorMember 2019-01-01 2019-12-31 0001389545 nby:KN95MasksMember 2021-01-01 2021-12-31 0001389545 nby:KN95MasksMember 2020-01-01 2020-12-31 0001389545 nby:KN95MasksMember 2019-01-01 2019-12-31 0001389545 nby:NeutrophaseMember 2021-01-01 2021-12-31 0001389545 nby:NeutrophaseMember 2020-01-01 2020-12-31 0001389545 nby:NeutrophaseMember 2019-01-01 2019-12-31 0001389545 nby:OtherProductsMember 2021-01-01 2021-12-31 0001389545 nby:OtherProductsMember 2020-01-01 2020-12-31 0001389545 nby:OtherProductsMember 2019-01-01 2019-12-31 0001389545 nby:TotalProductRevenueMember 2021-01-01 2021-12-31 0001389545 nby:TotalProductRevenueMember 2020-01-01 2020-12-31 0001389545 nby:TotalProductRevenueMember 2019-01-01 2019-12-31 xbrli:pure 0001389545 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember nby:AvenovaViaAmazonMember 2021-01-01 2021-12-31 0001389545 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember nby:AvenovaViaAmazonMember 2020-01-01 2020-12-31 0001389545 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember nby:AvenovaViaAmazonMember 2019-01-01 2019-12-31 0001389545 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember nby:DistributorAMember 2019-01-01 2019-12-31 0001389545 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember nby:DistributorBMember 2019-01-01 2019-12-31 0001389545 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember nby:DistributorCMember 2019-01-01 2019-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:MajorUSRetailerMember 2021-01-01 2021-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:DistributorAMember 2021-01-01 2021-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:DistributorAMember 2020-01-01 2020-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:DistributorCMember 2021-01-01 2021-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:DistributorCMember 2020-01-01 2020-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:ChongqingPioneerPharmaHoldingsLimitedMember 2020-01-01 2020-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:DistributorBMember 2020-01-01 2020-12-31 0001389545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember nby:AmazonMember 2020-01-01 2020-12-31 utr:Y 0001389545 us-gaap:EquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001389545 us-gaap:EquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001389545 nby:ComputerEquipmentAndSoftwareMember srt:MinimumMember 2021-01-01 2021-12-31 0001389545 nby:ComputerEquipmentAndSoftwareMember srt:MaximumMember 2021-01-01 2021-12-31 0001389545 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-01-01 2021-12-31 0001389545 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2021-01-01 2021-12-31 0001389545 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelationshipsMember 2021-12-31 0001389545 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0001389545 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:TradeSecretsMember 2021-12-31 0001389545 us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:TradeSecretsMember 2021-01-01 2021-12-31 0001389545 us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:TradeNamesMember 2021-12-31 0001389545 us-gaap:GoodwillMember 2021-12-31 utr:D 0001389545 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001389545 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001389545 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001389545 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001389545 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001389545 nby:DermadoctorMember 2021-11-05 2021-11-05 0001389545 nby:DermadoctorMember 2021-11-05 0001389545 nby:DermadoctorMember 2021-01-01 2021-12-31 0001389545 nby:DermadoctorMember 2020-01-01 2020-12-31 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001389545 nby:DermadoctorMember us-gaap:CustomerRelationshipsMember 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:TradeSecretsMember 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:TradeNamesMember 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelationshipsMember 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:CustomerRelationshipsMember 2021-11-05 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:TradeSecretsMember 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:FiniteLivedIntangibleAssetsMember us-gaap:TradeSecretsMember 2021-11-05 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:IndefinitelivedIntangibleAssetsMember us-gaap:TradeNamesMember 2021-11-05 0001389545 nby:DermadoctorMember us-gaap:GoodwillMember 2021-11-05 0001389545 2021-11-05 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001389545 nby:The2019DomesticForeignWarrantsMember 2021-01-01 2021-12-31 0001389545 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001389545 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001389545 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001389545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001389545 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001389545 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001389545 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001389545 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001389545 nby:WarrantLiabilityMember 2021-01-01 2021-12-31 0001389545 nby:WarrantLiabilityMember 2020-01-01 2020-12-31 0001389545 nby:EmbeddedDerivativeLiabilityMember 2020-01-01 2020-12-31 0001389545 nby:ExpirationOfWarrantsMember 2020-01-01 2020-12-31 0001389545 nby:The2019PreferredWarrantAnd2019CommonWarrantLiabilityMember 2020-01-01 2020-12-31 0001389545 nby:The2019LadenburgWarrantsMember 2020-01-01 2020-12-31 0001389545 nby:OfficeAndLaboratoryEquipmentMember 2021-12-31 0001389545 nby:OfficeAndLaboratoryEquipmentMember 2020-12-31 0001389545 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001389545 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001389545 nby:ComputerEquipmentAndSoftwareMember 2021-12-31 0001389545 nby:ComputerEquipmentAndSoftwareMember 2020-12-31 0001389545 nby:ProductionEquipmentMember 2021-12-31 0001389545 nby:ProductionEquipmentMember 2020-12-31 0001389545 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001389545 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001389545 nby:BankMidwestMember us-gaap:LineOfCreditMember 2021-11-06 0001389545 nby:BankMidwestMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2022-01-06 0001389545 nby:BankMidwestMember us-gaap:LineOfCreditMember us-gaap:PrimeRateMember 2021-12-31 2021-12-31 0001389545 nby:BankMidwestMember us-gaap:LineOfCreditMember 2021-12-31 0001389545 nby:KBSIIITowersMember 2021-12-31 utr:sqft 0001389545 nby:RiversideMissouriMember 2021-12-31 0001389545 nby:SubleaseAgreementMember 2020-01-01 2020-12-31 0001389545 nby:TLFBioInnovationRelatedPartyWarrantsMember 2021-01-22 2021-01-22 0001389545 nby:WarrantsInConnectionWithMicroprofitAgreementMember 2020-04-16 0001389545 nby:PromissoryNoteMember nby:PioneerHongKongMember 2019-02-27 0001389545 nby:PromissoryNoteMember nby:PioneerHongKongMember 2019-02-27 2019-02-27 0001389545 nby:PromissoryNoteMember nby:PioneerHongKongMember 2020-05-14 2020-05-14 0001389545 nby:ChinaKingtonMember 2019-02-27 2019-02-27 0001389545 nby:ChinaKingtonMember 2019-02-27 0001389545 nby:PromissoryNoteMember nby:PioneerHongKongMember 2020-01-01 2020-12-31 0001389545 nby:PromissoryNoteMember nby:PioneerHongKongMember 2021-01-01 2021-12-31 0001389545 nby:SecuredConvertiblePromissoryNoteMember nby:IliadResearchAndTradingLPMember 2019-03-26 0001389545 nby:SecuredConvertiblePromissoryNoteMember nby:IliadResearchAndTradingLPMember 2019-03-26 2019-03-26 0001389545 nby:SecuredConvertiblePromissoryNoteMember nby:IliadResearchAndTradingLPMember 2020-01-01 2020-12-31 0001389545 nby:TheJuly2011WarrantsMember 2020-03-06 2020-03-06 0001389545 nby:TheJuly2011WarrantsMember 2021-12-31 0001389545 nby:TheJuly2011WarrantsMember 2020-12-31 0001389545 nby:October2015WarrantsMember 2020-10-01 2020-12-31 0001389545 nby:October2015WarrantsMember 2020-10-27 2020-10-27 0001389545 nby:October2015WarrantsMember 2021-12-31 0001389545 nby:October2015WarrantsMember 2020-12-31 0001389545 nby:The2019DomesticWarrantsMember 2019-08-13 0001389545 nby:The2019ForeignWarrantsMember 2019-08-13 0001389545 nby:The2019LadenburgWarrantsMember 2019-08-13 0001389545 nby:The2019DomesticWarrantsMember 2020-12-31 0001389545 nby:The2019ForeignWarrantsMember 2020-12-31 0001389545 nby:The2019DomesticWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001389545 nby:The2019ForeignWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001389545 nby:The2019DomesticWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001389545 nby:The2019ForeignWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001389545 nby:The2019DomesticWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001389545 nby:The2019ForeignWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001389545 nby:The2019DomesticWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001389545 nby:The2019ForeignWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001389545 nby:The2019DomesticWarrantsMember us-gaap:MeasurementInputSharePriceMember 2019-12-31 0001389545 nby:The2019ForeignWarrantsMember us-gaap:MeasurementInputSharePriceMember 2019-12-31 0001389545 nby:The2019DomesticWarrantsMember 2021-12-31 0001389545 nby:The2019LadenburgWarrantsMember 2020-12-31 0001389545 nby:The2019LadenburgWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001389545 nby:The2019LadenburgWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001389545 nby:The2019LadenburgWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001389545 nby:The2019LadenburgWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001389545 nby:The2019LadenburgWarrantsMember us-gaap:MeasurementInputSharePriceMember 2019-12-31 0001389545 nby:The2021WarrantsMember 2021-11-02 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-11-02 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-11-02 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-11-02 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-11-02 0001389545 2021-11-02 0001389545 nby:The2021WarrantsMember 2021-12-31 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001389545 nby:The2021WarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2021PrivatePlacementProgramMember 2021-10-29 2021-10-29 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember nby:The2021PrivatePlacementProgramMember 2021-10-29 0001389545 nby:The2021WarrantsMember 2021-10-29 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2021PrivatePlacementProgramMember 2021-10-29 0001389545 us-gaap:SubsequentEventMember 2022-01-31 0001389545 nby:ConversionOfSeriesBPreferredStockToCommonStockMember 2021-10-01 2021-12-31 0001389545 nby:The2021PrivatePlacementProgramMember 2021-01-01 2021-12-31 0001389545 us-gaap:SeriesBPreferredStockMember nby:The2021PrivatePlacementProgramMember 2021-01-01 2021-12-31 0001389545 nby:ATMProgramMember 2020-04-01 2020-06-30 0001389545 nby:ATMProgramMember 2021-04-01 2021-06-30 0001389545 nby:TheJuly2011WarrantsMember 2011-07-01 2011-09-30 0001389545 nby:TheJuly2011WarrantsMember 2011-09-30 0001389545 nby:TheJuly2011WarrantsMember 2015-10-31 0001389545 nby:TheJuly2011WarrantsMember 2016-02-29 0001389545 nby:TheJuly2011WarrantsMember 2019-05-31 0001389545 nby:TheJuly2011WarrantsMember 2020-03-01 2020-03-31 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2015-01-01 2015-03-31 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2015-03-31 0001389545 nby:March2015WarrantsMember srt:MinimumMember 2015-03-31 0001389545 nby:March2015WarrantsMember srt:MaximumMember 2015-03-31 0001389545 nby:March2015WarrantsExpiringMarch62020Member 2015-01-01 2015-03-31 0001389545 nby:March2015WarrantsExpiringJune62015Member 2015-01-01 2015-03-31 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2015-10-31 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2016-02-29 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2019-05-31 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2020-01-01 2020-03-31 0001389545 nby:March2015ShortTermAndLongTermWarrantsMember 2021-12-31 0001389545 nby:October2015WarrantsMember 2015-10-01 2015-12-31 0001389545 nby:October2015WarrantsMember 2015-12-31 0001389545 nby:October2015WarrantsMember 2016-02-29 0001389545 nby:October2015WarrantsMember 2019-05-31 0001389545 nby:October2015WarrantsMember 2020-07-01 2020-09-30 0001389545 nby:ThreeAccreditedInvestorsMember us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001389545 nby:TheJune2019WarrantsMember 2019-04-01 2019-06-30 0001389545 nby:TheJune2019WarrantsMember 2019-06-30 0001389545 nby:XiaoRuiLiuMember us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001389545 nby:HaiDongPangMember us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001389545 nby:PingHuangMember us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001389545 nby:ChinaKingtonMember us-gaap:PrivatePlacementMember 2019-06-30 0001389545 nby:ChinaKingtonMember us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001389545 us-gaap:PrivatePlacementMember 2019-04-01 2019-06-30 0001389545 nby:TheJune2019WarrantsMember 2020-01-01 2020-03-31 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2020-01-01 2020-03-31 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2020-03-31 0001389545 nby:TheJune2019WarrantsMember 2020-04-01 2020-06-30 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2020-04-01 2020-06-30 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2020-06-30 0001389545 nby:TheJune2019WarrantsMember 2021-12-31 0001389545 nby:August2019CommonStockPurchaseAgreementMember 2019-07-01 2019-09-30 0001389545 nby:The2019DomesticWarrantsMember 2019-07-01 2019-09-30 0001389545 nby:The2019DomesticWarrantsMember 2019-09-30 0001389545 nby:LadenburgThalmannAndCoIncMember 2019-09-30 0001389545 nby:LadenburgThalmannAndCoIncMember 2019-07-01 2019-09-30 0001389545 nby:The2019LadenburgWarrantsMember 2019-07-01 2019-09-30 0001389545 nby:The2019LadenburgWarrantsMember 2019-09-30 0001389545 nby:The2019ForeignWarrantsMember 2020-09-30 0001389545 2020-07-01 2020-09-30 0001389545 nby:ChinaKingtonMember 2020-07-01 2020-09-30 0001389545 nby:NewWarrantsMember 2020-09-30 0001389545 nby:The2019LadenburgWarrantsMember 2020-09-30 0001389545 nby:TlfBioInnovation2021WarrantsMember 2021-01-15 0001389545 nby:IncentiveStockOptionsISOMember nby:The2007OmnibusIncentivePlanMember srt:MaximumMember 2007-10-01 2007-10-31 0001389545 nby:The2017OmnibusIncentivePlanMember 2017-03-31 0001389545 nby:The2017OmnibusIncentivePlanMember 2021-01-15 2021-01-15 0001389545 nby:The2017OmnibusIncentivePlanMember 2021-12-31 0001389545 nby:The2017OmnibusIncentivePlanMember srt:MinimumMember 2017-03-01 2017-03-31 0001389545 nby:IncentiveStockOptionsISOMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 nby:IncentiveStockOptionsISOMember nby:ShareholderOfMoreThan10PercentMember nby:The2017OmnibusIncentivePlanMember srt:MinimumMember 2017-03-01 2017-03-31 0001389545 nby:The2017OmnibusIncentivePlanMember srt:MaximumMember 2017-03-01 2017-03-31 0001389545 nby:IncentiveStockOptionsISOMember nby:ShareholderOfMoreThan10PercentMember nby:The2017OmnibusIncentivePlanMember srt:MaximumMember 2017-03-01 2017-03-31 0001389545 us-gaap:EmployeeStockOptionMember nby:The2017OmnibusIncentivePlanMember 2017-03-01 2017-03-31 0001389545 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001389545 nby:EmployeesAndDirectorsMember 2021-01-01 2021-12-31 0001389545 nby:EmployeesAndDirectorsMember 2020-01-01 2020-12-31 0001389545 nby:EmployeesAndDirectorsMember 2019-01-01 2019-12-31 0001389545 us-gaap:RestrictedStockUnitsRSUMember nby:EmployeesAndDirectorsMember 2020-01-01 2020-12-31 0001389545 us-gaap:RestrictedStockUnitsRSUMember nby:EmployeesAndDirectorsMember 2019-01-01 2019-12-31 0001389545 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001389545 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:MessrsMaMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:MrLiuMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:MrSieczkarekMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:MrToddZavodnickMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:MsGailMaderisMember 2021-01-01 2021-12-31 0001389545 us-gaap:EmployeeStockOptionMember nby:MrXiaopeiWangMember 2021-01-01 2021-12-31 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-12-31 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2020-01-01 2020-12-31 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember nby:PartnerAndSeniorVicePresidentOfChinaKingtonMember 2020-01-01 2020-12-31 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2019-01-01 2019-12-31 0001389545 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-12-31 0001389545 us-gaap:RestrictedStockMember nby:MrMarkSieczkarekMember 2019-01-01 2019-12-31 0001389545 us-gaap:RestrictedStockMember nby:MrMarkSieczkarekMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-07-01 2021-07-31 0001389545 us-gaap:RestrictedStockMember nby:MrMarkSieczkarekMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-07-01 2021-07-31 0001389545 us-gaap:RestrictedStockMember nby:MrMarkSieczkarekMember 2020-07-01 2021-07-31 0001389545 us-gaap:RestrictedStockMember nby:MrMarkSieczkarekMember 2020-07-01 2020-07-31 0001389545 us-gaap:RestrictedStockMember nby:MrMarkSieczkarekMember 2021-07-01 2021-07-31 0001389545 us-gaap:RestrictedStockMember nby:MsMoonAndMsXiaoMember 2019-10-01 2019-12-31 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001389545 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001389545 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001389545 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001389545 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001389545 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001389545 us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001389545 us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0001389545 us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001389545 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001389545 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001389545 us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001389545 nby:McKessonCorporationMember nby:AvenovaProductMember 2021-01-01 2021-12-31 0001389545 nby:McKessonCorporationMember nby:AvenovaProductMember 2020-01-01 2020-12-31 0001389545 nby:McKessonCorporationMember nby:AvenovaProductMember 2019-01-01 2019-12-31 0001389545 us-gaap:AccountsPayableAndAccruedLiabilitiesMember nby:McKessonCorporationMember nby:AvenovaProductMember 2021-12-31 0001389545 us-gaap:AccountsPayableAndAccruedLiabilitiesMember nby:McKessonCorporationMember nby:AvenovaProductMember 2020-12-31 0001389545 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember nby:McKessonCorporationMember nby:AvenovaProductMember 2021-12-31 0001389545 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember nby:McKessonCorporationMember nby:AvenovaProductMember 2020-12-31 0001389545 nby:AvenovaDirectMember 2021-01-01 2021-12-31 0001389545 nby:AvenovaDirectMember 2020-01-01 2020-12-31 0001389545 nby:AvenovaDirectMember 2019-01-01 2019-12-31 0001389545 nby:The401KPlanMember 2021-01-01 2021-12-31 0001389545 nby:The401KPlanMember 2020-01-01 2020-12-31 0001389545 nby:The401kPlanContributionLevelOneMember srt:ScenarioForecastMember 2022-01-01 2022-01-01 0001389545 nby:The401kPlanContributionLevelTwoMember srt:ScenarioForecastMember 2022-01-01 2022-01-01 0001389545 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember nby:NotSubjectToExpirationMember 2021-12-31 0001389545 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember nby:ExpirationYears20242037Member 2021-12-31 0001389545 us-gaap:StateAndLocalJurisdictionMember nby:ExpirationYears20282037Member 2021-12-31 0001389545 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember nby:ExpirationYears20262035Member 2021-12-31 0001389545 us-gaap:StateAndLocalJurisdictionMember nby:NotSubjectToExpirationMember 2021-12-31 0001389545 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001389545 us-gaap:StateAndLocalJurisdictionMember 2021-01-01 2021-12-31 0001389545 nby:LicensingMember 2021-01-01 2021-12-31 0001389545 nby:LicensingMember 2020-01-01 2020-12-31 0001389545 nby:LicensingMember 2019-01-01 2019-12-31 0001389545 nby:TheOpWarrantsMember nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:TheOpWarrantsMember nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:TheOpWarrantsMember nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:TheJune2019WarrantsMember nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:TheAugust2019WarrantsMember nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:TheAugust2019WarrantsMember nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:TheAugust2019WarrantsMember nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:BrokerFeeForTheExerciseOfTheJune2019WarrantsMember nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:BrokerFeeForTheExerciseOfTheJune2019WarrantsMember nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:BrokerFeeForTheExerciseOfTheJune2019WarrantsMember nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:The2019ForeignWarrantsMember nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:The2019ForeignWarrantsMember nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:The2019ForeignWarrantsMember nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:PromissoryNoteMember nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:PromissoryNoteMember nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:PromissoryNoteMember nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:ChinaKingtonMember 2021-01-01 2021-12-31 0001389545 nby:ChinaKingtonMember 2020-01-01 2020-12-31 0001389545 nby:ChinaKingtonMember 2019-01-01 2019-12-31 0001389545 nby:DirectorBobWuMember 2021-01-01 2021-12-31 0001389545 nby:DirectorBobWuMember 2020-01-01 2020-12-31 0001389545 nby:DirectorBobWuMember 2019-01-01 2019-12-31 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember nby:PartnerAndSeniorVicePresidentOfChinaKingtonMember 2020-11-17 2020-11-17 0001389545 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember nby:PartnerAndSeniorVicePresidentOfChinaKingtonMember 2020-11-17 2020-11-17 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember nby:EricWuMember 2021-01-01 2021-12-31 0001389545 us-gaap:ShareBasedPaymentArrangementNonemployeeMember nby:EricWuMember 2020-01-01 2020-12-31 0001389545 nby:PaycheckProtectionProgramCARESActMember nby:WellsFargoBankMember 2020-05-06 2020-05-06 0001389545 nby:PaycheckProtectionProgramCARESActMember 2020-01-01 2020-12-31 0001389545 nby:PaycheckProtectionProgramCARESActMember 2021-01-01 2021-12-31 0001389545 nby:PaycheckProtectionProgramCARESActMember nby:WellsFargoBankMember 2021-05-24 2021-05-24 0001389545 nby:OpticalAndWoundCareMember 2021-01-01 2021-12-31 0001389545 nby:SkincareMember 2021-01-01 2021-12-31 0001389545 us-gaap:LineOfCreditMember 2021-01-01 2021-12-31 0001389545 nby:Covid19MemberMember 2021-01-01 2021-12-31

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☒ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-33678

NOVABAY PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware | 68-0454536
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.)

2000 Powell Street, Suite 1150, Emeryville, California 94608

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 899-8800

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class | Trading Symbol(s) | Name of Each Exchange On Which Registered
Common Stock, par value $0.01 per share | NBY | NYSE American

Securities Registered Pursuant to Section 12(g) of the Act: None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer | ☐ | Accelerated filer | ☐ | Emerging growth company | ☐
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |  |

Table of Contents

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 30, 2021, the aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the last sale price of such stock as of such date on the NYSE American, was approximately $23,677,038. This figure excludes an aggregate of 9,276,143 shares of common stock held by affiliates, including officers and directors, as of June 30, 2021. Exclusion of shares held by any of these persons should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.

As of March 24, 2022, there were 51,418,364 shares of the registrant's common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Proxy Statement for the 2022 Annual Meeting of Stockholders (Part III) to be filed within 120 days after the end of the Registrant’s year ended December 31, 2021.

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

ANNUAL REPORT ON FORM 10-K

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021

TABLE OF CONTENTS

|  | Page
PART I |
ITEM 1. | BUSINESS | 1
ITEM 1A. | RISK FACTORS | 7
ITEM 1B. | UNRESOLVED STAFF COMMENTS | 17
ITEM 2. | PROPERTIES | 17
ITEM 3. | LEGAL PROCEEDINGS | 17
ITEM 4. | MINE SAFETY DISCLOSURES | 17
PART II |
ITEM 5. | MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES | 18
ITEM 6. | [RESERVED] | 18
ITEM 7. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 18
ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 26
ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 27
ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE | 67
ITEM 9A. | CONTROLS AND PROCEDURES | 67
ITEM 9B. | OTHER INFORMATION | 67
ITEM 9C. | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | 67
PART III |
ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE | 68
ITEM 11. | EXECUTIVE COMPENSATION | 68
ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS | 68
ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE | 68
ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES | 68
PART IV |
ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES | 69

Unless the context requires otherwise, all references in this report to “we,” “our,” “us,” the “Company” and “NovaBay” refer to NovaBay Pharmaceuticals, Inc., a Delaware corporation, and its wholly-owned subsidiary, DERMAdoctor, LLC, a Missouri limited liability company.

The Company owns over 45 live trademark registrations, which include NovaBay®, NovaBay Pharma®, Avenova®, NeutroPhase®, CelleRx®, Aganocide®, AgaDerm®, Neutrox®, Going Beyond Antibiotics®, Kakadu C®, AIN’T Misbehavin’® and KP Duty®. All other trademarks and trade names are the property of their respective owners.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements regarding our product candidates, the integration of DERMAdoctor, market opportunities, competitors, strategies, anticipated trends and challenges in our business and the markets in which we operate, and anticipated expenses and capital requirements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail under the heading “Risk Factors” in Item 1A of this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this report and the documents that we reference and have filed as exhibits thoroughly and with the understanding that forward-looking statements represent our management’s beliefs and assumptions only as of the date of this report and our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

PART I

ITEM 1. | BUSINESS

NovaBay Pharmaceuticals, Inc. develops and sells scientifically-created and clinically-proven eyecare and skincare products.

Our leading product, Avenova® Antimicrobial Lid and Lash Solution (“Avenova Spray”), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the U.S. Food and Drug Administration (“FDA”) for sale in the United States. Other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress, and the i-Chek.

On November 5, 2021 (the “Acquisition Closing”), we significantly expanded our business by acquiring DERMAdoctor, LLC (“DERMAdoctor”) as our wholly-owned subsidiary (the “DERMAdoctor Acquisition”). DERMAdoctor offers over 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. DERMAdoctor branded products are marketed and sold through the DERMAdoctor website, well-known traditional and digital beauty retailers, and a network of international distributors.

We expect to grow commercial sales of both Avenova and DERMAdoctor branded products through an expansion of domestic and international market penetration, with a particular focus on online channels, and the development of new product offerings under both brand names.

Products

Avenova Branded Optical Products

Avenova Spray is a proprietary solution of hypochlorous acid that acts as an antimicrobial preservative in solution and has been shown to neutralize bacterial toxins in laboratory tests. Because it is a gentle isotonic solution, it is well suited for daily use on the lids and lashes. Avenova Spray offers distinct advantages when compared to alternative lid and lash regimens that contain soaps, bleach, and other impurities, as Avenova Spray removes unwanted microorganisms from the skin without the use of those harmful ingredients. Avenova Spray’s target market is the millions of Americans who suffer from minor irritation of the skin around the eye (commonly referred to as blepharitis) as well as anyone who suffers from dry eye (commonly described as a gritty sandy sensation while blinking). Avenova Spray is available both over-the-counter and as a prescription. We promote Avenova Spray direct to consumers and make it available through Avenova.com, other online channels and at select brick-and-mortar stores. In total, this was our leading sales channel by unit sales and net revenue in 2021. Avenova Spray is also available (1) at optometrists’ and ophthalmologists’ offices, through our physician dispensed channel; (2) at national pharmacy chains across all 50 states; and (3) through our Partner Pharmacy Program, providing a consistent patient experience at contracted pricing.

1

Table of Contents

Because Avenova Spray can be purchased as both an over-the-counter and prescription product, it is available to a wide range of potential customers and addressable markets. Making it available over-the-counter capitalizes on a trend to sell pharmaceutical products directly to consumers in response to increased cost shifting to consumers through high-deductible health plans. Our ongoing focus on promoting Avenova Spray online is reflected in increasing our spend on digital marketing and public relations initiatives. Avenova Spray is available on Avenova.com, Amazon.com, Walmart.com, and select other online channels. Avenova Spray also became available at CVS store locations throughout the U.S. and on CVS.com beginning in the first quarter of 2021.

Support from ophthalmologists and optometrists for Avenova Spray remains strong. The continual endorsement of medical professionals has created a “doctor recommended” halo effect around our brand. This is a key differentiating factor in a crowded consumer space and is a result of our high quality and reliable efficacy. Our Buy-and-Sell physician dispensed channel is particularly important in this regard as it gives patients the opportunity to purchase Avenova Spray conveniently and immediately upon recommendation in the doctor’s office. We believe this also creates repeat Avenova Spray customers who subsequently purchase Avenova Spray and often other Avenova branded products through other channels.

We also make Avenova Spray accessible nationwide in nearly all retail pharmacies across the United States through agreements with McKesson Corporation, Cardinal Health, and AmerisourceBergen Corporation. We continue to build our prescription business under a value pricing model. We maintain a rebate program for electronic payment transactions and in the form of instant rebate cards. The rebate cards are intended to be used by patients who either do not have insurance coverage or whose insurance coverage does not cover Avenova Spray, thereby lowering the price for the patient at the pharmacy.

We also have agreements directly with some preferred pharmacy networks through our Partner Pharmacy Program. These agreements provide greater control over the patient experience at consistent contract pricing. Our Partner Pharmacy Program also ensures that proper insurance reimbursement occurs, and that our patients are receiving the best possible price. In 2021, we added ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, to our Partner Pharmacy Program.

There are many companies that sell lid and lash solutions, most of which, to the best of our knowledge, are surfactant (soap) based. Unlike these detergent-based products that contain a mix of numerous chemicals, Avenova Spray consists solely of saline and 0.01% pure hypochlorous acid, a molecule naturally produced by the human body. Elegant in its simplicity, Avenova Spray works without the toxic impurities included in competitive offerings. While cheaper antibacterial soaps are commonly used to reduce or prevent bacterial contamination on the skin, we do not view them as true competitors of Avenova Spray.

DERMAdoctor Branded Dermatology Products

Through the DERMAdoctor Acquisition, we added a comprehensive portfolio of dermatological solutions to address common skincare concerns including: keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne. These products are organized into several product families, including: (i) Kakadu C®; (ii) KP Duty®; (iii) Total Non-scents Antiperspirant; (iv) Wrinkle Revenge®; (v) AIN’T Misbehavin’®; and (vi) Calm, Cool & Corrected®. DERMAdoctor continues to develop its pipeline of additional new products to address a variety of common skin conditions.

DERMAdoctor products are offered within the large and steadily growing skincare category of the beauty industry. The skincare market is divided into facial care, hand and body care and sun care. Within the skincare market, our DERMAdoctor products sell and compete across all major product categories with a wide variety of products at various price points. Skincare products can also be subdivided into prestige and mass segments. Prestige products are characterized by higher price points and are typically sold in high-end specialty stores and department stores.

Our marketing strategy for the DERMAdoctor brand is to focus on educating our target consumers about the unique attributes of such products, developing intimate relationships with these consumers and capitalizing on our omni-channel distribution strategy to effectively reach and engage these consumers. Our target demographic for both the Avenova and DERMAdoctor brands encompasses women between the ages of 25 to 65 who have a college education and an above average household income. We plan to continue DERMAdoctor’s efforts to engage in educational media such as appearances on television shows, information and research provided on our websites and physical presence at specialty retailers and department stores, primarily by Dr. Audrey Kunin, to further strengthen the DERMAdoctor brand image and provide additional points of contact to educate consumers about such products. In addition, we also plan to leverage our consumer focused messaging and the products’ pharmaceutical pedigree to create brand awareness through digital marketing, influencers and third-party advertising companies.

2

Table of Contents

The skincare industry is highly competitive and subject to rapid changes due to consumer preferences and industry trends. Competition in the skincare industry is generally based on the introduction of new products, pricing of products, quality of products and packaging, brand awareness, perceived value and quality, innovation, in-store presence and visibility, promotional activities, advertising, editorials, e-commerce and mobile-commerce initiatives and other activities. These products compete with a high volume of new product introductions and existing products by diverse companies across several different distribution channels, including large multinational consumer products companies that have many skincare brands under ownership, as well as standalone skincare brands, including those that may target the latest trends or specific distribution channels. We expect our DERMAdoctor products to encounter competition for consumer recognition and market share with products that have achieved significant national and international brand name recognition and consumer loyalty, such as those offered by global prestige beauty companies like Avon Products, Inc., Elizabeth Arden, Inc., The Estée Lauder Companies, Inc., L’Oréal Group, Shiseido, Coty, Mary Kay, Inc. and The Proctor & Gamble Company, each of which have skincare brands.

NeutroPhase and PhaseOne Branded Wound Care Products

Consisting of higher concentrations of hypochlorous acid, NeutroPhase and PhaseOne are used for the cleansing and irrigation of intraoperative pocket lavage, before subcutaneous closure, stage I to IV pressure injuries, stasis ulcers, leg ulcers, diabetic foot ulcers, first-degree and second-degree burns, post-surgical wounds, grafted and donor sites, minor burns, superficial abrasions, wounds, and moistening absorbent wound dressings.

Both NeutroPhase and PhaseOne compete in a crowded wound cleanser market with many older and lower-priced products with similar uses, such as Vashe and Betadine Surgical Scrub. However, we believe our NeutroPhase and PhaseOne solutions have distinct competitive advantages because they are made without the toxic chemicals found in other products. NeutroPhase and PhaseOne are gentle, non-irritating, and non-sensitizing to skin and new tissue. PhaseOne is distributed through commercial partners in the United States, and NeutroPhase is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.

DERMAdoctor Acquisition and Financing Transaction

On September 27, 2021, we entered into a Membership Unit Purchase Agreement (the “Acquisition Purchase Agreement”) by and among (i) us, (ii) DERMAdoctor, (iii) Dr. Jeffrey Kunin and Dr. Audrey Kunin (the “Founders”); (iv) Papillon Partners, Inc., a Missouri corporation that is owned by the Founders (“Papillon”); and (v) Midwest Growth Partners, L.L.L.P., an Iowa limited liability limited partnership (“MGP” and together with Papillon, the “Sellers”). Pursuant to the Acquisition Purchase Agreement, we acquired 100% of the membership units of DERMAdoctor for an agreed upon purchase price of approximately $15.0 million (the “Purchase Price”). The Purchase Price was comprised of a payment of approximately $12.0 million in cash to the Sellers at closing, which amount was (i) reduced to account for payments we made to satisfy DERMAdoctor’s indebtedness and its transaction expenses as of closing, and (ii) increased by the DERMAdoctor cash and cash equivalents that remained as of closing. The remaining amount of the Purchase Price is comprised of up to an aggregate of $3.0 million in earn out payments after the Acquisition Closing, which are contingent upon the legacy DERMAdoctor business achieving predetermined contribution margin financial targets for the 2022 and the 2023 calendar fiscal years (the “Earn Out Payments”). DERMAdoctor is now a wholly-owned subsidiary of NovaBay.

On October 29, 2021, we entered into a Securities Purchase Agreement with various institutional investors (the “Purchasers”). Pursuant to the Securities Purchase Agreement, we agreed to sell in a private placement offering (the “2021 Private Placement”) (i) an aggregate of 15,000 shares of our newly-created Series B Non-Voting Convertible Preferred Stock (the “Preferred Stock”) convertible into an aggregate of 37,500,000 shares of common stock, par value $0.01 (“Common Stock”), and (ii) warrants (the “2021 Warrants”) exercisable for 37,500,000 shares of Common Stock for an aggregate purchase price of $15.0 million. The 2021 Private Placement closed on November 2, 2021. We used a portion of the net proceeds from the 2021 Private Placement to partially fund the Purchase Price of the DERMAdoctor Acquisition, with the remaining amount to be used for working capital purposes.

Customers, Manufacturing and Suppliers

Avenova branded products are available on Amazon.com, Walmart.com, CVS.com and Avenova.com. Online sales now account for the majority of Avenova Spray revenue. Internationally, Avenova Spray is available in Australia through a distribution partner. NeutroPhase and PhaseOne sales rely solely on distribution partners in China and the U.S., respectively.

Our DERMAdoctor products are sold in the United States and internationally (including in China, the Middle East, Europe, Canada, and Central and South America). Such products are distributed online, through wholesale distribution, in physical store locations and, particularly as relates to international sales, through marketing and distribution agreements with local partners.

For the Avenova Spray, we currently outsource manufacturing to two contract manufacturers with facilities located in the United States. For our DERMAdoctor products, we also use third-party contract manufacturers and suppliers to obtain substantially all raw materials, components, and packaging products and to manufacture finished products relating to the DERMAdoctor brand. We utilize a total of seven different product fillers and numerous ingredient and packaging suppliers from which we source and contract the manufactures of our DERMAdoctor products.

3

Table of Contents

We believe that we have good relationships with our manufacturers and that our manufacturers have adequate manufacturing capacity to satisfy our demands for all products. Further, we believe that there are often alternative sources available in the event that one or more of these manufacturers are not available. However, the products manufactured by alternative manufacturers may not be identical to our current products as some of our product formulations, particularly as relates to our DERMAdoctor products, are sometimes owned by that particular manufacturer. We continually review our manufacturing needs against the capacity of our contract manufacturers to ensure that we are able to meet our production goals, reduce costs, and operate more efficiently.

Intellectual Property

We believe that our intellectual property has substantial value and has contributed significantly to the success of our business. We rely on patents, trademarks, trade secrets and know-how to maintain our competitive position. We own over 40 live trademark registrations in the U.S., as well as trademark registrations and pending applications in many other countries internationally, with our primary trademarks including “Avenova®”, “CelleRx®”, “DERMAdoctor®”, “Kakadu C®”, “AIN’T Misbehavin’®”, “KP Duty®” and depictions of Dr. Audrey Kunin, some of which are held directly by NovaBay and others by our wholly-owned subsidiary DERMAdoctor.

We seek to protect our intellectual property rights by a variety of means, including obtaining patents, maintaining trade secrets and proprietary know-how and technological innovation to operate, without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary rights. In order to maintain our trade secrets, we rely on and use reasonable business activities to protect trade secrets, such as confidentiality/invention rights agreements with employees, confidentiality agreements with manufacturers, proprietary expertise and product formulations, continuing innovation efforts and techniques, and other know-how to develop and maintain a competitive position.

Research and Development

For the years ended December 31, 2021 and 2020, we incurred total research and development expenses of approximately $44 thousand and $285 thousand, respectively. DERMAdoctor focuses a significant portion of its product development efforts on creating new products and improving existing products based on feedback and suggestions from its consumers. Many of these suggestions are the catalyst for new DERMAdoctor product development, as well as product extensions. DERMAdoctor’s testing activities are performed by laboratories with ISO 17025 accreditation and FDA registration. The finished products DERMAdoctor develops, including packaging, must meet adequate quality control, and performance tests before they are marketed. Pursuant to our current business strategy, we plan to continue DERMAdoctor’s practice of creating new products and improving existing products in our core product lines by incorporating consumer feedback into our product development efforts.

Seasonality

Avenova Branded Products

Consistent with our peers in the United States pharmaceutical industry, prescriptions for Avenova Spray experience seasonality with the first quarter of each year typically being the lowest revenue quarter. This annual phenomenon is due to consumers facing the need to satisfy health insurance deductibles and changes to copays as each new insurance year begins. Sales of Avenova Spray through non-prescription channels, along with the other Avenova branded products, experience less seasonality with demands, consistent throughout the year.

Dermatology/Skincare Products

Our DERMAdoctor products are sold through wholesale distribution relationships with third parties such as Costco and others; therefore, we may receive periodic large orders that result in large chunks of revenue that are received in irregular intervals during the year. Historically, sales of DERMAdoctor products that contain sunscreen and antiperspirants are higher in the summer seasons and sales of DERMAdoctor products that contain moisturizers are higher in the fall and winter months. In addition, DERMAdoctor products will typically experience an uptick in sales during the fourth quarter around the holidays of each country in which its products are sold, particularly in the United States and China.

Government Regulation

We are subject to extensive government regulation, principally by the FDA and state and local authorities in the United States and by comparable agencies in foreign countries. Governmental authorities in the United States extensively regulate the pre-clinical and clinical testing, safety, efficacy, research, development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution, among other things, of pharmaceutical, medical device and cosmetic products under various federal laws including the Federal Food, Drug and Cosmetic Act, the Public Health Service Act and under comparable laws by the states in the United States and in most foreign countries. We also hold our CE Mark and ISO 13485 certifications. To maintain these certifications, we undergo significant quality control audits with the relevant European authorities every year.

4

Table of Contents

FDA Approval/Clearance Requirements

Some of our products that we market in the U.S. require FDA 510(k) clearance or approval through the OTC Drug Monograph process. We believe we have obtained the required FDA clearance or approval for each of our current products, if necessary.

The FDA decides whether a device line must undergo either the 510(k) clearance or premarket approval (“PMA”). PMA is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. Class III medical devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential, unreasonable risk of illness or injury. The PMA process is based on statutory criteria. These criteria include the level of risk that the agency perceives is associated with the device and a determination of whether the product is a type of device that is similar to devices that are already legally marketed. Devices deemed to pose relatively less risk are placed in either Class I or II, which requires the manufacturer to submit a premarket notification ("PMN") requesting 510(k) clearance, unless an exemption applies. The PMN must demonstrate that the proposed device is “substantially equivalent” in intended use and in safety and effectiveness to a legally marketed predicate device, which is a pre-existing medical device to which equivalence can be drawn, that is either in Class I, Class II, or is a Class III device that was in commercial distribution before May 28, 1976, for which the FDA has not yet called for submission of a PMA application.

Class I devices are those for which safety and effectiveness can be assured by adherence to the FDA's general regulatory controls for medical devices, or the “General Controls”, which include compliance with the applicable portions of the FDA's quality system regulations, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) PMN process described below. Avenova Spray is classified as a Class I medical device. None of our products are Class II or Class III medical devices. All DERMAdoctor products are classified either as a cosmetic or an OTC monograph drug.

Pervasive and Continuing FDA Regulation

A host of regulatory requirements apply to our marketed devices, including the quality system regulation (which requires manufacturers to follow elaborate design, testing, control, documentation and other quality assurance procedures), the Medical Reporting Regulations (which require that manufacturers report to the FDA specified types of adverse events involving their products), labeling regulations, and the FDA's general prohibition against promoting products for unapproved or "off-label" uses. Unanticipated changes in existing regulatory requirements or adoption of new current Good Manufacturing Practice (“cGMP”) requirements could hurt our business, financial condition, and results of operations.

Health Care Fraud and Abuse

In the United States, there are federal and state anti-kickback laws that generally prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business. For example, the federal Anti-Kickback Law (42 U.S.C. §1320a-7b(b)) prohibits anyone from, among other things, knowingly and willfully offering, paying, soliciting or receiving any bribe, kickback or other remuneration intended to induce the referral of patients for, or the purchase, order or recommendation of, health care products and services reimbursed by a federal health care program (including Medicare and Medicaid). Recognizing that the federal Anti-Kickback Law is broad and potentially applicable to many commonplace arrangements, the Office of Inspector General within the Department of Health and Human Services, or OIG, has issued regulations, known as the safe harbors, which identify permissible practices. If all of the requirements of an applicable safe harbor are met, an arrangement will not be prosecuted under this law. Safe harbors exist for a number of arrangements relevant to our business, including, among other things, payments to bona fide employees, certain discount arrangements, and certain payment arrangements involving GPOs. The failure of an arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal. However, conduct that does not fully satisfy each requirement of an applicable safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG or the Department of Justice. Violations of this federal law can result in significant penalties, including imprisonment, monetary fines and assessments, and exclusion from Medicare, Medicaid and other federal health care programs. Exclusion of a manufacturer would preclude any federal health care program from paying for its products. In addition to the federal Anti-Kickback Law, many states have their own anti-kickback laws. Often, these state laws closely follow the language of the federal law. Some state anti-kickback laws apply regardless of whether a federal health care program payment is involved. Federal and state anti-kickback laws may affect our sales, marketing and promotional activities, and relationships with health care providers or pharmacies by limiting the kinds of arrangements we may have with them.

Federal and state false claims laws prohibit anyone from presenting, or causing to be presented, claims for payment to third-party payors that are false or fraudulent. For example, the federal False Claims Act (31 U.S.C. §3729 et seq.) imposes liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program (including Medicaid and Medicare). Manufacturers, like us, can be held liable under false claims laws, even if they do not submit claims to the government, where they are found to have caused submission of false claims by, among other things, providing incorrect coding or billing advice about their products to customers that file claims, or by engaging in kickback arrangements with customers that file claims. A number of states also have false claims laws, and some of these laws may apply to claims for items or services reimbursed under Medicaid and/or commercial insurance. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer's products from reimbursement under government programs, and imprisonment.

5

Table of Contents

The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), created certain criminal statutes relating to health care, including health care fraud and false statements related to healthcare matters. The health care fraud statute prohibits, among others, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors. A violation of this statute is a felony and may result in fines, imprisonment, or exclusion from government sponsored programs. The false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, health care benefits, items or services. A violation of this statute is a felony and may result in fines or imprisonment.

The federal Physician Payments Sunshine Act requires certain pharmaceutical and medical device manufacturers to monitor and report certain payments and other transfers of value to physicians and other healthcare providers to the Centers for Medicare and Medicaid Services, or CMS, for disclosure to the public. Failure to submit required information may result in significant civil monetary penalties. In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians for marketing, medical directorships, and other purposes. Some states mandate implementation of corporate compliance programs, along with the tracking and reporting of gifts, compensation and other remuneration to physicians, and some states limit or prohibit such gifts.

Due to the breadth of some of these laws, it is possible that some of our current or future practices might be challenged under one or more of these laws. In addition, there can be no assurance that we would not be required to alter one or more of our practices to be in compliance with these laws. Evolving interpretations of current laws or the adoption of new federal or state laws or regulations could adversely affect many of the arrangements we have with customers and physicians. Our risk of being found in violation of these laws is increased by the fact that some of these laws are open to a variety of interpretations. If our past or present operations are found to be in violation of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, results of operations and financial condition.

Third-Party Reimbursement

Historically, many customers who were prescribed Avenova Spray relied on third-party payors, such as indemnity insurers and managed care plans, to cover and reimburse all or part of the cost. As a result, demand of Avenova Spray is partially dependent in part on the coverage and reimbursement policies of these payors. Private payors often follow the coverage and reimbursement policies of Medicare. We cannot assure you that private third-party payors will cover and reimburse Avenova Spray or any of our other products in whole or in part in the future or that payment rates will be adequate. Currently, none of our products are reimbursed by federal healthcare programs, such as Medicare and Medicaid, and we do not anticipate they will be reimbursed by such programs in the future.

Trade Regulation

Our products, particularly our DERMAdoctor products, are also subject to regulation by the U.S. Consumer Product Safety Commission (“CPSC”) and the U.S. Federal Trade Commission (“FTC”). These laws and regulations principally relate to the ingredients, proper labeling, advertising, packaging, marketing, manufacture, safety, shipment and disposal of products.

Foreign Regulation

Many foreign countries in which we market or may market our products have regulatory bodies and restrictions similar to those of the FDA, CPSC and FTC. International sales are subject to foreign government regulation, the requirements of which vary substantially from country to country. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA approval and the requirements may differ.

In addition, we export DERMAdoctor products outside of the United States, and those products are subject to several United States statutes and regulations that regulate exportation from the United States. These products do not require an export license so long as the product is not shipped or otherwise transferred to a comprehensively embargoed country or for a potentially prohibited purpose. DERMAdoctor has developed, maintains and follows internal controls to ensure that it is not exporting its products to embargoed countries or for prohibited purposes.

Other U.S. Regulation

We must also comply with numerous federal, state, municipal and local laws relating to matters such as health and safety laws and regulations relating to, among other matters, safe working conditions, product stewardship and environmental protection, including those relating to the handling, storage, transportation, treatment and disposal of hazardous substances and waste materials, and the registration and evaluation of chemicals. We maintain policies and procedures to monitor and control environmental, health and safety risks, and to monitor compliance with applicable environmental, health and safety requirements.

6

Table of Contents

Human Resources

As of December 31, 2021, on a consolidated basis, we had a total of 31 employees, 29 of whom were full-time employees and 2 were part-time employees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We comply with the latest employment best practices and consider our relationship with our employees to be good.

Facilities

Our principal executive office is located in Emeryville, California. We are party to an Office Lease (the “Lease”), dated August 24, 2016, as subsequently amended on January 24, 2022, pursuant to which we lease approximately 7,675 rentable square feet of real property located on the eleventh floor (Suite 1150) at 2000 Powell Street, Emeryville, California 94608 from KBSIII Towers at Emeryville, LLC (the “Landlord”), for our principal executive offices. The expiration date of the Lease is July 31, 2027, unless earlier terminated pursuant to the provisions of the Lease. We believe that our office and administration facilities are suitable and adequate for our current operations and its current purpose, but we may require additional space and facilities as our business expands.

Our wholly-owned subsidiary, DERMAdoctor, is party to a lease with Green Bay Packaging Inc., as landlord, and DERMAdoctor, as tenant, dated August 27, 2019 (the “Subsidiary Lease”), for 19,136 square feet of space located at 4346 Belgium Boulevard, Building 2, Riverside, Missouri, which DERMAdoctor utilizes for light manufacturing, storage, distribution of products and administrative functions. The lease commenced on October 1, 2019 and expires on December 31, 2024.

Available Information

Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our corporate website, located at www.novabay.com, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the “SEC”). Our website is not part of this annual report on Form 10-K. The SEC also maintains an Internet site that contains reports, proxy, information statements and other information regarding issuers at http://www.sec.gov.

ITEM 1A. | RISK FACTORS

Our business is subject to a number of risks, the most important of which are discussed below. You should consider carefully the following risks in addition to the other information contained in this report and our other filings with the SEC before deciding to buy, sell or hold our Common Stock. If any of the following risks actually occur, our business, financial condition, results of operations and the market price of our Common Stock could be materially adversely affected, the value of our Common Stock could decline and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones facing our Company, but those that we consider to be material. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. Please also read carefully the section below entitled “Special Note Regarding Forward-Looking Statements.”

Risks Relating to Our Business

Our business may be adversely affected by the continuing coronavirus outbreak.

In March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. In response to the COVID-19 outbreak, “shelter in place” orders and other public health measures were implemented across much of the United States, including the San Francisco Bay area counties where our headquarters is located. Due to “shelter in place” orders and other public health guidance measures, we implemented a temporary work-from-home policy for all staff members that has since been lifted. Overall, the impact of COVID-19 to date has been minimal on the sales of Avenova Spray as an increase in online sales has made up for the decrease in revenue from other channels. In addition, we recently acquired DERMAdoctor and have not yet fully integrated its business, operations or products with ours and the impact of COVID-19 on this integration and/or the future sales of our DERMAdoctor products is uncertain given the shift in sales channels away from brick-and-mortar retail stores. Although we and DERMAdoctor have not experienced a material disruption in our supply chain to date due to COVID-19, as the pandemic continues, the availability of raw materials, goods and/or services from our suppliers could be disrupted and/or not provided in a timely manner or in the quantities that we require in order to operate our business in the ordinary course, which could materially and adversely affect our product sales, customer service levels and our overall business. In addition, any increases in the costs of goods and services for our business that could result from such disruptions in our supply chain or as a result of inflation in the overall costs of goods and services may adversely affect our profit margins if we are unable to pass along any higher costs in the form of price increases or otherwise achieve cost efficiencies in our operations.

7

Table of Contents

The COVID-19 global pandemic continues to evolve. The extent to which the outbreak and the different variants may continue to affect our business, financial condition and results of operations will depend on future developments, which are uncertain and cannot be predicted at this time, such as the duration of the outbreak, evolution of COVID-19 into novel strands of the disease, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing, quarantines or lock-downs in the United States and elsewhere, business closures or business disruptions and the effectiveness of actions taken in the United States and elsewhere to contain and treat the disease through vaccination. Future developments in these and other areas present material uncertainty and risk with respect to our business, financial condition, and results of operations. Since the success of our business, including DERMAdoctor’s business, relies upon the strength of the United States and other retail economies, any sustained economic downturn in the United States or the other countries in which we conduct business could materially and adversely affect our business, operating results and financial condition.

Our future success is largely dependent on the successful commercialization of our products, particularly Avenova Spray, and of the newly acquired DERMAdoctor products.

If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into or maintain agreements with third parties to do so, we may be unable to successfully commercialize our products, including the products that we recently acquired as a result of the DERMAdoctor Acquisition. While we believe we are creating an efficient commercial organization, we may not be able to correctly judge the size and experience of the sales and marketing force and the scale of distribution necessary to be successful. Establishing and maintaining sales, marketing, and distribution capabilities are expensive and time-consuming. Such expenses may be disproportionate compared to the revenues we may be able to generate on sales of Avenova branded, and/or our DERMAdoctor branded products, which could cause our commercialization efforts to be unprofitable or less profitable than expected.

Acceptance and use of Avenova and/or DERMAdoctor branded products by physicians, retail partners and other customers may depend on a number of factors including: (i) perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products; (ii) published studies demonstrating the cost-effectiveness of our products relative to competing products; (iii) availability of reimbursement for our products from government or commercial payers as relates to Avenova Spray; and (iv) effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any. The failure of any of our products to find market acceptance would harm our business and could require us to seek additional financing to fund our operations.

We face substantial competition in the eyecare and the skincare markets in which we operate.

Avenova Spray faces intense competition in the eyecare market, which is focused on cost-effectiveness, price, service, product effectiveness and quality, patient convenience and technological innovation. There is substantial competition in the eyecare market from companies of all sizes in the United States and abroad, including, among others, large companies such as Allergan plc and Shire plc, and against products such as Restasis, Xiidra, eye wipes, baby shampoo and soap. There are also over-the-counter products that contain hypochlorous acid that compete with Avenova Spray.

For our newly acquired DERMAdoctor products that operate in the skincare and beauty industries, we also face vigorous competition from companies globally, including large multinational consumer products companies that have many skincare brands under ownership and standalone skincare brands, including those that may target the latest trends or specific distribution channels. The skincare and beauty industries are highly competitive and subject to rapid changes due to consumer preferences and industry trends. Competition in the skincare industry is generally based on the introduction of new products, pricing of products, quality of products and packaging, brand awareness, perceived value and quality, innovation, in-store presence and visibility, promotional activities, advertising, editorials, e-commerce and mobile-commerce initiatives and other activities. We must compete with a high volume of new product introductions and existing products by diverse companies across several different distribution channels. Our skincare and other beauty products face, and will continue to face, competition for consumer recognition and market share with products that have achieved significant national and international brand name recognition and consumer loyalty, such as those offered by global prestige beauty companies like Avon Products, Inc., Elizabeth Arden, Inc., The Estée Lauder Companies, Inc., Johnson & Johnson, Inc., L’Oréal Group, Shiseido, Coty, Mary Kay, Inc. and The Proctor & Gamble Company, each of which have launched skincare brands. In addition, we compete with brands including Dr. Dennis Gross, Kate Somerville, Murad, Perricone M.D., Dr. Brandt, Clarins, Clinique, Dermalogica, Exuviance, La Roche-Posay and Vichy. We also compete with numerous other companies that market skincare products. Competition may increase further as existing competitors enhance their offerings or additional companies enter our markets or modify their existing products to compete directly with our products.

These companies that we compete against in the eyecare, skincare and beauty industries may have substantially greater financial, technical and marketing resources, longer operating histories, greater brand recognition and larger customer bases than we do and may be able to respond more effectively to changing business and economic conditions than we can. If our competitors respond more quickly to new or emerging technologies and changes in customer requirements, our products may be rendered obsolete or non-competitive. In addition, if our competitors develop more effective or affordable products, or achieve earlier intellectual property protection or product commercialization than we do, our operating results will materially suffer. Competition may increase further as existing competitors enhance their offerings or additional companies enter our markets or modify their existing products to compete directly with our products. We may not be able to sustain growth as competitive pressures, including pricing pressure from competitors, increase. Our ability to compete depends on the continued strength of our brand and products, the success of our marketing, innovation and execution strategies, the continued diversity of our product offerings, the successful management of new product introductions and innovations, strong operational execution, including in order fulfillment, and our success in entering new markets and expanding our business in existing geographies. If we are unable to continue to compete effectively, it could have a material adverse effect on our business, results of operations and financial condition.

8

Table of Contents

We are dependent on third parties to supply raw materials used in our products and to manufacture our products. Any interruption or failure by these suppliers or other disruptions to our supply chain may materially adversely affect our business, financial condition, results of operations and cash flows.

Our ability to make, move, and sell our products is critical to our success. Historically, we have predominately relied on a single product, Avenova Spray, for our primary revenue stream, which is comprised of our proprietary, stable and pure form of hypochlorous acid. In acquiring DERMAdoctor, we are greatly expanding our product offerings and operations, as DERMAdoctor has an extensive global platform, currently selling over 30 products in various countries, with over 40 commercial relationships that supply its products from around the globe. While product sales in the United States have historically driven DERMAdoctor’s revenue, it has strategically sought international opportunities for the sale and distribution of its products. DERMAdoctor’s products are currently offered internationally in China, the Middle East, Europe, Canada, and Central and South America. With this larger operational business and range of product offerings around the globe, comes additional opportunity for us as well as corresponding risk in certain areas. A key risk area, which is emphasized further by the current pandemic environment and conflict between Russia and Ukraine, is that of supply chain risk. Our subsidiary, DERMAdoctor, also uses third party contract manufacturers and suppliers, some internationally, to obtain substantially all raw materials, components, and packaging products and to manufacture finished products.

Damage or disruption to our supply chain, including third-party manufacturing, assembly or transportation and distribution capabilities, due to weather, including any potential effects of climate change, natural disaster, fire or explosion, terrorism, pandemics (such as the COVID-19 pandemic), strikes, government action, war (such as the conflict between Russia and Ukraine) or other reasons beyond our control or the control of our suppliers and business partners, could impair our ability to manufacture or sell our products. Failure to take adequate steps to mitigate the likelihood or potential impact of such events, or to effectively manage such events if they occur, particularly when a product is sourced from a single supplier or location, could adversely affect our business or financial results.

Further, we rely on third parties to supply raw materials, components, and packaging products, to manufacture finished products, and distribute our products. Any interruption or failure by our suppliers, distributors and other partners to meet their obligations on schedule or in accordance with our expectations, misappropriation of our proprietary information, including trade secrets and know-how, or any termination by these third parties of their arrangements with us, which, in each case, could be the result of one or many factors outside of our control, could delay or prevent the manufacture or commercialization of our products, disrupt our operations or cause reputational harm to our company, particularly with wholesale customers, any or all of which could have a material adverse effect on our business, financial condition, results of operations and cash flows.

In particular, a large portion of DERMAdoctor’s revenue is from wholesale customers, which in accordance with standard industry practice, do not typically operate under written contracts or advance commitments for products. Such wholesale customers generally place large orders shortly before such products are needed. Due to cost and product shelf life, the DERMAdoctor business does not keep a large inventory on hand, however, it must have the ability to quickly provide products to wholesale customers upon demand. Therefore, our DERMAdoctor business relies on its third-party suppliers to be able to quickly respond to DERMAdoctor product needs, and if such supply chain is interrupted, could cause a material adverse effect on our business, reputation with wholesale customers and financial condition.

DERMAdoctor’s operating results are dependent on sales to a few significant retail partners and the loss of, or substantial decline in, sales to one of these retail partners could have a material adverse effect on our expected future revenues and profitability.

Retail partners that purchase our DERMAdoctor products account for a substantial percentage of net sales revenue, and the loss of all or a portion of the sales to any one of these customers could have a material adverse effect on the results of operations generated by the DERMAdoctor business. In particular, prior to the DERMAdoctor Acquisition, sales to retail partners accounted for approximately 50.8% of DERMAdoctor’s gross sales revenue in fiscal 2020. We expect that a small group of retail partners will continue to account for a significant portion of DERMAdoctor’s gross sales revenue for the foreseeable future. Although DERMAdoctor developed long-standing relationships with its major retail partners, it generally does not, consistent with industry norms, have written agreements or advance commitments that require these retail partners to buy from DERMAdoctor or to purchase a minimum amount of DERMAdoctor products. A substantial decrease in sales to any of DERMAdoctor’s major retail partners could have a material adverse effect on the DERMAdoctor business and our financial condition and operating results.

9

Table of Contents

Potential disruptions to our distribution facility could cause interruptions or delays in our business and adversely affect our net sales and results of operations.

Our ability to meet the needs of our consumers and retail customers depends on the proper operation of our Riverside, Missouri distribution facility, where a significant portion of our inventory that is not in transit is housed. Although we currently insure our inventory, our insurance coverage may not be sufficient to cover the full extent of any loss or damage to our inventory or distribution facility, and any loss, damage or disruption of this facility, or loss or damage of the inventory and contents stored there, could materially and adversely affect our business, financial condition and results of operations. A natural disaster or other catastrophic event, such as a fire, flood, severe storm, break-in, terrorist attack or other comparable event could cause loss of inventory and interruptions or delays in our business and could render us unable to accept or fulfill customer orders in a timely manner, or at all. Our warehouse is located in an area that has historically been subject to severe storms and tornados. This increases our susceptibility to the risk that severe weather conditions could harm the operations of our distribution facility. In the event that a storm, tornado, fire, natural disaster or other catastrophic event were to destroy a significant part of the facility or interrupt our operations for an extended period of time, our net sales could be reduced, and our results of operations could be harmed.

Significant disruptions of information technology systems or breaches of information security could adversely affect our businesses.

We rely upon information technology systems to operate our businesses. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. We also have outsourced aspects of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing independent vendor relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract, make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from attacks by malicious third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives and expertise, including organized criminal groups, “hacktivists,” nation states and others. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us.

Adverse U.S. or international economic conditions could negatively affect our business, financial condition and results of operations.

We face risks associated with U.S. and international economic conditions and are subject to events beyond our control including war, public health crises (such as the COVID-19 pandemic), trade disputes, economic sanctions, and their collateral impacts. In particular, consumer spending on skincare and beauty products, as well as eyecare products, is influenced by general economic conditions and the availability of discretionary income. Adverse U.S. or international economic conditions or periods of inflation or high energy prices may contribute to higher unemployment levels, decreased consumer spending, reduced credit availability and declining consumer confidence and demand, each of which poses a risk to our business. A decrease in consumer spending or in retailer and consumer confidence and demand for our products could have a significant negative impact on our net sales and profitability, including our operating margins and return on invested capital. These economic conditions could cause some of our retail customers or suppliers to experience cash flow or credit problems and impair their financial condition, which could disrupt our business and adversely affect product orders, payment patterns and default rates and increase our bad debt expense. In addition, deterioration in global financial markets could make future financing difficult or more expensive, which could have a material adverse effect on our ability to finance the acquisition of inventory for sale to our customers. In February 2022, armed conflict escalated between Russia and Ukraine. The sanctions imposed by the U.S. and other countries against Russia, following Russia’s invasion of Ukraine, to date include restrictions on selling or importing goods, services, or technology in or from affected regions and travel bans and asset freezes impacting connected individuals and political, military, business and financial organizations in Russia. The U.S. and other countries could impose wider sanctions and take other actions should the conflict further escalate. It is not possible to predict the broader consequences of this conflict, which could include further sanctions, embargoes, regional instability, geopolitical shifts and adverse effects on macroeconomic conditions, currency exchange rates and financial markets, all of which could impact our business, financial condition and results of operations.

Risks Related to the DERMAdoctor Acquisition and DERMAdoctor’s Products

Uncertainty about the DERMAdoctor Acquisition may adversely affect the relationships that we and DERMAdoctor have with our respective customers, service providers and employees.

Parties with whom we or DERMAdoctor do business may experience uncertainty associated with the recent DERMAdoctor Acquisition, including with respect to current or future business relationships with us or DERMAdoctor. These business relationships may be subject to disruption as end customers, suppliers, manufacturers, distributors and others may attempt to (i) negotiate changes in existing business relationships, (ii) delay, defer or cease supplying or manufacturing for, or purchasing products from, us or DERMAdoctor or (iii) consider entering into business relationships with parties other than us or DERMAdoctor, including our competitors or those of DERMAdoctor. These disruptions, if they occur, could have a material adverse effect on the combined business and upon our operating results and financial condition.

Uncertainties associated with the DERMAdoctor Acquisition may cause a loss of management personnel and other key employees that could adversely affect our future business, operations and financial results.

With the DERMAdoctor Acquisition having been completed, the ongoing integration of the combined businesses could disrupt our business. We and DERMAdoctor are both dependent on the experience and industry knowledge of our respective senior management and other key employees to develop new products and execute our respective business plans. Our success will depend in part upon our ability to retain both key management personnel and key employees of DERMAdoctor. Although we entered into employment agreements with Dr. Audrey Kunin and Dr. Jeffrey Kunin, who are also incentivized to team with us over the next two years to achieve potential Earn Out Payments pursuant to the terms of the Purchase Agreement, and all of the other employees of DERMAdoctor continued as employees after the Acquisition Closing, there is no guarantee that current and prospective future employees we hire for the DERMAdoctor business will continue with us, which may have an adverse effect on our ability to effectively integrate DERMAdoctor into our business or for us to attract or retain key management and other key personnel. All of DERMAdoctor’s existing and new products in development were conceived by its product design team led by Dr. Audrey Kunin, who is a board-certified dermatologist. Dr. Kunin is continuing post-transaction in her leadership role of new product development, and the loss of Dr. Kunin’s service in this capacity could have a material and adverse effect on our ability to effectively develop and launch new products until such position could be filled by us.

10

Table of Contents

The DERMAdoctor Acquisition involves risks associated with acquisitions and integrating acquired businesses and the intended benefits of the DERMAdoctor Acquisition may not be realized by us.

The DERMAdoctor Acquisition, which was completed on November 5, 2021, involves risks that are associated with acquisitions and integrating acquired businesses and their operations with existing operations, including:

| ● | our senior management’s attention may be diverted from the management of daily operations to the integration of DERMAdoctor’s products and business that we have acquired;
| ● | the challenges, including delays or any other unanticipated changed circumstances, and costs involved in integrating and/or developing DERMAdoctor products and other assets that we have acquired;
| ● | failure of the products and other assets that we acquired in the DERMAdoctor Acquisition to generate anticipated revenues, and/or otherwise perform in accordance with our expectations; and
| ● | failure to achieve the anticipated efficiencies and cost savings or realize other expected benefits of the DERMAdoctor Acquisition within the expected time frame or at all.

If these risks or other unexpected costs and liabilities were to materialize, any desired benefits of the DERMAdoctor Acquisition may not be fully realized, if at all, and our future financial performance and results of operations could be negatively impacted. In addition, if the combined company does not perform as we or the market expects, then this could have an adverse effect on the price of our Common Stock.

Actual results may differ from any statements made by us concerning the anticipated impact of the DERMAdoctor Acquisition on the operating results of the combined company, and these differences could be material.

Although we believe that we have a reasonable basis for such forward-looking statements, these statements are based on our projections of future events that are subject to risks, uncertainties and other factors that may cause the combined company’s actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements to differ in a material way. Additional risks and uncertainties that could cause actual results to differ materially from currently anticipated results include, but are not limited to, risks relating to our ability to successfully integrate DERMAdoctor; unanticipated increases in costs or expenses; our ability to realize expected cost synergies; our ability to reach profitability as a result of the DERMAdoctor Acquisition, and the other risks identified herein and the documents included herein that we urge you to read. Our actual financial condition and results of operations as a result of the DERMAdoctor Acquisition may not be consistent with, or evident from, the statements for the periods covered by this report. Consequently, actual results or developments anticipated by us may not be realized or, even if substantially realized, may not have the expected consequences to, or effects on, us. In particular, while the DERMAdoctor Acquisition is expected to be accretive to NovaBay’s profitability in the first year after close, there can be no assurance with respect to the timing and scope of the accretive effect or whether it will be accretive at all. Any failure to meet expectations regarding the prospects for the combined company could have a material adverse effect on our business, financial condition, results of operation, as well as the trading price and/or volume of our Common Stock.

Charges to earnings resulting from the application of the purchase method of accounting following the Closing of the DERMAdoctor Acquisition may adversely affect the market value of our Common Stock.

The DERMAdoctor Acquisition will be accounted for using the purchase method of accounting, which will result in charges to earnings that could have an adverse impact on the market value of our Common Stock. Under the purchase method of accounting, the total estimated Purchase Price will be allocated to DERMAdoctor’s pro forma net tangible assets and identifiable intangible assets based on their respective fair values as of the Acquisition Closing. Any excess of the Purchase Price over those fair values will be recorded as goodwill. As a result of the consolidation of DERMAdoctor with our Company, we will incur additional amortization expense based on the identifiable amortizable intangible assets acquired pursuant to the Purchase Agreement and their relative useful lives. Additionally, to the extent the value of goodwill or identifiable intangible assets or other long-lived assets may become impaired, we may be required to incur charges relating to the impairment. These amortization and potential impairment charges could have a material impact on the combined company’s results of operations.

Risk Related to Government Regulation

We expect continuous revenue from sales of Avenova Spray, which is classified as a cleared medical device by the FDA, but we cannot guarantee that the FDA will continue to allow us to market and sell Avenova Spray as a cleared medical device, which marketing inability would halt our sales and marketing of Avenova Spray and cause us to lose revenue and materially and adversely affect our results of operations and the value of our business.

Our ability to continue to commercialize Avenova Spray and generate revenue from Avenova Spray depends upon, among other things:

| ● | the FDA allowing us to continue marketing Avenova Spray as an FDA cleared medical device;

| ● | acceptance in the medical community;

| ● | the safety of Avenova Spray’s predicate devices;

| ● | the number of patients who use Avenova Spray;

| ● | coverage or reimbursement by third-party payors of Avenova Spray;

| ● | our ability to successfully market Avenova Spray to both doctors and patients; and

| ● | the amount and nature of competition from competing companies with similar products.

11

Table of Contents

Revenue from the Avenova brand will be subject to, among other things, regulatory and commercial and market uncertainties that may be outside of our control. The clearance that we have received from the FDA for our Avenova Spray, NeutroPhase, PhaseOne and other products is subject to strict limitations on the indicated uses for which the products may be marketed. The labeling, packaging, adverse event reporting, storage, advertising, promotion, and record keeping for all of our products, including those that are not subject to FDA clearance, are subject to extensive regulatory requirements.

In addition, there can be no assurance that government regulations applicable to our products will not change and thereby prevent the marketing of some or all of our products for a period of time or permanently. The FDA’s policies may change and additional government regulations may be enacted that could modify, prevent or delay regulatory approval of our products. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or in other countries. We cannot guarantee that Avenova Spray, our other cleared products, or products that may be approved or cleared for marketing in the future, will not be materially adversely impacted by a change in industry standards or regulations. If changes to industry standards, practices or regulations applicable to Avenova Spray or our other cleared products that we may market and sell in the future cause a delay in continued commercialization or if we cannot make a change to satisfy the industry standards, practices or regulations, we may not be able to meet market demand which may have a materially adverse effect on our business, financial condition, results of operations, and prospects.

Additionally, the FDA may request that we submit another 510(k) premarket submission that compares to another predicate device. If we are unable to find an adequate predicate device that is substantially equivalent to Avenova Spray for the treatment claims that we use to sell and market Avenova Spray, we may not be able to obtain the necessary FDA clearance to continue to market and sell Avenova Spray without performing comprehensive clinical trials. In such event, we would need to seek premarket approval from the FDA for the applicable product before we could continue to sell and market Avenova Spray in the United States, which would be significantly more time consuming, expensive, and uncertain.

Our commercialized products such as Avenova and DERMAdoctor branded products are not approved by the FDA as a drug, and we rely solely on the 510(k) clearance for Avenova Spray and certain of our other products as a medical device.

Our business and future growth depend on the development, use and sale of products that are subject to FDA regulation, clearance and approval. Under the U.S. Federal Food, Drug, and Cosmetic Act and other laws, we are prohibited from promoting our products for off-label uses. This means that we may not make claims about the safety or effectiveness of our products and may not proactively discuss or provide information on the use of our products, except as allowed by the FDA. Our products, particularly our DERMAdoctor products, are also subject to regulation by the CPSC and the FTC. These laws and regulations principally relate to the ingredients, proper labeling, advertising, packaging, marketing, manufacture, safety, shipment and disposal of such products. As Avenova Spray is a medical device, we may only make very limited claims that pertain to its cleared intended use. Without claims of efficacy, market acceptance of our products may be slow. The 510(k) status of Avenova Spray also affects our ability to obtain formal insurance reimbursement by payors and affects our ability to obtain Medicare coverage.

The FDA does not currently require pre-market approval for products intended to be sold as non-prescription skincare products, so long as they are not marketed for the treatment or prevention of a disease, or as affecting the structure or function of the human body. However, the FDA may in the future require pre-market approval, clearance, or registration/notification of skincare products. Moreover, such products could also be regulated as both drugs and skincare simultaneously, as the categories are not mutually exclusive. If the FDA determines that any of our products intended to be sold as skincare should be classified and regulated as drug products, and we are unable to comply with applicable drug requirements, we may be unable to continue to market those products. Any inquiry into the regulatory status of our skincare products and any related interruption in the marketing and sale of these products could damage our reputation and image in the marketplace.

There is significant risk that the FDA or other federal or state law enforcement authorities may determine that the nature and scope of our sales and marketing activities constitutes the promotion of our products for non-FDA-approved uses in violation of applicable law and as the sale of unapproved drugs, which is prohibited under applicable law. We face the risk that the FDA may take enforcement action against us for the way that we promote and sell our products. This risk may grow with the increased visibility of Avenova Spray online, as well as the FDA’s increased focus on antimicrobial products in the wake of the COVID-19 pandemic. We also face the risk that the FDA or other regulatory authorities might pursue enforcement actions based on past activities that we have discontinued or changed, including sales activities, arrangements with institutions and doctors, educational and training programs and other activities.

Government investigations concerning the promotion of unapproved drug products, off-label uses and related issues are typically expensive, disruptive and burdensome and generate negative publicity. If our promotional activities are found to be in violation of applicable law or if we agree to a settlement in connection with an enforcement action, we would likely face significant fines and penalties and be required to substantially limit and change our sales and promotion activities.

12

Table of Contents

Developments after a product reaches the market may adversely affect sales of our products.

Even after obtaining regulatory clearances, certain developments may decrease demand for our products, including the re-review of products that are already marketed; new scientific information and evolution of scientific theories; the recall or loss of regulatory clearance of products that are already marketed; changing government standards or public expectations regarding safety, efficacy, or labeling changes; and greater scrutiny in advertising and promotion. If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of a product, it could significantly reduce demand for the product or require us to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. In addition, some health authorities appear to have become more cautious when examining new products and are re-reviewing select products that are already marketed, adding further to the uncertainties in the regulatory processes.

There is also greater regulatory scrutiny, especially in the United States, on advertising (in particular, direct to consumer advertising), promotion and pricing of pharmaceutical products. Certain regulatory changes or decisions could make it more difficult for us to sell our products. If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory clearance, product recalls, seizure of products, operating restrictions, injunctions, warning letters, criminal prosecution and other enforcement actions. Any of these events could prevent us from marketing our products and our business may not be able to continue past such concerns. If any of the above occurs to Avenova Spray, or our DERMAdoctor products, our business, results of operations, financial condition and cash flows could be materially adversely affected.

We do not have our own manufacturing capacity, and we rely on partnering arrangements or third-party manufacturers for the manufacture of our products and potential products.

The FDA and other governmental authorities require that all of our products, including those of DERMAdoctor, be manufactured in strict compliance with federal Quality Systems Regulations (“QSR”) and other applicable government regulations and corresponding foreign standards. We do not currently operate manufacturing facilities for production of our products. As a result, we have partnered with third parties to manufacture our products or rely on contract manufacturers to supply, store and distribute our products and help us meet legal requirements. As we have limited control over our commercial partners, any performance failure on their part (including failure to deliver compliant, quality components or finished goods on a timely basis or properly branded products) could affect the commercialization of our products, producing additional losses and reducing or delaying product revenues. If any of our commercial partners or manufacturers have violated or is alleged to have violated any laws or regulations during the performance of their obligations to us, it is possible that we could suffer significant financial, operational and reputational harm or other negative outcomes, including costly corrective actions, including suspending manufacturing operations, changing product formulations, suspending sales of nonconforming products, or initiating product recalls, change product labelling, packaging or advertising or take other corrective action and possible legal consequences.

Our products require precise, high-quality manufacturing. The failure to achieve and maintain high manufacturing standards could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could seriously harm our business. Contract manufacturers and partners often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Accordingly, we and our third-party manufacturers are also subject to periodic unannounced inspections by the FDA to determine compliance with the FDA's requirements, including primarily current cGMP, the QSR, medical device reporting regulations (where applicable for Avenova Spray), proper and compliant labeling and other applicable government regulations and corresponding foreign standards, including ISO 13485.

The results of these inspections can include inspectional observations on FDA’s Form 483, untitled letters, warning letters, or other forms of enforcement. If the FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our FDA-cleared products are ineffective, make additional therapeutic claims that are not commensurate to the accepted labeling claims, or pose an unreasonable health risk, the FDA could take a number of regulatory actions, including preventing us from manufacturing any or all of our products or performing laboratory testing on human specimens, which could materially adversely affect our business. In addition, a prolonged interruption in the manufacturing of one or more of our products as a result of non-compliance could decrease our supply of products available for sale, which could reduce our net sales, gross profits and market share, as well as harm our overall business, prospects, financial condition and results of operations.

Avenova Spray’s FDA-clearance and our other products that have been cleared by the FDA or products that we may obtain FDA-clearance in the future, if at all, are subject to limitations on the intended uses for which the product may be marketed, which can reduce our potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that our promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved use, it could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities. In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements where applicable for Avenova Spray, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory clearance to one or all of our products that may be cleared in the future, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.

13

Table of Contents

If we were to lose, or have restrictions imposed on, FDA clearances we may receive in the future, our business, operations, financial condition and results of operations would likely be materially adversely impacted.

Risks Relating to Our Liquidity

We have a history of losses and we may never achieve or maintain sustained profitability.

We have historically incurred net losses, and we may never achieve or maintain sustained profitability. In addition, at this time, we expect to incur expenses, including marketing and sales expenses, as we integrate the DERMAdoctor business and its products with ours and our continued efforts to increase sales of our Avenova branded and newly acquired DERMAdoctor products, and our results of operations may fluctuate significantly.

While we believe that increased revenues and operating expense efficiencies expected to be achieved as a result of the DERMAdoctor Acquisition will result in our Company achieving profitability, there is no assurance that this will occur. We will need to generate significant revenues to achieve and maintain profitability. Even with the combined sales of Avenova branded and DERMAdoctor products, there is no assurance that we will be able to generate sufficient revenues to achieve or maintain profitability. Our failure to achieve and subsequently maintain profitability could have a material adverse impact on the market price of our Common Stock.

Risks Relating to Owning Our Common Stock

The price of our Common Stock may fluctuate substantially, which may result in losses to our stockholders.

The stock prices of many companies in our market segments have generally experienced wide fluctuations, which are often unrelated to the operating performance of those companies. The market price of our Common Stock is likely to be volatile and could fluctuate in response to, among other things:

| ● | the announcement of new products by us or our competitors;

| ● | the announcement of partnering arrangements by us or our competitors;

| ● | quarterly variations in our or our competitors’ results of operations;

| ● | changes in our earnings estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts' earnings estimates;

| ● | developments in our industry;

| ● | the sale of a substantial number of shares of Common Stock by any large stockholder, especially within a short period of time; and

| ● | general, economic and market conditions, including volatility in the financial markets, a decrease in consumer confidence and other factors unrelated to our operating performance or the operating performance of our competitors.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation’s ability to use its pre-change net operating loss (“NOL”) carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. Since our formation, we have raised capital through the issuance of capital stock on many occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in one or more changes of control, as defined by Section 382 of the Code. We have not currently completed a study to assess whether any change of control has occurred, or whether there have been multiple changes of control since our formation, due to the significant complexity and cost associated with such study. If we have experienced a change of control at any time since our formation, our NOL carryforwards and tax credits may not be available, or their utilization could be subject to an annual limitation under Section 382. In addition, since we may need to raise additional funding to finance our operations, we may undergo further ownership changes in the future. If we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset United States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.

We have not paid dividends or repurchased stock in the past and do not expect to pay dividends or repurchase stock in the future, and any return on investment may be limited to the value of our stock.

We have never paid cash dividends on, or repurchased shares of, our Common Stock and do not anticipate paying cash dividends or repurchasing shares of our Common Stock in the foreseeable future. In addition, we do not anticipate paying any dividends or repurchasing any shares of our Preferred Stock; however, if we pay dividends on our shares of Common Stock, we are required to pay dividends on our Preferred Stock on an as converted basis. The payment of dividends on, or the repurchase of shares of, our Common Stock or Preferred Stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our Board of Directors may consider relevant. If we do not pay dividends or repurchase stock, holders of our Common Stock will experience a return on their investment in our shares only if our stock price appreciates.

14

Table of Contents

If our stockholders' equity does not meet the minimum standards of the NYSE American or we are not able to comply with other continued listing requirements, we may be subject to delisting procedures.

Our Common Stock is currently listed on the NYSE American. If we are unable to comply with the continued listing requirements of the NYSE American, our Common Stock would be delisted from the NYSE American, which would limit investors’ ability to effect transactions in our Common Stock and subject us to additional trading restrictions. In order to maintain our listing, we must maintain certain share prices, financial and share distribution targets, including maintaining a minimum amount of stockholders’ equity and a minimum number of public stockholders. In addition to these objective standards, NYSE American may delist the securities of any issuer for other reasons involving the judgment of NYSE American. Historically, our stockholders’ equity has at times been below the minimum requirements of Section 1003(a) of the Company Guide though we have met all such minimum requirements since October 13, 2020. In accordance with Section 1009(h) of the Company Guide, if we are again determined to be below any of the continued listing standards in the future, the NYSE American will take the appropriate action which, depending on the circumstances, may include initiating its compliance procedures or initiating delisting proceedings. If our Common Stock is delisted, this could, among other things, substantially impair our ability to raise additional funds; result in a loss of institutional investor interest and fewer financing opportunities for us; and/or result in potential breaches of representations or covenants of our warrants, subscription agreements or other agreements pursuant to which we made representations or covenants relating to our compliance with applicable listing requirements. Claims related to any such breaches, with or without merit, could result in costly litigation, significant liabilities and diversion of our management's time and attention and could have a material adverse effect on our financial condition, business and results of operations.

We may issue additional shares of our Common Stock, other series or classes of preferred stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of your shares.

We may issue additional shares of our Common Stock, other series or classes of preferred stock, in addition to the Preferred Stock and 2021 Warrants that we recently issued and sold in the 2021 Private Placement, or other equity securities of equal or senior rank in the future in connection with, among other things, future acquisitions, repayment of outstanding indebtedness or under our 2017 Omnibus Incentive Plan, without stockholder approval, in a number of circumstances.

Our issuance of additional shares of our Common Stock, preferred stock or other equity securities of equal or senior rank could have the following effects:

| ● | your proportionate ownership interest in NovaBay will decrease;

| ● | the relative voting strength of each previously outstanding share of Common Stock may be diminished; or

| ● | the market price of your shares of Common Stock may decline.

We may require additional capital funding, the receipt of which may impair the value of our Common Stock and Preferred Stock.

If we expand more rapidly than currently anticipated or if our working capital needs exceed our current expectations, we may need to raise additional capital through public or private equity offerings or debt financings. Our future capital requirements depend on many factors including our research, development, sales and marketing activities. We do not know whether additional financing will be available when needed or will be available on terms favorable to us. If we cannot raise needed funds on acceptable terms, we may not be able to develop or enhance our products, take advantage of future opportunities or respond to competitive pressures or unanticipated requirements. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution and the new equity securities may have greater rights, preferences or privileges than our existing Common Stock. In addition, the new equity securities may be offered in the future at a price that is below the then in effect conversion price of the Preferred Stock, which would result in the lowering of the conversion price of the Preferred Stock and a greater number of shares of Common Stock being issuable upon conversion of the Preferred Stock for no additional consideration, causing even greater dilution to our stockholders.

15

Table of Contents

Offers or availability for sale of a substantial number of shares of our Common Stock, including as a result of the conversion of the Preferred Stock and/or the exercise of the 2021 Warrants, may cause the price of our publicly traded securities to decline.

Sales of a significant number of shares of our Common Stock in the public market could harm the market price of our Common Stock and make it more difficult for us to raise funds through future offerings of Common Stock. The Preferred Stock that we issued in the 2021 Private Placement provides for conversion into an aggregate of 37,500,000 shares of Common Stock (based on the current conversion price). In addition, the Preferred Stock may become convertible into a greater number of shares of Common Stock that would be available for sale as a result of the full-ratchet anti-dilution price protection in the Certificate of Designation for the Preferred Stock, which would be triggered if we were to issue Common Stock in the future at an effective Common Stock purchase price that is less than the current conversion price for the Preferred Stock. In the 2021 Private Placement, we also issued 2021 Warrants that are exercisable into 37,500,000 shares of Common Stock. Assuming that all of the shares of Preferred Stock issued in the 2021 Private Placement are converted based on the conversion price as of the date hereof, and all of the 2021 Warrants are exercised, it would result in a total of 75,000,000 additional shares of Common Stock becoming issued and outstanding, which represents approximately 50% of the total number of shares of Common Stock authorized as of January 31, 2022. In addition, our stockholders and the holders of our stock options and other warrants that we issued may also sell amounts of our Common Stock in the public market. The sale of a significant portion of any of these shares of Common Stock in the public market at one time could create downward pressure on the market price of our Common Stock. In addition, the fact that our stockholders, including the holders of Preferred Stock, option holders and warrant holders, including the 2021 Warrants, could sell substantial amounts of our Common Stock in the public market, whether or not sales have occurred or are occurring, could make it more difficult for us to raise additional financing through the sale of equity or equity-related securities in the future at a time and/or at a price that we deem reasonable or appropriate, or at all.

Risks Related to Potential Litigation

The pharmaceutical and biopharmaceutical industries are characterized by patent litigation, and any litigation or claim against us may impose substantial costs on us, place a significant strain on our financial resources, divert the attention of management from our business and harm our reputation.

There has been substantial litigation in the pharmaceutical and biopharmaceutical industries with respect to the manufacture, use and sale of new products that are the subject of conflicting patent rights. For the most part, these lawsuits relate to the validity, enforceability, and infringement of patents. We rely upon patents, trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position, and we may initiate claims to defend our intellectual property rights as a result. Other parties may have issued patents or be issued patents that may prevent the sale of our products or know-how or require us to license such patents and pay significant fees or royalties to produce our products. In addition, future patents may be issued to third parties which our technology may infringe. Because patent applications can take many years to issue and because patent applications are not published for a period of time, or in some cases at all, there may be applications now pending of which we are unaware that may later result in issued patents that our products infringe.

Intellectual property litigation, regardless of outcome, is expensive and time-consuming, would divert management's attention from our business and could have a material negative effect on our business, operating results, or financial condition. If a dispute involving our proprietary technology were resolved against us, it could mean the earlier entry of some or all third parties seeking to compete in the marketplace for a given product, and a consequent significant decrease in the price we could charge for our product. If such a dispute alleging that our technology or operations infringed third-party patent rights were to be resolved against us, we might be required to pay substantial damages, including treble damages and attorney's fees if we were found to have willfully infringed a third party's patent, to the party claiming infringement, to develop non-infringing technology, to stop selling any products we develop, to cease using technology that contains the allegedly infringing intellectual property or to enter into royalty or license agreements that may not be available on acceptable or commercially practical terms, if at all.

If our product or products cause an unexpected reaction to a patient or patients in certain ways that may have caused or contributed to serious injury, we may be subject to product liability claims, and if product liability lawsuits are brought against us, they could result in costly litigation and significant liabilities.

Despite all reasonable efforts to ensure safety, it is possible that we or our distributors will sell our products or products that we currently do not sell but may sell in the future, which are defective, to which patients/customers react in an unexpected manner, or which are alleged to have side effects or otherwise not work for the product’s intended purpose. The manufacture and sale of such products may expose us to potential liability, including regulatory enforcement actions, and the industries in which our products are likely to be sold have been subject to significant product liability litigation.

Any claims, with or without merit, could result in costly litigation, reduced sales, significant liabilities and diversion of our management's time and attention, and could have a material adverse effect on our reputation, financial condition, business and results of operations. We cannot make assurances that any liability insurance coverage that we qualify for, if at all, will fully satisfy any liabilities brought for any event or injury that is attributed to our product or products.

If a product liability claim is brought against us, we may be required to pay legal and other expenses to defend the claim and, if the claim is successful, damage awards may not be covered, in whole or in part, by our insurance. We may not have sufficient capital resources to pay a judgment, in which case our creditors could levy against our assets. We may also be obligated to indemnify our collaborators and make payments to other parties with respect to product liability damages and claims. Defending any product liability claims, or indemnifying others against those claims, could require us to expend significant financial and managerial resources.

16

Table of Contents

If we are unable to protect our intellectual property, our competitors could develop and market products similar to ours that may reduce demand for our products.

Our success, competitive position and potential future revenues will depend in significant part on our ability to protect our intellectual property. We rely on the patent, trademark, copyright and trade secret laws of the U.S. and other countries, as well as confidentiality and nondisclosure agreements, to protect our intellectual property rights. We apply for patents covering our technologies as we deem appropriate.

There is no assurance that any patents issued to us, or in-licensed or assigned to us by third parties will not be challenged, invalidated, found unenforceable or circumvented, or that the rights granted thereunder will provide competitive advantages to us. If we or our collaborators or licensors fail to file, prosecute, obtain or maintain certain patents, our competitors could market products that contain features and clinical benefits similar to those of any products we develop, and demand for our products could decline as a result. Further, although we have taken steps to protect our intellectual property and proprietary technology, third parties may be able to design around our patents or, if they do infringe upon our technology, we may not be successful or have sufficient resources in pursuing a claim of infringement against those third parties. Any pursuit of an infringement claim by us may involve substantial expense and diversion of management attention.

We also rely on trade secrets and proprietary know-how that we seek to protect by confidentiality agreements with our employees, consultants, and collaborators. If these agreements are not enforceable, or are breached, we may not have adequate remedies for any breach, and our trade secrets and proprietary know-how may become known or be independently discovered by competitors.

We operate in the State of California. California law prevents us from imposing a delay before an employee, who may have access to trade secrets and proprietary know-how, can commence employment with a competing company. Although we may be able to pursue legal action against competitive companies improperly using our proprietary information, we may not be aware of any use of our trade secrets and proprietary know-how until after significant damage has been done to our Company.

Furthermore, the laws of foreign countries may not protect our intellectual property rights to the same extent as the laws of the U.S. If our intellectual property does not provide significant protection against foreign or domestic competition, our competitors, including generic manufacturers, could compete more directly with us, which could result in a decrease in our market share. All of these factors may harm our competitive position.

ITEM 1B. | UNRESOLVED STAFF COMMENTS

Not Applicable.

ITEM 2. | PROPERTIES

Our principal executive offices and administrative operations are located at 2000 Powell Street, Suite 1150, Emeryville, California. In total, we lease approximately 7,675 square feet of office space in the facility pursuant to the Lease expiring on July 31, 2027.

Our wholly-owned subsidiary, DERMAdoctor, leases approximately 19,136 square feet of space at 4346 Belgium Boulevard, Building 2, Riverside, Missouri, for light manufacturing, storage, distribution of products and administrative functions, pursuant to the Subsidiary Lease expiring on December 31, 2024.

ITEM 3. | LEGAL PROCEEDINGS

From time to time, the Company may be involved in various legal proceedings arising in the ordinary course of business. As of December 31, 2021, there were no matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.

ITEM 4. | MINE SAFETY DISCLOSURES

Not Applicable.

17

Table of Contents

PART II

ITEM 5. | MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common stock is listed on the NYSE American, under the symbol “NBY.”

Holders

As of March 24, 2022, there were approximately 123 holders of record of our common stock. This figure does not reflect persons or entities that hold their stock in nominee or “street” name through various brokerage firms.

Dividend Policy

We have not paid cash dividends on our common stock since our inception. We currently expect to retain earnings primarily for use in the operation and expansion of our business; therefore, we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements, restrictions under any existing indebtedness and other factors the Board of Directors deems relevant.

ITEM 6. | [RESERVED]

ITEM 7. | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read together with our consolidated financial statements and related notes included in Part II, Item 8 of this report. This discussion contains forward-looking statements that involve risks and uncertainties. Words such as "expects," "anticipated," "will," "may," "goals," "plans," "believes," "estimates," "concludes," determines," variations of these words, and similar expressions are intended to identify these forward-looking statements. As a result of many factors, including those set forth under the section entitled "Risk Factors" in Item 1A. and elsewhere in this report, our actual results may differ materially from those anticipated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions based upon assumptions made that we believed to be reasonable at the time and are subject to risks and uncertainties. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements.

Overview

We are a company focused on the development and sale of scientifically-created and clinically-proven eyecare and skincare products. Our portfolio of products includes a number of eyecare products under our Avenova brand, led by Avenova Spray which contains our proprietary, stable and pure form of hypochlorous acid, and over 30 dermatologist-developed skincare products under our DERMAdoctor brand, as further described in Item 1. (Business).

On November 5, 2021, we purchased DERMAdoctor, LLC (“DERMAdoctor”) (the “DERMAdoctor Acquisition”) for approximately $12.0 million as well as $3.0 million of contingent consideration payable in cash or our common stock over the next two years upon the achievement of certain contribution margin targets. For additional information regarding the DERMAdoctor Acquisition, see Note 3 “Business Combination” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report.

The DERMAdoctor Acquisition was funded, in part, through the sale of an aggregate of 15,000 shares of Preferred Stock (convertible into an aggregate of 37,500,000 shares of Common Stock) and the 2021 Warrants (exercisable for 37,500,000 shares of Common Stock) for an aggregate purchase price of $15.0 million. For additional information regarding the Preferred Stock and the 2021 Warrants, see Note 13, “Warrant Liability” and Note 14, “Stockholders’ Equity” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report.

In 2021, we also continued to expand our Avenova product offerings, including adding the following products under the Avenova eyecare brand: (1) Avenova Moist Heating Eye Compress and (2) the i-Chek. We expanded our distribution efforts through our partnership with ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses to promote Avenova Spray.

Financial Overview and Outlook

We have incurred net losses and generated negative cash flows from operations since inception and expect to incur losses in the future as we continue to commercialize our eyecare and skincare products and integrate the DERMAdoctor business. Our net losses were $5.8 million and $11.0 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $141.9 million and current assets totaling $13.2 million.

We expect to grow commercial sales of Avenova and DERMAdoctor branded products through an expansion of domestic and international market penetration, with a particular focus on online channels, and the development of new product offerings under both brand names.

18

Table of Contents

Critical Accounting Policies and Estimates

Our consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. On an ongoing basis, we evaluate our estimates and judgments related to revenue recognition, research and development costs, patent costs, stock-based compensation, income taxes, earnout contingency, and warrant liability. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

While our significant accounting policies are more fully described in Note 2, “Summary of Significant Accounting Policies” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report, we believe that the following accounting policies are most critical to fully understanding and evaluating our reported financial results.

Allowance for Doubtful Accounts

The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute, and it believes are unlikely to be collected. Management recorded no reserve for accounts receivable at December 31, 2021 and December 31, 2020.

Inventory

Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes, and pumps; (2) goods in progress; and (3) finished goods. We utilize contract manufacturers to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At December 31, 2021 and 2020, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $641 thousand and $236 thousand, respectively.

Business Combinations

We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill.

The determination of estimated fair value requires us to make significant estimates and assumptions. These fair value determinations require judgment and involve the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, and asset lives, among other items. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill.

Transaction costs associated with business combinations are expensed as they are incurred.

Goodwill and Intangible Assets

Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. We do not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired.

Intangible Asset |  | Fair Value (in thousands) |  |  | Useful Life (in years) |  |  | Amortization Method |
Customer relationships |  | $ | 290 |  |  |  | 7 |  |  | Straight line |
Trade secrets / product formulations |  |  | 2,890 |  |  |  | 9 |  |  | Straight line |
Trade names |  |  | 2,080 |  |  | Indefinite |  |  |  | N/A |
Goodwill |  |  | 4,528 |  |  | Indefinite |  |  |  | N/A |
|  | $ | 9,788 |  |  |  |  |  |  |  |  |

Valuation of Contingent Consideration Resulting from a Business Combination

In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value within our consolidated statements of operations until such time as the specified milestone achievement period is complete.

Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.

Impairment of Long-Lived Assets

The Company accounts for long-lived assets, other than goodwill and intangible assets, and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use or right-of-use assets are present. The Company reviews long-lived assets and right-of-use assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the statements of operations. There were no impairment charges during the years ended December 31, 2021 and 2020, respectively.

19

Table of Contents

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.

Revenue Recognition

Revenue generated through the Company’s webstores, primarily Avenova.com and DERMAdoctor.com, is recognized upon fulfillment, which generally occurs upon delivery of the related products to multiple third-party carriers. Shipping and handling costs are expensed as incurred and included in cost of goods sold in the consolidated statements of operations and comprehensive loss. We present revenue net of sales taxes and refunds.

Revenue generated through third-party online retailers is also recognized upon fulfillment, which generally occurs upon delivery of the related products to a third-party carrier. We present revenue net of commissions and any related fulfillment and shipping fees charged by these partners. Fees paid to partners for promoting our product are expensed as incurred and are included in sales and marketing expenses within the operating expenses in the consolidated statements of operations and comprehensive loss.

The Company also generates Avenova Spray revenue through major pharmacy distribution partners. Product supply of Avenova Spray is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon delivery to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor.

Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer.

Revenue for product sales to other retailers is generally recognized upon transfer of control to the retailer, which generally occurs upon delivery of the related products to a third-party carrier, net of estimated future product returns.

The following table summarizes the activity in the accounts related to product revenue allowances (in thousands):

|  | Wholesaler/ Pharmacy fees |  |  | Cash discounts |  |  | Rebate |  |  | Returns |  |  | Total |
Balance at December 31, 2020 |  | $ | (91 | ) |  | $ | (10 | ) |  | $ | 55 |  |  | $ | (527 | ) |  | $ | (573 | )
Current provision related to sales made during current period |  |  | (249 | ) |  |  | (60 | ) |  |  | (723 | ) |  |  | (819 | ) |  |  | (1,851 | )
Payments |  |  | 256 |  |  |  | 57 |  |  |  | 293 |  |  |  | 548 |  |  |  | 1,154 |
Balance at December 31, 2021 |  | $ | (84 | ) |  | $ | (13 | ) |  | $ | (375 | ) |  | $ | (798 | ) |  | $ | (1,270 | )

20

Table of Contents

Cost of Goods Sold

Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, and other costs associated with products sold. Cost of goods sold also includes any necessary allowance for excess and obsolete inventory along with lower of cost and estimated net realizable value.

Research and Development Costs

The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development, and regulatory activities, including submissions to the Food and Drug Administration (“FDA”).

Stock-Based Compensation

The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s consolidated statements of stockholders’ equity based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 15, “Equity-Based Compensation” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for further information regarding stock-based compensation expense and the assumptions used in estimating that expense. The Company accounts for RSUs issued to employees and non-employees (consultants and advisory board members) based on the fair market value of the Company’s common stock as of the date of issuance.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

Common Stock Warrant Liabilities

The Company accounts for common stock warrants issued in connection with its equity offerings in accordance with the provisions of Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging.

The Company accounts for common stock warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, which encompasses the provisions of ASC 480, Distinguishing Liabilities from Equity.

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).

For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment.

Recent Accounting Pronouncements

See Note 2, “Summary of Significant Accounting Policies”, in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for information on recent accounting pronouncements.

21

Table of Contents

Results of Operations

Comparison of Years Ended December 31, 2021 and 2020

|  | Year Ended December 31, |  |  | Dollar |  |  | Percent |
|  | 2021 |  |  | 2020 |  |  | Change |  |  | Change |
|  | (in thousands) |  |  | (in thousands) |  |  |  |  |
Statement of Operations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 8,397 |  |  | $ | 9,916 |  |  | $ | (1,519 | ) |  |  | (15 | %)
Other revenue, net |  |  | 24 |  |  |  | 18 |  |  |  | 6 |  |  |  | 33 | %
Total sales, net |  |  | 8,421 |  |  |  | 9,934 |  |  |  | (1,513 | ) |  |  | (15 | %)
Cost of goods sold |  |  | 2,776 |  |  |  | 3,970 |  |  |  | (1,194 | ) |  |  | (30 | %)
Gross profit |  |  | 5,645 |  |  |  | 5,964 |  |  |  | (319 | ) |  |  | (5 | %)
Research and development |  |  | 44 |  |  |  | 285 |  |  |  | (241 | ) |  |  | (85 | %)
Sales and marketing |  |  | 7,223 |  |  |  | 6,173 |  |  |  | 1,050 |  |  |  | 17 | %
General and administrative |  |  | 7,240 |  |  |  | 5,932 |  |  |  | 1,308 |  |  |  | 22 | %
Total operating expenses |  |  | 14,507 |  |  |  | 12,390 |  |  |  | 2,117 |  |  |  | 17 | %
Operating loss |  |  | (8,862 | ) |  |  | (6,426 | ) |  |  | (2,436 | ) |  |  | 38 | %
Non-cash gain (loss) on changes in fair value of warrant liability |  |  | 4,615 |  |  |  | (5,216 | ) |  |  | 9,831 |  |  |  | (188 | %)
Non-cash gain on changes in fair value of embedded derivative liability |  |  | - |  |  |  | 3 |  |  |  | (3 | ) |  |  | (100 | %)
Other (expense) income, net |  |  | (1,577 | ) |  |  | 605 |  |  |  | (2,182 | ) |  |  | (361 | %)
Loss before provision for income taxes |  |  | (5,824 | ) |  |  | (11,034 | ) |  |  | 5,210 |  |  |  | (47 | %)
Provision for income taxes |  |  | - |  |  |  | (5 | ) |  |  | 5 |  |  |  | (100 | %)
Net loss and comprehensive loss |  | $ | (5,824 | ) |  | $ | (11,039 | ) |  | $ | 5,215 |  |  |  | (47 | %)

Impact of DERMAdoctor Acquisition

The above results include the financial results of DERMAdoctor beginning at the time of the Acquisition Closing on November 5, 2021 (see Note 3, “Business Combination” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report) which includes product revenue, net, of $0.6 million, goods sold of $0.3 million, $0.2 million in sales and marketing costs and $0.3 million in general and administrative costs.

Total Net Sales, Cost of Goods Sold and Gross Profit

Product revenue, net, decreased by $1.5 million, or 15%, to $8.4 million for the year ended December 31, 2021, from $9.9 million for the year ended December 31, 2020. During the year ended December 31, 2020, we generated $3.1 million from the sale of KN95 Masks with no comparable revenue during the year ended December 31, 2021. We do not anticipate dedicating future Company resources toward the sale of KN95 Masks or other personal protective equipment and we do not expect any related future revenue.

Offsetting this decrease, revenue from Avenova Spray increased $0.8 million in 2021 from $6.0 million for the year ended December 31, 2020 to $6.8 million for the year ended December 31, 2021. The increase was the result of an overall increase in the number of Avenova Spray units sold. The increase in units sold reflects continued higher number of over-the-counter and physician dispensed units sold, partially offset by continued decrease in the number of units sold through pharmacy channels. The increase in over-the-counter units includes the impact of our ongoing focus and increasing spend on digital marketing and social media initiatives to promote Avenova Spray directly to end consumers. The overall increase in revenue due to unit sales was also partially offset by the lower average net selling price associated with over-the-counter and physician dispensed units as compared to units sold through our pharmacy channels.

We also recognized product revenue, net, of $0.6 million from the sale of DERMAdoctor products during the period after completion of the DERMAdoctor Acquisition on November 5, 2021, with no comparable revenue during the year ended December 31, 2020.

Cost of goods sold decreased by $1.2 million, or 30%, to $2.8 million for the year ended December 31, 2021, from $4.0 million for the year ended December 31, 2020. The decrease was primarily the result of cost of goods sold from the sale of KN95 Masks during the 2020 period, with no comparable cost in the 2021 period. This decrease was partially offset by the overall increase in the number of Avenova Spray units sold during the year ended December 31, 2021, as compared to the 2020 period. We also recognized cost of goods sold of $0.3 million from the sale of DERMAdoctor products during the period after completion of the DERMAdoctor Acquisition, with no comparable cost of goods sold during the year ended December 31, 2020.

22

Table of Contents

Gross profit decreased by $0.3 million, or 5%, to $5.6 million for the year ended December 31, 2021, from $6.0 million for the year ended December 31, 2020. The decrease reflects the lack of KN95 Mask sales during 2021, offset by an increase in sales of higher margin Avenova Spray during the 2021 period as well as the sale of DERMAdoctor products after the completion of the DERMAdoctor Acquisition.

Research and development

Research and development expenses decreased by $241 thousand, or 85%, to $44 thousand for the year ended December 31, 2021, from $285 thousand for the year ended December 31, 2020. The decrease was primarily the result of one-time regulatory expenses incurred in the 2020 period with no comparable expenditures in the 2021 period.

Sales and marketing

Sales and marketing expenses increased by $1.0 million, or 17%, to $7.2 million for the year ended December 31, 2021, from $6.2 million for the year ended December 31, 2020. This is reflective of an increase in marketing costs for Avenova branded products, primarily digital advertising, and costs associated with the Company’s relaunch of CelleRx Clinical Reset. Going forward, the Company anticipates focusing resources on the DERMAdoctor brand instead of driving growth of CelleRx Clinical Reset. The 2021 period also includes $0.2 million in sales and marketing costs incurred in connection with DERMAdoctor products during the period after the DERMAdoctor Acquisition on November 5, 2021 with no comparable expense during the year ended December 31, 2020. These increases were partially offset by a decrease in sales representative headcount and associated costs in the first quarter of 2021.

General and administrative

General and administrative expenses increased by $1.3 million, or 22%, to $7.2 million for the year ended December 31, 2021, from $5.9 million for the year ended December 31, 2020.

The increase was primarily a result of one-time costs incurred in conjunction with the DERMAdoctor Acquisition and the related financing during the year ended December 31, 2021 with no comparable expense in the 2020 period. Employee-related costs, consisting primarily of non-cash stock-based compensation costs, also increased in the 2021 period as compared to 2020. The 2021 period also includes $0.3 million in general and administrative costs incurred by DERMAdoctor during the period after the DERMAdoctor Acquisition on November 5, 2021 with no comparable costs during the year ended December 31, 2020.

These increases were partially offset overall by a decrease in 2021 in costs incurred in conjunction with a dispute with the Company’s former Interim President and Chief Executive Officer and Chief Financial Officer as further described in Note 10, “Commitments and Contingencies”, in the Notes to Consolidated Financial Statements, included in Part II, Item 8 of this report. The Company also received an insurance reimbursement for these costs which further reduced general and administrative costs in the 2021 period.

Non-cash gain (loss) on changes in fair value of warrant liability

The adjustments to the fair value of warrant liability resulted in a gain of $4.6 million for the year ended December 31, 2021 and a loss of $5.2 million for the year ended December 31, 2020. For additional information regarding the warrants and their valuation, please see Note 13, “Warrant Liability”, in the Notes to Consolidated Financial Statements, in Part II, Item 8 of this report.

Other (expense) income, net

Other (expense) income, net, was a net expense of $1.6 million for the year ended December 31, 2021 as compared to a net income of $0.6 million for the year ended December 31, 2020. The expense of $1.6 million for the year ended December 31, 2021 represented issuance costs related to the 2021 Warrants. For additional information regarding the issuance of the 2021 Warrants, please see Note 14 “Stockholders’ Equity”. During the year ended December 31, 2020, the Company recorded income of $0.9 million as the result of income recognized as qualifying expenses incurred under the PPP Loan. Please see Note 20, “Paycheck Protection Program”, to the Notes to Consolidated Financial Statements, included in Part II, Item 8 of this report.

Comparison of Years Ended December 31, 2020 and 2019

For this discussion, see the “Comparison of Years Ended December 31, 2020 and 2019 in Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Liquidity and Capital Resources

As of December 31, 2021, our cash and cash equivalents were $7.5 million, compared to $12.0 million as of December 31, 2020. Based primarily on the funds available at December 31, 2021, management believes that the Company’s existing cash and cash equivalents and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses at least through March 29, 2023. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control that impact the broader economy such as the COVID-19 pandemic and the conflict between Russia and Ukraine.

23

Table of Contents

Cash Used in Operating Activities

Net cash used in operating activities was $9.2 million for the year ended December 31, 2021, which consisted primarily of a net loss of $5.8 million, adjusted primarily by non-cash gain of $4.6 million on the change in fair value of warrant liability, stock-based compensation expenses of $0.9 million, and a net decrease of $38 thousand in our net operating assets and liabilities.

Net cash used in operating activities was $4.7 million for the year ended December 31, 2020, which consisted primarily of a net loss of $11.0 million, adjusted primarily by non-cash loss of $5.2 million on the change in fair value of warrant liability, stock-based compensation expenses of $0.5 million, issuance of RSUs for services of $0.2 million, non-cash interest expense related to amortization of debt issuance cost and debt discount of $0.2 million, and a net increase of $0.2 million in our net operating assets and liabilities.

Cash Used in Investing Activities

For the years ended December 31, 2021, cash used in investing activities was $12.0 million which was primarily the result of $12.0 million, net of cash, paid at closing of the DERMAdoctor Acquisition (see Note 3, “Business Combination” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report). Capital expenditures were $52 thousand and $26 thousand for the years ended December 31, 2021 and 2020, respectively, for the purchase of property and equipment.

Cash Provided by Financing Activities

Net cash provided by financing activities was $17.0 million for the year ended December 31, 2021. The Company received net proceeds of $14.9 million from the 2021 Private Placement. Additionally, the Company received net proceeds of $1.8 million from an at-the-market offering and equity program (“ATM Program”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”). See Note 14, “Stockholders’ Equity” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for further information regarding the 2021 Private Placement and the ATM Program.

Net cash provided by financing activities was $9.8 million for the year ended December 31, 2020. The Company received net proceeds of $5.2 million from an ATM Program, and an additional $7.1 million from the exercise of warrants. These amounts were offset by repayments of $1.5 million on the Convertible Note (as later defined) issued to Iliad Research and Trading L.P. and repayment of $1.0 million on the Promissory Note (as later defined), both paid using proceeds raised through an ATM Program with Ladenburg. See Note 14, “Stockholders’ Equity,” Note 12, “Convertible Note” and Note 11, “Related Party Note Payable” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for further information regarding the ATM Program, Convertible Note and Promissory Note.

24

Table of Contents

Quarterly Results of Operations (unaudited)

The following table presents unaudited quarterly results of operations for the eight most recent quarters ending with the quarter ended December 31, 2021. This information has been derived from our unaudited consolidated financial statements and has been prepared by us on a basis consistent with our audited annual consolidated financial statements and includes all adjustments, consisting only of normal recurring adjustments, which management considers necessary for a fair presentation of the information for the periods presented.

|  | Quarter Ended |
|  | December 31, |  |  | September 30, |  |  | June 30, |  |  | March 31, |  |  | December 31, |  |  | September 30, |  |  | June 30, |  |  | March 31, |
|  | 2021 |  |  | 2021 |  |  | 2021 |  |  | 2021 |  |  | 2020 |  |  | 2020 |  |  | 2020 |  |  | 2020 |
|  | (in thousands, except per share data) |
Statements of Operations Data: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 2,636 |  |  | $ | 1,834 |  |  | $ | 2,126 |  |  | $ | 1,801 |  |  | $ | 1,878 |  |  | $ | 2,167 |  |  | $ | 3,979 |  |  | $ | 1,892 |
Other revenue, net |  |  | 5 |  |  |  | 6 |  |  |  | 7 |  |  |  | 6 |  |  |  | 10 |  |  |  | 3 |  |  |  | 5 |  |  |  | — |
Total sales, net |  |  | 2,641 |  |  |  | 1,840 |  |  |  | 2,133 |  |  |  | 1,807 |  |  |  | 1,888 |  |  |  | 2,170 |  |  |  | 3,984 |  |  |  | 1,892 |
Cost of goods sold |  |  | 1,214 |  |  |  | 493 |  |  |  | 614 |  |  |  | 455 |  |  |  | 813 |  |  |  | 536 |  |  |  | 2,040 |  |  |  | 581 |
Gross profit |  |  | 1,427 |  |  |  | 1,347 |  |  |  | 1,519 |  |  |  | 1,352 |  |  |  | 1,075 |  |  |  | 1,634 |  |  |  | 1,944 |  |  |  | 1,311 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  | 9 |  |  |  | 10 |  |  |  | 21 |  |  |  | 5 |  |  |  | 36 |  |  |  | 125 |  |  |  | 115 |  |  |  | 9 |
Sales and marketing |  |  | 1,900 |  |  |  | 1,855 |  |  |  | 1,788 |  |  |  | 1,680 |  |  |  | 1,498 |  |  |  | 1,692 |  |  |  | 1,423 |  |  |  | 1,560 |
General and administrative |  |  | 2,713 |  |  |  | 1,771 |  |  |  | 1,569 |  |  |  | 1,187 |  |  |  | 1,299 |  |  |  | 1,879 |  |  |  | 1,477 |  |  |  | 1,277 |
Total operating expenses |  |  | 4,622 |  |  |  | 3,636 |  |  |  | 3,378 |  |  |  | 2,872 |  |  |  | 2,833 |  |  |  | 3,696 |  |  |  | 3,015 |  |  |  | 2,846 |
Operating loss |  |  | (3,195 | ) |  |  | (2,289 | ) |  |  | (1,859 | ) |  |  | (1,520 | ) |  |  | (1,758 | ) |  |  | (2,062 | ) |  |  | (1,071 | ) |  |  | (1,535 | )
Non-cash gain (loss) on changes in fair value of warrant liability |  |  | 4,615 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 8 |  |  |  | (1,589 | ) |  |  | (3,772 | ) |  |  | 137 |
Non-cash gain (loss) on changes in fair value of embedded derivative liability |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  |  |  |  |  | — |  |  |  | 2 |
Other (expense) income, net |  |  | (1,579 | ) |  |  | — |  |  |  | — |  |  |  | 2 |  |  |  | — |  |  |  | 429 |  |  |  | 362 |  |  |  | (186 | )
Loss before provision for income taxes |  |  | (159 | ) |  |  | (2,289 | ) |  |  | (1,859 | ) |  |  | (1,518 | ) |  |  | (1,750 | ) |  |  | (3,221 | ) |  |  | (4,481 | ) |  |  | (1,582 | )
Provision for income taxes |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (4 | ) |  |  | — |  |  |  | (1 | ) |  |  | — |
Net loss |  | $ | (159 | ) |  | $ | (2,289 | ) |  | $ | (1,859 | ) |  | $ | (1,518 | ) |  | $ | (1,754 | ) |  | $ | (3,221 | ) |  | $ | (4,482 | ) |  | $ | (1,582 | )
Less: Preferred deemed dividend |  |  | 735 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Net loss attributable to common stockholders |  | $ | (894 | ) |  | $ | (2,289 | ) |  | $ | (1,859 | ) |  | $ | (1,518 | ) |  | $ | (1,754 | ) |  | $ | (3,221 | ) |  | $ | (4,482 | ) |  | $ | (1,582 | )
Net loss per share attributable to common stockholders: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic and diluted |  | $ | (0.02 | ) |  | $ | (0.05 | ) |  | $ | (0.04 | ) |  | $ | (0.04 | ) |  | $ | (0.04 | ) |  | $ | (0.08 | ) |  | $ | (0.15 | ) |  | $ | (0.06 | )
Shares used in computing net loss per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic and diluted |  |  | 45,311 |  |  |  | 44,921 |  |  |  | 42,561 |  |  |  | 41,782 |  |  |  | 41,776 |  |  |  | 40,037 |  |  |  | 30,384 |  |  |  | 27,978 |

As of December 31, 2021, we had net operating loss carryforwards for federal and state income tax purposes of $125.9 million and $106.8 million, respectively. The federal net operating loss carryforwards consist of $94.9 million generated before January 1, 2018, which will begin to expire in 2024 and $31.0 million that will carryforward indefinitely but are subject to an 80% limitation for years following December 31, 2021. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) changed net loss carryforward provisions, allowing a full utilization of NOL carryforwards through December 31, 2020. The state net operating loss carryforwards will begin to expire in 2028. As of December 31, 2021, we also had tax credit carryforwards for federal income tax purposes of $1.3 million and $0.3 million for state tax purposes. If not utilized, the federal tax credits will begin expiring in 2026. The state tax credits have an indefinite carryover period.

Current federal and California tax laws include substantial restrictions on the utilization of net operating loss carryforwards in the event of an ownership change of a corporation. Accordingly, our ability to utilize net operating loss carryforwards may be limited as a result of such ownership changes. Such a limitation could result in the expiration of carryforwards before they are utilized.

25

Table of Contents

Inflation

We do not believe that inflation has had a material impact on our business and operating results during the periods presented, and we do not expect it to have a material impact in the near future, although there can be no assurances that our business will not be affected by inflation in the future.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements at December 31, 2021 and December 31, 2020 as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

Seasonality

Avenova Branded Products

Consistent with our peers in the United States pharmaceutical industry, prescriptions for Avenova Spray experience seasonality with the first quarter of each year typically being the lowest revenue quarter. This annual phenomenon is due to consumers facing the need to satisfy health insurance deductibles and changes to copays as each new insurance year begins. Sales of Avenova Spray through non-prescription channels, along with the other Avenova branded products, experience less seasonality with demands consistent throughout the year.

Dermatology/Skincare Products

Our DERMAdoctor products are sold through wholesale distribution relationships with third parties such as Costco, Amazon and others; therefore, we may receive periodic large orders that result in large chunks of revenue that are received in irregular intervals during the year. Historically sales of DERMAdoctor products that contain sunscreen and antiperspirants are higher in the summer seasons and sales of DERMAdoctor products that contain moisturizers are higher in the fall and winter months. In addition, DERMAdoctor products will typically experience an uptick in sales during the fourth quarter around the holidays of each country in which its products are sold, particularly in the United States and China.

Contractual Obligations

Our contractual cash commitments as of December 31, 2021 were as follows (in thousands):

Contractual Obligations |  | Less than 1 year |  |  | 1-3 years |  |  | 3-5 years |  |  | More than 5 years |  |  | Total |
Facility leases |  | $ | 203 |  |  | $ | 259 |  |  | $ | — |  |  | $ | — |  |  | $ | 462 |
Equipment leases |  |  | 13 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 13 |
Total |  | $ | 216 |  |  | $ | 259 |  |  | $ | — |  |  | $ | — |  |  | $ | 475 |

Our commitments as of December 31, 2021 consisted primarily of facility operating leases and an operating lease for two copiers.

The total commitment for the facility leases were $0.5 million due over the leases’ terms as of December 31, 2021 and December 31, 2020, respectively. Our corporate headquarters lease was subsequently amended on January 19, 2022, which included extending the lease term until 2027.

We had an operating lease for two copiers as of December 31, 2021. The total commitment for the lease as of December 31, 2021 was $13 thousand due over the lease terms, compared to $29 thousand as of December 31, 2020.

See Note 10, “Commitments and Contingencies” and Note 22, “Subsequent Events” in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for further information regarding these leases.

ITEM 7A. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our market risk consists principally of interest rate risk on our cash and cash equivalents. Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in interest rates, particularly because our current liquid assets at December 31, 2021 were held in cash and cash equivalents.

Our investment policy restricts our investments to high-quality investments and limits the amounts invested with any one issuer, industry, or geographic area. The goals of our investment policy are as follows: preservation of capital, assurance of liquidity needs, best available return on invested capital, and minimization of capital taxation. Some of the securities in which we invest may be subject to market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with an interest rate fixed at the then-prevailing rate and the prevailing interest rate later rises, the principal amount of our investment will probably decline. To minimize this risk, in accordance with our investment policy, we maintain our cash and cash equivalents in short-term marketable securities, including money market mutual funds, Treasury bills, Treasury notes, certificates of deposit, commercial paper, and corporate and municipal bonds. The risk associated with fluctuating interest rates is limited to our investment portfolio. Due to the short-term nature of our investment portfolio, we believe we have minimal interest rate risk arising from our investments. As of December 31, 2021 and 2020, a 10% change in interest rates would have had an immaterial effect on the value of our investment portfolio. We do not use derivative financial instruments in our investment portfolio. We do not hold any instruments for trading purposes.

With most of our focus on the domestic U.S. market, we have not had any material exposure to foreign currency rate fluctuations.

26

Table of Contents

ITEM 8. | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements required by this Item 8 are set forth below. Our quarterly financial information is set forth in Item 7 of this report and is hereby incorporated into this Item 8 by reference.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page
Reports of Independent Registered Public Accounting Firms | 28
Consolidated Balance Sheets as of December 31, 2021 and 2020 | 32
Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021, 2020 and 2019 | 33
Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2021, 2020 and 2019 | 34
Consolidated Statements of Cash Flows for the Years Ended December 31, 2021, 2020 and 2019 | 35
Notes to Consolidated Financial Statements | 37

27

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors

NovaBay Pharmaceuticals Inc.

Emeryville, California

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of NovaBay Pharmaceuticals Inc. (the “Company”) as of December 31, 2021, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for the year ended December 31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and the results of its operations and its cash flows for the year ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America.

The consolidated financial statements of the Company as of December 31, 2020 and for each of the two years in the period ended December 31, 2020 were audited by OUM & Co. LLP, who joined WithumSmith+Brown PC on July 15, 2021, and rendered their opinion on such statements on March 25, 2021.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements whether due to error or fraud and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Acquisition of DERMAdoctor, LLC – Valuation of Certain Intangible Assets

Description of the Matter

As described in Note 3 to the consolidated financial statements, the Company completed the acquisition of DERMAdoctor, LLC. (“DERMAdoctor”) on November 5, 2021. The acquisition was accounted for under the acquisition method of accounting for business combinations. Accordingly, the purchase price was allocated to the assets acquired and liabilities assumed based on their respective fair values, including $2.1 million for the DERMAdoctor trade names and $2.9 million for proprietary product formulations.

28

Table of Contents

Auditing the Company’s accounting for the acquisition was complex due to the significant estimates and assumptions management made to determine the fair value of the DERMAdoctor trade names and proprietary product formulations. Trade names were valued using the relief-from-royalty method and proprietary product formulations were valued using the multi-period excess earnings model. The determination of the fair value of these intangible assets required management to make significant estimates and assumptions related to forecasted sales growth rates, cash flows, market-based royalty rates, and estimated discount rates. These significant assumptions are forward looking and could be affected by future economic and market conditions.

How We Addressed the Matter in Our Audit

We obtained an understanding of the Company’s accounting for the acquisition, including reviewing the purchase agreement, evaluating the significant assumptions and methods used in developing the fair value estimates, and testing the recognition of (1) the tangible assets acquired and liabilities assumed at fair value; (2) the identifiable intangible assets acquired at fair value; (3) the fair value of contingent consideration (as discussed below) and (4) goodwill measured as a residual.

To test the estimated fair value of the trade names and proprietary product formulations intangible assets, we performed audit procedures that included, among others, assessing the appropriateness of the valuation methodologies used and testing the significant assumptions used in the model, including the completeness and accuracy of the underlying data. For example, we compared the significant assumptions to current industry, market and economic trends, and to the historical results of the acquired business and other guideline companies. We involved our valuation specialists to assist in our evaluation of the significant assumptions and models used in the fair value estimates.

Valuation of Contingent Consideration

Description of the Matter

As described in Note 2 to the consolidated financial statements, in accounting for the acquisition of DERMAdoctor, the Company recognized contingent consideration liabilities at the estimated fair value on the acquisition date. As mentioned above, the Company applied the acquisition method of accounting for business combinations. Subsequent changes to the fair value of the contingent consideration liabilities would be recorded within the consolidated statements of operations and comprehensive loss in the period of change. The contingent consideration liability is based on the achievement of certain predetermined financial targets for the 2022 and 2023 fiscal years. At December 31, 2021, the Company recorded $0.6 million in contingent earnout liability that was associated with DERMAdoctor business combination. This amount represented a ‘Level 3’ fair value measurement in the fair value hierarchy due to the significant unobservable inputs used in determining the fair value and the use of management judgment about the assumptions market participants would use in pricing the liabilities.

Auditing the valuation of the contingent consideration liability was complex and required significant auditor judgment due to the complexity of the valuation method and the high degree of subjectivity in evaluating certain assumptions required to estimate the fair value of the contingent consideration liability. Management determined the estimated fair value of the contingent consideration liability using a Monte Carlo simulation model. The significant assumptions and estimates include the probability the Company will achieve a specified range of revenue, profitability levels, volatility and discount rate. These significant assumptions are forward looking and consider anticipated market conditions, which in turn, requires subjective auditor judgement.

How We Addressed the Matter in Our Audit

To test the estimated fair value of the contingent consideration liability, our audit procedures included, among others, inspecting the terms of the executed acquisition agreement, assessing the scenario analysis valuation method used, and testing the key inputs and significant assumptions discussed above. We involved our valuation specialists who assisted in evaluating the appropriateness of the selected valuation methodology and evaluating the reasonableness of certain significant assumptions used to estimate the fair value of the contingent consideration. We evaluated whether the assumptions and estimates used, including the probability the Company will achieve a specified range of revenue and profitability levels, by considering the past performance of the acquired business and current market forecasts, and whether such assumptions were consistent with evidence obtained in other areas of the audit.

Product Revenue Allowances for Product Returns

Description of the Matter

As described in Note 2 to the consolidated financial statements, when recognizing revenue from product sales of Avenova Spray to the Company’s major distribution partners, the Company makes an estimate of the amount of consideration the Company expects to be entitled to receive. Upon recognition of these product sales, the Company records estimates for variable consideration consisting of service fees, discounts, rebates, and product returns, resulting in a reduction in product revenue. The variable consideration provisions are recorded within accrued liabilities and in the same period that the related revenue is recognized. Liabilities related to allowance for product returns involve the use of significant assumptions and judgments in their calculation. These significant assumptions and judgments include historical sales and return rates and inventory levels in the distribution channel and utilizing existing return policies with customers.

29

Table of Contents

Management’s estimated allowance for product returns requires a high degree of judgment and is subject to change based on various quantitative and qualitative factors. Accordingly, extensive audit effort and a high degree of auditor judgment were needed to evaluate management’s estimates and assumptions used in the determination of rebates and product returns.

How We Addressed the Matter in Our Audit

We obtained an understanding of and evaluated the design of controls relating to the Company’s processes for estimating product returns. We evaluated the significant accounting policies relating to product returns, as well as management’s application of the policies, for appropriateness and reasonableness.

To test management’s estimate of product returns, we obtained management’s calculations for the estimates and performed one or more of the following procedures: clerically tested the calculation, agreed relevant inputs to the terms of relevant policies, assessed subsequent events related to these estimates, evaluated the methodologies and assumptions used and the underlying data used by the Company, evaluated the assumptions used by management against historical trends, evaluated the change in estimated accruals from the prior periods, and assessed the historical accuracy of the Company’s estimates against actual results.

/s WithumSmith+Brown, PC

We have served as the Company's auditor since 2010.

San Francisco California

March 29, 2022

PCAOB ID Number 100

30

Table of Contents

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors

NovaBay Pharmaceuticals, Inc.

Emeryville, California

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of NovaBay Pharmaceuticals, Inc. (the “Company”) as of December 31, 2020, and the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ OUM & CO. LLP

We served as the Company's auditor since 2010.

San Francisco, California

March 25, 2021

PCAOB ID Number 252

31

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except par value amounts)

|  | December 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
ASSETS |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 7,504 |  |  | $ | 11,952 |
Accounts receivable, net of allowance for doubtful accounts ($0 at December 31, 2021 and December 31, 2020) |  |  | 1,668 |  |  |  | 1,106 |
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($641 and $236 at December 31, 2021 and December 31, 2020, respectively) |  |  | 3,220 |  |  |  | 608 |
Prepaid expenses and other current assets |  |  | 778 |  |  |  | 576 |
Total current assets |  |  | 13,170 |  |  |  | 14,242 |
Operating lease right-of-use assets |  |  | 411 |  |  |  | 436 |
Property and equipment, net |  |  | 193 |  |  |  | 84 |
Goodwill |  |  | 4,528 |  |  |  | — |
Other intangible assets, net |  |  | 5,200 |  |  |  | — |
Other assets |  |  | 476 |  |  |  | 476 |
TOTAL ASSETS |  | $ | 23,978 |  |  | $ | 15,238 |
LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |  |  |  |  |  |
Liabilities: |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,045 |  |  | $ | 302 |
Accrued liabilities |  |  | 2,092 |  |  |  | 2,115 |
Line of credit |  |  | 105 |  |  |  | — |
Operating lease liabilities |  |  | 200 |  |  |  | 416 |
Total current liabilities |  |  | 3,442 |  |  |  | 2,833 |
Operating lease liabilities-non-current |  |  | 246 |  |  |  | 87 |
Warrant liability |  |  | 9,558 |  |  |  | — |
Contingent earnout liability |  |  | 561 |  |  |  | — |
Total liabilities |  |  | 13,807 |  |  |  | 2,920 |
Commitments & contingencies (Note 10) |  |  |  |  |  |  |  |
Stockholders' equity: |  |  |  |  |  |  |  |
Preferred stock, $0.01 par value; 5,000 shares authorized; 14 and 0 issued and outstanding at December 31, 2021 and December 31, 2020, respectively |  |  | 680 |  |  |  | — |
Common stock, $0.01 par value; 100,000 and 75,000 shares authorized, 47,766 and 41,782 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively |  |  | 478 |  |  |  | 418 |
Additional paid-in capital |  |  | 150,900 |  |  |  | 147,963 |
Accumulated deficit |  |  | (141,887 | ) |  |  | (136,063 | )
Total stockholders' equity |  |  | 10,171 |  |  |  | 12,318 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |  | $ | 23,978 |  |  | $ | 15,238 |

The accompanying notes are an integral part of these consolidated financial statements.

32

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands except per share data)

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Sales: |  |  |  |  |  |  |  |  |  |  |  |
Product revenue, net |  | $ | 8,397 |  |  | $ | 9,916 |  |  | $ | 6,556 |
Other revenue, net |  |  | 24 |  |  |  | 18 |  |  |  | 43 |
Total sales, net |  |  | 8,421 |  |  |  | 9,934 |  |  |  | 6,599 |
Cost of goods sold |  |  | 2,776 |  |  |  | 3,970 |  |  |  | 1,738 |
Gross profit |  |  | 5,645 |  |  |  | 5,964 |  |  |  | 4,861 |
Research and development |  |  | 44 |  |  |  | 285 |  |  |  | 184 |
Sales and marketing |  |  | 7,223 |  |  |  | 6,173 |  |  |  | 8,767 |
General and administrative |  |  | 7,240 |  |  |  | 5,932 |  |  |  | 5,310 |
Total operating expenses |  |  | 14,507 |  |  |  | 12,390 |  |  |  | 14,261 |
Operating loss |  |  | (8,862 | ) |  |  | (6,426 | ) |  |  | (9,400 | )
Non-cash gain (loss) on changes in fair value of warrant liability |  |  | 4,615 |  |  |  | (5,216 | ) |  |  | 749 |
Non-cash gain on changes in fair value of embedded derivative liability |  |  | — |  |  |  | 3 |  |  |  | 424 |
Other (expense) income, net |  |  | (1,577 | ) |  |  | 605 |  |  |  | (1,425 | )
Loss before provision for income taxes |  |  | (5,824 | ) |  |  | (11,034 | ) |  |  | (9,652 | )
Provision for income taxes |  |  | — |  |  |  | (5 | ) |  |  | (6 | )
Net loss and comprehensive loss |  | $ | (5,824 | ) |  | $ | (11,039 | ) |  | $ | (9,658 | )
Less: Preferred deemed dividend |  |  | 735 |  |  |  | — |  |  |  | 800 |
Less: Retained earnings reduction related to warrants down round feature triggered |  |  | — |  |  |  | — |  |  |  | 29 |
Net loss attributable to common stockholders |  | $ | (6,559 | ) |  | $ | (11,039 | ) |  | $ | (10,487 | )
Net loss per share attributable to common stockholders (basic and diluted) |  | $ | (0.15 | ) |  | $ | (0.31 | ) |  | $ | (0.48 | )
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) |  |  | 43,657 |  |  |  | 35,076 |  |  |  | 21,641 |

The accompanying notes are an integral part of these consolidated financial statements.

33

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(in thousands)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Additional |  |  |  |  |  |  | Total |
|  | Preferred Stock |  |  | Common Stock |  |  | Paid-In |  |  | Accumulated |  |  | Stockholders' |
|  | Shares |  |  | Amount |  |  | Shares |  |  | Amount |  |  | Capital |  |  | Deficit |  |  | Equity |
Balance at December 31, 2018 |  |  | — |  |  | $ | — |  |  |  | 17,089 |  |  | $ | 171 |  |  | $ | 119,764 |  |  | $ | (114,981 | ) |  | $ | 4,954 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9,658 | ) |  |  | (9,658 | )
Reclassification of warrant liability to equity related to adoption of ASU 2017-11 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 412 |  |  |  | (356 | ) |  |  | 56 |
Down round feature adjustment related to warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 29 |  |  |  | (29 | ) |  |  | — |
Issuance of Series A Preferred Stock and common stock warrants, net of offering costs |  |  | 2,700 |  |  |  | 584 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Conversion of Series A Preferred Stock to common stock |  |  | (2,700 | ) |  |  | (584 | ) |  |  | 2,700 |  |  |  | 27 |  |  |  | 557 |  |  |  | — |  |  |  | 584 |
Beneficial conversion feature upon issuance of Series A Preferred Stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 800 |  |  |  | — |  |  |  | 800 |
Deemed dividend from beneficial conversion feature of Series A Preferred Stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (800 | ) |  |  | — |  |  |  | (800 | )
Issuance of common stock in connection with offering, net of offering costs |  |  | — |  |  |  | — |  |  |  | 7,467 |  |  |  | 75 |  |  |  | 3,427 |  |  |  | — |  |  |  | 3,502 |
Issuance of common stock in connection with exercise of warrants |  |  | — |  |  |  | — |  |  |  | 389 |  |  |  | 4 |  |  |  | 616 |  |  |  | — |  |  |  | 620 |
Issuance of RSUs related to employee separation agreement |  |  | — |  |  |  | — |  |  |  | 168 |  |  |  | 2 |  |  |  | 218 |  |  |  | — |  |  |  | 220 |
Issuance of common stock for option exercises |  |  | — |  |  |  | — |  |  |  | 83 |  |  |  | — |  |  |  | 189 |  |  |  | — |  |  |  | 189 |
Issuance of RSUs to non-employees for services |  |  | — |  |  |  | — |  |  |  | 36 |  |  |  | — |  |  |  | 20 |  |  |  | — |  |  |  | 20 |
Vesting of employee restricted stock awards |  |  | — |  |  |  | — |  |  |  | 6 |  |  |  | — |  |  |  | 10 |  |  |  | — |  |  |  | 10 |
Stock-based compensation expense related to employee and director stock options |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 334 |  |  |  | — |  |  |  | 334 |
Stock-based compensation expense related to non-employee stock options |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 37 |  |  |  | — |  |  |  | 37 |
Stock option modification |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 105 |  |  |  | — |  |  |  | 105 |
Balance at December 31, 2019 |  |  | — |  |  | $ | — |  |  |  | 27,938 |  |  | $ | 279 |  |  | $ | 125,718 |  |  | $ | (125,024 | ) |  | $ | 973 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (11,039 | ) |  |  | (11,039 | )
Reclassification of warrant liability to equity related to warrant modification |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 197 |  |  |  | — |  |  |  | 197 |
Issuance of common stock, net of offering costs |  |  | — |  |  |  | — |  |  |  | 5,838 |  |  |  | 58 |  |  |  | 5,162 |  |  |  | — |  |  |  | 5,220 |
Issuance of common stock in connection with exercise of warrants, net |  |  | — |  |  |  | — |  |  |  | 7,791 |  |  |  | 78 |  |  |  | 16,128 |  |  |  | — |  |  |  | 16,206 |
Issuance of RSUs to non-employees for services |  |  | — |  |  |  | — |  |  |  | 193 |  |  |  | 2 |  |  |  | 218 |  |  |  | — |  |  |  | 220 |
Issuance of stock for option exercises |  |  | — |  |  |  | — |  |  |  | 20 |  |  |  | 1 |  |  |  | 6 |  |  |  | — |  |  |  | 7 |
Vesting of employee restricted stock awards |  |  | — |  |  |  | — |  |  |  | 2 |  |  |  | — |  |  |  | 2 |  |  |  | — |  |  |  | 2 |
Stock-based compensation expense related to employee and director stock options |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 415 |  |  |  | — |  |  |  | 415 |
Stock-based compensation expense related to non-employee stock options |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 64 |  |  |  | — |  |  |  | 64 |
Stock option modification |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 53 |  |  |  | — |  |  |  | 53 |
Balance at December 31, 2020 |  |  | — |  |  | $ | — |  |  |  | 41,782 |  |  | $ | 418 |  |  | $ | 147,963 |  |  | $ | (136,063 | ) |  | $ | 12,318 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5,824 | ) |  |  | (5,824 | )
Issuance of warrants in connection with TLF warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 13 |  |  |  | — |  |  |  | 13 |
Issuance of common stock, net of offering costs |  |  | — |  |  |  | — |  |  |  | 2,673 |  |  |  | 27 |  |  |  | 1,749 |  |  |  | — |  |  |  | 1,776 |
Vesting of employee restricted stock awards |  |  | — |  |  |  | — |  |  |  | 160 |  |  |  | 2 |  |  |  | (2 | ) |  |  | — |  |  |  | — |
Issuance of RSUs to non-employees for services |  |  | — |  |  |  | — |  |  |  | 328 |  |  |  | 3 |  |  |  | 217 |  |  |  | — |  |  |  | 220 |
Issuance of Series B Preferred Stock and common stock warrants, net of offering costs |  |  | 15 |  |  |  | 735 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 735 |
Conversion of Series B Preferred Stock to common stock |  |  | (1 | ) |  |  | (55 | ) |  |  | 2,823 |  |  |  | 28 |  |  |  | 27 |  |  |  | — |  |  |  | — |
Beneficial conversion feature upon Issuance of Series B Preferred Stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 735 |  |  |  | — |  |  |  | 735 |
Deemed dividend from beneficial Conversion feature of Series B Preferred Stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (735 | ) |  |  | — |  |  |  | (735 | )
Stock-based compensation expense related to employee and director stock options |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 693 |  |  |  | — |  |  |  | 693 |
Stock-based compensation expense related to non-employee stock options |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 240 |  |  |  | — |  |  |  | 240 |
Balance at December 31, 2021 |  |  | 14 |  |  | $ | 680 |  |  |  | 47,766 |  |  | $ | 478 |  |  | $ | 150,900 |  |  | $ | (141,887 | ) |  | $ | 10,171 |

The accompanying notes are an integral part of these consolidated financial statements.

34

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

|  | Year ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (5,824 | ) |  | $ | (11,039 | ) |  | $ | (9,658 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 119 |  |  |  | 51 |  |  |  | 65 |
Gain from early operating lease termination |  |  | — |  |  |  | (54 | ) |  |  | — |
Impairment of property and equipment |  |  | — |  |  |  | — |  |  |  | 32 |
Loss on disposal of property and equipment |  |  | — |  |  |  | 1 |  |  |  | 3 |
Impairment of operating lease right-of-use assets |  |  | — |  |  |  | — |  |  |  | 125 |
Stock-based compensation expense for options and stock issued to employees and directors |  |  | 693 |  |  |  | 415 |  |  |  | 334 |
Stock-based compensation expense for options and stock issued to non-employees |  |  | 240 |  |  |  | 64 |  |  |  | 37 |
Stock option modification expense |  |  | — |  |  |  | 53 |  |  |  | 105 |
Issuance of RSUs to employees |  |  | — |  |  |  | 2 |  |  |  | 10 |
Issuance of RSUs related to employee separation agreement |  |  | — |  |  |  | — |  |  |  | 220 |
Issuance of RSUs to non-employees for services |  |  | 233 |  |  |  | 220 |  |  |  | 20 |
Non-cash (gain) loss on changes in fair value of warrant liability |  |  | (4,615 | ) |  |  | 5,216 |  |  |  | (749 | )
Non-cash (gain) on changes in fair value of embedded derivative liability |  |  | — |  |  |  | (3 | ) |  |  | (424 | )
Interest expense related to amortization of debt issuance and debt discount |  |  | — |  |  |  | 141 |  |  |  | 670 |
Interest expense related to amortization of debt issuance related to related party note payable |  |  | — |  |  |  | 2 |  |  |  | 18 |
Issuance of warrants for services |  |  | — |  |  |  | — |  |  |  | 59 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  | 452 |  |  |  | (317 | ) |  |  | 2,319 |
Inventory |  |  | (243 | ) |  |  | (116 | ) |  |  | (212 | )
Prepaid expenses and other current assets |  |  | (52 | ) |  |  | 310 |  |  |  | 888 |
Operating lease right-of-use assets |  |  | 25 |  |  |  | 816 |  |  |  | 861 |
Other assets |  |  | — |  |  |  | 1 |  |  |  | 9 |
Accounts payable and accrued liabilities |  |  | (163 | ) |  |  | (321 | ) |  |  | (1,841 | )
Operating lease liabilities |  |  | (57 | ) |  |  | (878 | ) |  |  | (1,066 | )
Deferred rent |  |  | — |  |  |  | — |  |  |  | — |
Related party note payable |  |  | — |  |  |  | 73 |  |  |  | 204 |
Long-term obligations |  |  | — |  |  |  | — |  |  |  | 42 |
Net cash used in operating activities |  |  | (9,192 | ) |  |  | (4,721 | ) |  |  | (7,929 | )
Investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Acquisition, net of cash |  |  | (11,993 | ) |  |  | — |  |  |  | — |
Purchases of property and equipment |  |  | (52 | ) |  |  | (26 | ) |  |  | (19 | )
Net cash used in investing activities |  |  | (12,045 | ) |  |  | (26 | ) |  |  | (19 | )
Financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from preferred stock issuances, net |  |  | 14,908 |  |  |  | — |  |  |  | 2,598 |
Proceeds from common stock issuances, net |  |  | 1,776 |  |  |  | 5,220 |  |  |  | 6,698 |
Proceeds from exercise of warrants |  |  | — |  |  |  | 7,098 |  |  |  | 67 |
Proceeds from exercise of options, net |  |  | — |  |  |  | 7 |  |  |  | 189 |
Proceeds from issuance of related party note payable |  |  | — |  |  |  | — |  |  |  | 1,000 |
Proceeds from stock options & RSUs sold to cover taxes |  |  | — |  |  |  | — |  |  |  | 4 |
Proceeds from convertible notes, net of discount |  |  | — |  |  |  | — |  |  |  | 2,000 |
Proceeds from line of credit |  |  | 105 |  |  |  | — |  |  |  | — |
Payment on the convertible note (Note 12) |  |  | — |  |  |  | (1,563 | ) |  |  | (652 | )
Payment on the related party loan (Note 11) |  |  | — |  |  |  | (1,000 | ) |  |  | — |
Debt issuance cost |  |  | — |  |  |  | — |  |  |  | (202 | )
Net cash provided by financing activities |  |  | 16,789 |  |  |  | 9,762 |  |  |  | 11,702 |
Net (decrease) increase in cash, cash equivalents, and restricted cash |  |  | (4,448 | ) |  |  | 5,015 |  |  |  | 3,754 |
Cash, cash equivalents and restricted cash, beginning of year |  |  | 12,427 |  |  |  | 7,412 |  |  |  | 3,658 |
Cash, cash equivalents and restricted cash, end of year |  | $ | 7,979 |  |  | $ | 12,427 |  |  | $ | 7,412 |

35

Table of Contents

|  | Year ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |  |  |  |  |  |  |
Interest paid |  | $ | — |  |  | $ | 49 |  |  | $ | 148 |
Income taxes paid |  | $ | 21 |  |  | $ | 14 |  |  | $ | 14 |

|  | Year ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Supplemental disclosure of non-cash information: |  |  |  |  |  |  |  |  |  |  |  |
Warrant liability transferred to equity in connection with exercise of warrants |  | $ | — |  |  | $ | 9,108 |  |  | $ | 553 |
Warrant liability transferred to equity related to warrant modification |  | $ | — |  |  | $ | 197 |  |  | $ | — |
Non-cash payment of related party loan accrued interest by offsetting related party accounts receivables - see Note 11 |  | $ | — |  |  | $ | 277 |  |  | $ | — |
Cumulative effect of adoption of ASU 2017-11 |  | $ | — |  |  | $ | — |  |  | $ | 56 |
Addition of operating lease, right-of-use asset |  | $ | 376 |  |  | $ | — |  |  | $ | 2,473 |
Fixed asset purchases, included in accounts payable and accrued liabilities |  | $ | — |  |  | $ | — |  |  | $ | 10 |
Fair value of warrants issued in connection with financings |  | $ | 14,172 |  |  | $ | — |  |  | $ | 5,269 |
Conversion of preferred stock to common stock |  | $ | 55 |  |  | $ | — |  |  | $ | 584 |
Reclassification of EmeryStation lease security deposit from long term to short term |  | $ | — |  |  | $ | — |  |  | $ | 65 |
Reclassification of EmeryStation sublease security deposit from long term to short term |  | $ | — |  |  | $ | — |  |  | $ | 198 |

The accompanying notes are an integral part of these consolidated financial statements.

36

Table of Contents

NOVABAY PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION

NovaBay Pharmaceuticals, Inc. develops and sells scientifically-created and clinically-proven eyecare and skincare products. Our leading product, Avenova® Antimicrobial Lid and Lash Solution (“Avenova Spray”), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is formulated with our proprietary, stable and pure form of hypochlorous acid and is cleared by the U.S. Food and Drug Administration (“FDA”) for sale in the United States. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. Other eyecare products offered under the Avenova eyecare brand include Novawipes by Avenova, Avenova Lubricant Eye Drops, Avenova Moist Heating Eye Compress, and the i-Chek.

On November 5, 2021, we significantly expanded our business by acquiring DERMAdoctor, LLC (“DERMAdoctor”) (the “DERMAdoctor Acquisition”). DERMAdoctor offers over 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration and keratosis pilaris. DERMAdoctor branded products are marketed and sold through the DERMAdoctor website, well-known traditional and digital beauty retailers, and a network of international distributors. See Note 3, “Business Combination” below.

The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, it changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In June 2010, the Company changed the state in which it was incorporated (the “Reincorporation”) and is now incorporated under the laws of the State of Delaware. All references to “the Company” herein refer to the California corporation prior to the date of the Reincorporation and to the Delaware corporation on and after the date of the Reincorporation. The Company is managed as a single segment focused on commercializing Avenova Spray in the United States.

Liquidity

Based primarily on the funds available at December 31, 2021, management believes that the Company’s existing cash and cash equivalents and cash flows generated from product sales will be sufficient to enable the Company to meet its planned operating expenses at least through March 29, 2023. However, changing circumstances may cause the Company to expend cash significantly faster than currently anticipated, and the Company may need to spend more cash than currently expected because of circumstances beyond its control. Additionally, our future results, cash expenditures and ability to obtain additional external financing could be adversely affected by the COVID-19 pandemic and general adverse economic conditions.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars.

Use of Estimates

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, the fair value of contingent consideration, intangible assets, and goodwill, stock-based compensation, income taxes and other contingencies

These estimates are based on management’s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Cash, Cash Equivalents, and Restricted Cash

The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of December 31, 2021 and 2020, the Company’s cash and cash equivalents were held in a highly-rated, major financial institution in the United States.

37

Table of Contents

The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows (in thousands):

|  | December 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Cash and cash equivalents |  | $ | 7,504 |  |  | $ | 11,952 |
Restricted cash included in other assets |  |  | 475 |  |  |  | 475 |
Total cash, cash equivalents, and restricted cash in the consolidated statements of cash flows |  | $ | 7,979 |  |  | $ | 12,427 |

The restricted cash amount included in other assets on the consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.

Concentrations of Credit Risk and Major Partners

Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States.

Deposits in this bank may exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institution in which the deposits are held.

During the year ended December 31, 2021, revenues were derived primarily from sales of Avenova Spray directly to doctors through the Company’s webstore, directly to consumers through Amazon.com, national retailers and to pharmacies via three major distribution partners and specialty pharmacies. During the year ended December 31, 2020, revenues were derived primarily from sales of Avenova Spray directly to three major distribution partners, to doctors through the Company's internal sales team, and also generated revenue from the sale of KN95 Masks in response to the national need for personal protective equipment.

During the years ended December 31, 2021, 2020 and 2019, revenues from each product were as follows (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Avenova Spray |  | $ | 6,844 |  |  | $ | 5,974 |  |  | $ | 6,347 |
DERMAdoctor |  |  | 587 |  |  |  | — |  |  |  | — |
KN95 Masks |  |  | — |  |  |  | 3,124 |  |  |  | — |
NeutroPhase |  |  | 368 |  |  |  | 524 |  |  |  | 209 |
Other products |  |  | 598 |  |  |  | 294 |  |  |  | — |
Total product revenue, net |  |  | 8,397 |  |  |  | 9,916 |  |  |  | 6,556 |
Other revenue, net |  |  | 24 |  |  |  | 18 |  |  |  | 43 |
Total sales, net |  | $ | 8,421 |  |  | $ | 9,934 |  |  | $ | 6,599 |

38

Table of Contents

During the years ended December 31, 2021, 2020 and 2019, Avenova Spray revenues from our major distribution partners greater than 10% were as follows:

|  | Year Ended December 31, |
Major distribution |  | 2021 |  |  | 2020 |  |  | 2019 |
Avenova Direct via Amazon |  |  | 59 | % |  |  | 50 | % |  |  | 15 | %
Avenova distributor A |  |  | * | % |  |  | * | % |  |  | 17 | %
Avenova distributor B |  |  | * | % |  |  | * | % |  |  | 16 | %
Avenova distributor C |  |  | * | % |  |  | * | % |  |  | 15 | %

*Not greater than 10%

As of December 31, 2021 and 2020, accounts receivable from our major distribution partners and major retailers greater than 10% were as follows:

|  | Year Ended December 31, |
Major distribution partner |  | 2021 |  |  | 2020 |
Major U.S. Retailer |  |  | 33 | % |  |  | * | %
Avenova Spray Pharmacy Distributor A |  |  | 13 | % |  |  | 18 | %
Avenova Spray Pharmacy Distributor C |  |  | 11 | % |  |  | 14 | %
Chongqing Pioneer Pharma Holdings Limited |  |  | * | % |  |  | 16 | %
Avenova Spray Pharmacy Distributor B |  |  | * | % |  |  | 14 | %
Amazon |  |  | * | % |  |  | 11 | %

*Not greater than 10%

The Company relies on seven contract manufacturers to produce its products. The Company does not own any manufacturing facilities and intends to continue to rely on third parties for the supply of finished goods. Contract manufacturers may or may not be able to meet the Company’s needs with respect to timing, quantity or quality. In particular, it is possible that we may suffer from unexpected supply chain delays in light of the worldwide COVID-19 pandemic.

Fair Value of Financial Assets and Liabilities

The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, and contingent consideration. The Company’s cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities;

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and

Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).

Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Allowance for Doubtful Accounts

The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and believes are unlikely to be collected. Management recorded no reserve for accounts receivable at December 31, 2021 and December 31, 2020.

39

Table of Contents

Inventory

Inventory is comprised of (1) raw materials and supplies, such as bottles, packaging materials, labels, boxes and pumps; (2) goods in progress, which are normally filled but unlabeled bottles; and (3) finished goods. We utilize contract manufacturers to produce our products and the price paid to these manufacturers is included in inventory. Inventory is stated at the lower of cost or estimated net realizable value determined by the first-in, first-out method. At December 31, 2021 and 2020, management had recorded an allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $641 thousand and $236 thousand, respectively.

Property and Equipment, net

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the lease term.

The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.

Business Combinations

We account for business combinations using the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The acquisition method requires identifiable assets acquired and liabilities assumed be recognized and measured at fair value on the acquisition date, which is the date that the acquirer obtains control of the acquired business. The amount by which the fair value of consideration transferred as the purchase price exceeds the net fair value of assets acquired and liabilities assumed is recorded as goodwill.

The determination of estimated fair value requires us to make significant estimates and assumptions. These fair value determinations require judgment and involve the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, discount rates, and asset lives, among other items. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill.

Transaction costs associated with business combinations are expensed as they are incurred.

Goodwill and Intangible Assets

Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the acquisition date and may be subject to adjustment within the measurement period, which may be up to one year from the acquisition date. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. There were no impairment charges during the years ended December 31, 2021 and 2020, respectively.

Intangible Asset |  | Fair Value (in thousands) |  |  | Useful Life (in years) |  |  | Amortization Method |
Customer relationships |  | $ | 290 |  |  |  | 7 |  |  | Straight line |
Trade secrets / product formulations |  |  | 2,890 |  |  |  | 9 |  |  | Straight line |
Trade names |  |  | 2,080 |  |  | Indefinite |  |  |  | N/A |
Goodwill |  |  | 4,528 |  |  | Indefinite |  |  |  | N/A |
|  | $ | 9,788 |  |  |  |  |  |  |  |  |

Valuation of Contingent Consideration Resulting from a Business Combination

In connection with certain acquisitions, we may be required to pay future consideration that is contingent upon the achievement of specified milestone events. We record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each quarter thereafter, we revalue these obligations and record increases or decreases in their fair value within our Statement of Income until such time as the specified milestone achievement period is complete.

Increases or decreases in fair value of the contingent consideration liabilities can result from updates to assumptions such as the expected timing or probability of achieving the specified milestones. Significant judgment is employed in determining these assumptions as of the acquisition date and for each subsequent period. Updates to assumptions could have a significant impact on our results of operations in any given period. Actual results may differ from estimates.

Impairment of Long-Lived Assets

The Company accounts for long-lived assets, other than goodwill and intangible assets, and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use or right-of-use assets are present. The Company reviews long-lived assets and right-of-use assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the statements of operations. There were no impairment charges during the years ended December 31, 2021 and 2020, respectively.

40

Table of Contents

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.

The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.

Comprehensive Income (Loss)

ASC 220, Comprehensive Income, requires that an entity's change in equity or net assets during a period from transactions and other events from non-owner sources be reported.

Revenue Recognition

Revenue is recognized from sale of goods in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when or as the Company’s performance obligations are satisfied by transferring control of the promised goods to customers in an amount that reflects the consideration to which the Company expects to receive. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:

| i. | identify the contract(s) with a customer;

| ii. | identify the performance obligations in the contract;

| iii. | determine the transaction price;

| iv. | allocate the transaction price to the performance obligations in the contract; and

| v. | recognize revenue when (or as) the entity satisfies performance obligations.

Revenue is generated through the Company’s webstores, Avenova.com and DERMAdoctor.com, for Avenova Spray and DERMAdoctor direct to consumer sales which are recognized upon fulfillment, which generally occurs upon delivery of the related products to a third-party carrier. Shipping and handling costs are expensed as incurred and included in cost of goods sold in the consolidated statements of operations and comprehensive loss. We present revenue net of sales taxes and refunds.

Revenue generated through Amazon.com and Walmart.com is recognized upon fulfillment, which generally occurs upon delivery of the related products to a third-party carrier. We present revenue net of commissions and any related fulfillment and shipping fees charged by these partners. Fees paid to partners for promoting our products are expensed as incurred and are included in sales and marketing expenses within the operating expenses in the consolidated statements of operations and comprehensive loss.

The Company also generates Avenova Spray revenue through major pharmacy distribution partners. Product supply of Avenova Spray is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon delivery to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 days after control transfers to the distributor.

Revenue generated through the Company’s partner pharmacies is recognized when control of the product transfers to the end customer.

Revenue for product sales to other retailers, such as Costco and CVS, is generally recognized upon transfer of control to the retailer, which generally occurs upon delivery of the related products to a third-party carrier, net of estimated future product returns.

41

Table of Contents

Cost of Goods Sold

Cost of goods sold includes third-party manufacturing costs, shipping and handling costs, and other costs associated with products sold. Cost of goods sold also includes any necessary allowance for excess and obsolete inventory along with lower of cost and estimated net realizable value.

Research and Development Costs

The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”).

Patent Costs

Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss.

Advertising Costs

Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $3.2 million, $1.7 million, and $0.5 million, respectively, for the years ended December 31, 2021, 2020, and 2019.

Stock-Based Compensation

The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s consolidated statements of stockholders’ equity based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 15, “Equity-Based Compensation” for further information regarding stock-based compensation expense and the assumptions used in estimating that expense. The Company accounts for RSUs issued to employees and non-employees (consultants and advisory board members) based on the fair market value of the Company’s common stock as of the date of issuance.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.

42

Table of Contents

Common Stock Warrant Liabilities

The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging.

The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, which encompasses the provisions of ASC 480, Distinguishing Liabilities from Equity.

The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company), (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement) or (iii) do not become exercisable until the occurrence of contingent event. Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, the Company classifies as liabilities any contracts where it believes the warrants are deemed to be probable of issuance.

For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management’s judgment.

Net Loss per Share

The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”).

Basic EPS is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive.

For the year ended December 31, 2021, the Preferred Stock was excluded from the computation of diluted net income per share as their inclusion on an “if converted” basis would have been anti-dilutive. For the year ended December 31, 2021, the Preferred Stock was considered anti-dilutive as a result of such securities not having a contractual obligation to participate in losses of the Company.

43

Table of Contents

The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Numerator |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (5,824 | ) |  | $ | (11,039 | ) |  | $ | (9,658 | )
Less: Preferred deemed dividend |  |  | 735 |  |  |  | — |  |  |  | 800 |
Less: Retained earnings reduction related to warrants down round feature triggered |  |  | — |  |  |  | — |  |  |  | 29 |
Net loss attributable to common stockholders, basic and diluted |  | $ | (6,559 | ) |  | $ | (11,039 | ) |  | $ | (10,487 | )
Denominator |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares outstanding, basic and diluted |  |  | 43,657 |  |  |  | 35,076 |  |  |  | 21,641 |
Net loss per share, basic and diluted |  | $ | (0.15 | ) |  | $ | (0.31 | ) |  | $ | (0.48 | )

The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Stock options |  | 4,449 |  |  |  | 3,165 |  |  |  | 2,183 |
Stock warrants |  |  | 7,082 |  |  |  | 7,067 |  |  |  | 8,588 |
|  |  | 11,531 |  |  |  | 10,232 |  |  |  | 10,771 |

Recent Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 improved the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements. The Company adopted the new standard effective January 1, 2020, and the adoption of this guidance did not have a material impact on our consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. ASU 2016-13 is effective for the Company for annual and interim reporting periods beginning January 1, 2023. The Company will adopt the new standard effective January 1, 2023. We are currently evaluating the impact of the new guidance on our consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes. The Company adopted the new standard effective January 1, 2021, and the adoption of this guidance did not have a material impact on our consolidated financial statements.

In August 2020, FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. ASU 2020-06 also requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. ASU 2020-06 is effective for the Company in our first quarter of fiscal 2022. The Company adopted the new standard effective January 1, 2022, and the adoption of this guidance is not expected to have a material impact on our consolidated financial statements.

44

Table of Contents

NOTE 3. BUSINESS COMBINATION

On November 5, 2021, the Company completed the DERMAdoctor Acquisition. Pursuant to the Acquisition Purchase Agreement, NovaBay acquired 100% of the membership units of DERMAdoctor from the Sellers for a closing purchase price of $12.0 million and potential future earn out payments of up to an aggregate of $3.0 million over a period of two calendar years post-closing. The following pro forma financial information is based on the historical financial statements of the Company and presents the Company’s results as if the business combination had occurred as of January 1, 2020 (in thousands):

|  | Unaudited Pro Forma |
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Revenue |  | $ | 12,767 |  |  | $ | 18,170 |
Net Profit (Loss) |  | $ | (4,918 | ) |  | $ | (11,647 | )

The pro forma financial information is not indicative of the results of operations that the Company would have attained had the business combination occurred as of January 1, 2020, nor is the pro forma financial information indicative of the results of operations that may occur in the future. The unaudited pro forma information includes adjustments to reflect the $1.2 million of transaction costs as if they were incurred in the year ended December 31, 2020.

The Company funded the closing purchase price in part through the 2021 Private Placement (See Note 14, “Stockholders’ Equity”).

The Acquisition is accounted for as a business combination in accordance to ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recognized at their estimated fair values as of the Acquisition Closing. Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination.

The following table sets forth the final allocation of the purchase price for the DERMAdoctor Acquisition to the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed from DERMAdoctor (in thousands):

|  | Fair Value |
Tangible net assets and liabilities: |  |  |  |
Cash and cash equivalents |  | $ | 12 |
Accounts receivable, net of allowance for doubtful accounts |  |  | 1,015 |
Inventory, net of allowance |  |  | 2,369 |
Prepaid expenses and other current assets |  |  | 150 |
Property and equipment, net |  |  | 62 |
Other intangible assets |  |  | 54 |
Accounts payable |  |  | (200 | )
Accrued liabilities |  |  | (683 | )
Total net assets |  |  | 2,779 |
Intangible Assets: |  |  |  |
Customer relationships |  |  | 290 |
Trade secrets / product formulations |  |  | 2,890 |
Trade names |  |  | 2,080 |
Total intangible assets |  |  | 5,260 |
Net assets acquired |  |  | 8,039 |
Purchased consideration |  |  | 12,561 |
Goodwill |  | $ | 4,528 |

Goodwill is primarily attributable to assembled workforce, expected synergies and other factors.

The fair values of the identifiable intangible assets acquired at the date of the DERMAdoctor Acquisition are as follows (in thousands):

Intangible Asset |  | Fair Value |  |  | Useful Life (in years) |  |  | Amortization Method |
Customer relationships |  | $ | 290 |  |  |  | 7 |  |  | Straight line |
Trade secrets / product formulations |  |  | 2,890 |  |  |  | 9 |  |  | Straight line |
Trade names |  |  | 2,080 |  |  | Indefinite |  |  |  | N/A |
Goodwill |  |  | 4,528 |  |  | Indefinite |  |  |  | N/A |
|  | $ | 9,788 |  |  |  |  |  |  |  |  |

45

Table of Contents

The valuations of intangible assets incorporate significant unobservable inputs and require significant judgment and estimates, including the amount and timing of future cash flows.

The Company recognized approximately $1.2 million of transaction costs in the year ended December 31, 2021. These costs are recorded in “General and administrative expense” in the consolidated statements of operations and comprehensive loss.

The Company’s management reviews financial results and manages the business on an aggregate basis in accordance with ASC 280. Therefore, financial results are reported in two operating segments: (1) Optical & Wound Care and (2) Skincare (See Note 21, “Segment Reporting” below).

NOTE 4. FAIR VALUE MEASUREMENTS

The Company follows ASC 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date.

The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. The types of investments that are generally classified within Level 1 of the fair value hierarchy include money market securities and certificates of deposit.

As of December 31, 2021, the 2021 Warrants are classified within Level 3 of the fair value hierarchy as liabilities (see Note 13, “Warrant Liability” and Note 14, “Stockholders’ Equity”).

As of December 31, 2020, there were no warrants outstanding that were classified as liabilities. The Company’s outstanding warrants on December 31, 2020 consisted of the 2019 Domestic Warrants, 2019 Foreign Warrants and the 2019 Ladenburg Warrants, all of which were classified as equity. The 2019 Domestic Warrants and the 2019 Foreign Warrants were amended and exercised in July 2020 (see Note 14, “Stockholders’ Equity”), resulting in a decrease of $9.1 million in warrant liability. The 2019 Ladenburg Warrants were also amended in July 2020 (see Note 14, “Stockholders’ Equity”), resulting in a decrease of $0.2 million in warrant liability.

The embedded derivative liability related to the Convertible Note (as defined below) was fully settled in September 2020. See Note 12, “Convertible Note” for further discussion of the settlement of the Convertible Note and embedded derivative liability during the third quarter of 2020.

The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2021 (in thousands):

|  |  |  |  |  | Fair Value Measurements Using |
|  | Balance at |  |  | Quoted Prices in |  |  | Significant |  |  | Significant |
|  | December 31, |  |  | Active Markets |  |  | Other |  |  | Unobservable |
|  | 2021 |  |  | for Identical |  |  | Observable |  |  | Inputs |
|  |  |  |  |  | Items |  |  | Inputs |  |  | (Level 3) |
|  |  |  |  |  | (Level 1) |  |  | (Level 2) |  |  |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted cash held as a certificate of deposit |  | $ | 324 |  |  | $ | 324 |  |  | $ | — |  |  | $ | — |
Deposit held as a certificate of deposit |  |  | 151 |  |  |  | 151 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 475 |  |  | $ | 475 |  |  | $ | — |  |  | $ | — |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant liability |  | $ | 9,558 |  |  |  | — |  |  |  | — |  |  | $ | 9,558 |
Contingent earnout liability |  |  | 561 |  |  |  | — |  |  |  | — |  |  |  | 561 |
Total liabilities |  | $ | 10,119 |  |  | $ | — |  |  | $ | — |  |  | $ | 10,119 |

46

Table of Contents

The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2020 (in thousands):

|  |  |  |  |  | Fair Value Measurements Using |
|  | Balance at |  |  | Quoted Prices in |  |  | Significant |  |  | Significant |
|  | December 31, |  |  | Active Markets |  |  | Other |  |  | Unobservable |
|  | 2020 |  |  | for Identical |  |  | Observable |  |  | Inputs |
|  |  |  |  |  | Items |  |  | Inputs |  |  | (Level 3) |
|  |  |  |  |  | (Level 1) |  |  | (Level 2) |  |  |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted cash held as a certificate of deposit |  | $ | 324 |  |  | $ | 324 |  |  | $ | — |  |  | $ | — |
Deposit held as a certificate of deposit |  |  | 151 |  |  |  | 151 |  |  |  | — |  |  |  | — |
Total assets |  | $ | 475 |  |  | $ | 475 |  |  | $ | — |  |  | $ | — |

There were no liabilities measured at fair value on a recurring basis as of December 31, 2020.

The following is a reconciliation of the beginning and ending balances for the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ended December 31, 2021 (in thousands):

Fair value of warrant liability at December 31, 2020 |  | $ | — |
Fair value of 2021 Warrants issued |  |  | 14,172 |
Decrease in fair value of 2021 Warrants |  |  | (4,614 | )
Fair value of warrant liability at December 31, 2021 |  | $ | 9,558 |

The following is a reconciliation of the beginning and ending balances for the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ended December 31, 2020 (in thousands):

Fair value of warrant liability and embedded derivative liability at December 31, 2019 |  | $ | 4,092 |
Increase in fair value of warrant liability |  |  | 5,238 |
Decrease in fair value of embedded derivative liability |  |  | (2 | )
Decrease in fair value related to warrants expired |  |  | (22 | )
Fair value of warrant liability transferred to equity upon exercise |  |  | (9,108 | )
Fair value of 2019 Ladenburg Warrant liability transferred to equity upon warrant modification |  |  | (197 | )
Elimination of embedded derivative liability upon settlement of convertible note |  |  | (1 | )
Fair value of warrant liability and embedded derivative liability at December 31, 2020 |  | $ | — |

NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following (in thousands):

|  | December 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Prepaid inventory |  | $ | 368 |  |  | $ | — |
Prepaid insurance |  |  | 138 |  |  |  | 165 |
Prepaid consulting services |  |  | 68 |  |  |  | — |
Prepaid sales rebates |  |  | 19 |  |  |  | 144 |
Prepaid security deposit for lease |  |  | — |  |  |  | 65 |
Prepaid dues and subscription |  |  | 18 |  |  |  | 53 |
Prepaid rent |  |  | 14 |  |  |  | — |
Prepaid patents |  |  | 9 |  |  |  | 47 |
Other |  |  | 144 |  |  |  | 102 |
Total prepaid expenses and other current assets |  | $ | 778 |  |  | $ | 576 |

47

Table of Contents

NOTE 6. INVENTORY

Inventory consisted of the following (in thousands):

|  | December 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Raw materials and supplies |  | $ | 1,179 |  |  | $ | 159 |
Finished goods |  |  | 2,682 |  |  |  | 685 |
Less: Reserve for excess and obsolete inventory |  |  | (641 | ) |  |  | (236 | )
Total inventory, net |  | $ | 3,220 |  |  | $ | 608 |

NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following (in thousands):

|  | December 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Office and laboratory equipment |  | $ | 20 |  |  | $ | 20 |
Furniture and fixtures |  |  | 157 |  |  |  | 157 |
Computer equipment and software |  |  | 464 |  |  |  | 365 |
Production equipment |  |  | 114 |  |  |  | 65 |
Leasehold improvements |  |  | 79 |  |  |  | 79 |
Total property and equipment, at cost |  |  | 834 |  |  |  | 686 |
Less: accumulated depreciation and amortization |  |  | (641 | ) |  |  | (602 | )
Total property and equipment, net |  | $ | 193 |  |  | $ | 84 |

Depreciation and amortization expense was $59 thousand, $51 thousand, and $65 thousand for the years ended December 31, 2021, 2020 and 2019, respectively.

During the years ended December 31, 2021 and 2020, the Company disposed of damaged, unusable and fully depreciated property and equipment with cost of approximately $12 thousand and $10 thousand, respectively. As a result, the Company recognized an immaterial loss on the disposal of these assets in the consolidated statements of operation and comprehensive loss for such periods.

48

Table of Contents

NOTE 8. ACCRUED LIABILITIES

Accrued liabilities consisted of the following (in thousands):

|  | December 31, |  |  | December 31, |
|  | 2021 |  |  | 2020 |
Contract liabilities (see Note 16) |  | $ | 1,289 |  |  | $ | 730 |
Employee payroll and benefits |  |  | 443 |  |  |  | 632 |
Sublease security deposit |  |  | — |  |  |  | 198 |
Inventory purchases |  |  | — |  |  |  | 181 |
Consulting service |  |  | — |  |  |  | 98 |
Other |  |  | 360 |  |  |  | 276 |
Total accrued liabilities |  | $ | 2,092 |  |  | $ | 2,115 |

NOTE 9. LINE OF CREDIT

At the time of the DERMAdoctor Acquisition, DERMAdoctor had a line of credit agreement with Bank Midwest for $500 thousand. There was no balance outstanding on the line of credit at the time of Acquisition Closing. The agreement was terminated and repaid in full subsequent to December 31, 2021 on January 6, 2022. The line had an interest rate equal to the Wall Street Journal Prime Rate plus 1.50% with a floor of 5.00% on December 31, 2021. All borrowings were collateralized by substantially all assets of DERMAdoctor. As of December 31, 2021, the Company had $105 thousand outstanding on the line of credit.

NOTE 10. COMMITMENTS AND CONTINGENCIES

Indemnification Agreements

As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of December 31, 2021.

In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements is unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2021.

Legal Matters

As of December 31, 2021, there were no other matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.

Leases

The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term is through February 28, 2022. The Company has the option to extend the term of the lease for one five (5)-year period upon written notice to the landlord. Subsequent to December 31, 2021, on January 19, 2022, the Company amended the lease to extend the term through July 31, 2027 (see Note 22, “Subsequent Events”).

We are also party to a lease for 19,136 square feet of space located in Riverside, Missouri, which we utilize for light manufacturing, storage, distribution of products and administrative functions. The lease commenced on October 1, 2019 and expires on December 31, 2024.

The Company also had a lease commitment for laboratory facilities and office space at EmeryStation North in Emeryville, California (“EmeryStation”) under an operating lease. In July 2016, the Company subleased the EmeryStation space (the “Sublease Agreement”). The Sublease Agreement commenced September 8, 2016. The EmeryStation lease and Sublease Agreement were terminated as of August 31, 2020 pursuant to a sublease termination agreement executed on July 31, 2020. In conjunction with the termination, the Company recognized a gain of $54 thousand which is recorded within the operating expenses in the Company’s consolidated statements of operations and comprehensive loss for the year ended December 31, 2020.

49

Table of Contents

In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The Company has elected to account for each lease component and its associated non-lease components as a single lease component and has allocated all of the contract consideration across lease components only. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. The leases include variable components (e.g. common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability, but are reflected as an expense in the period incurred.

The components of net lease costs for the years ended December 31, 2021 and 2020 are as follows (in thousands):

Lease Costs |  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Operating lease cost |  | $ | 418 |  |  | $ | 826 |
Sublease income |  |  | — |  |  |  | (421 | )
Net lease cost |  | $ | 418 |  |  | $ | 405 |
Other information |  |  |  |  |  |  |  |
Operational cash flow used for operating leases |  | $ | 475 |  |  | $ | 927 |

The Company has measured its operating lease liabilities at its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows:

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Weighted-average remaining lease term (in years) |  |  | 2.5 |  |  |  | 1.2 |
Weighted-average discount rate |  |  | 6 | % |  |  | 12 | %

Future lease payments under non-cancelable leases as of December 31, 2021 were as follows (in thousands):

2022 |  | $ | 216 |
2023 |  |  | 129 |
2024 |  |  | 130 |
Thereafter |  |  | — |
Total future minimum lease payments |  |  | 475 |
Less imputed interest |  |  | (29 | )
Total |  | $ | 446 |
Reported as: |  |  |  |
Operating lease liability |  | $ | 200 |
Operating lease liability- non-current |  |  | 246 |
Total |  | $ | 446 |

50

Table of Contents

Contracts

On May 13, 2020, the Company entered into an agreement with TLF Bio Innovation Lab LLC (“TLF Bio Innovation”) to manage the relaunch of the Company’s CelleRx product (the “TLF Agreement”) which was further amended on September 4, 2020 and subsequently terminated on February 4, 2021. Under the agreement, the Company paid TLF Bio Innovation a monthly cash fee. Additionally, upon the successful completion of certain milestones, TLF Bio Innovation was eligible to receive warrants exercisable for up to 2 million shares of the Company’s common stock with an exercise price equal to the average closing price of the Company’s common stock for the last calendar month immediately prior to the date on which an individual milestone was achieved. TLF Bio Innovation was issued 15,000 warrants under the agreement on January 22, 2021.

On April 16, 2020, the Company entered into an international distribution agreement with Shenzhen Microprofit Biotech Co., LTD (“Microprofit”) (the “Microprofit Agreement”). In accordance with the Microprofit Agreement, the Company assisted Microprofit in applying for approval of Microprofit’s SARS-CoV-2 IgG and IgM Antibody Combined Test Kit (“Test Kits”) by the FDA. Under the terms of the Microprofit Agreement, if such approvals were granted, the Company would issue warrants to certain Microprofit officers exercisable for an aggregate number of shares of the Company’s common stock equivalent to 12% of the Company’s outstanding common stock on the date of approval. If FDA approval was received, the Microprofit Agreement granted the Company exclusive rights to distribute the Test Kits in the United States through December 31, 2021. On December 31, 2020, the Microprofit Agreement expired with no warrants being issued.

In connection with the Microprofit Agreement, on April 16, 2020, the Company entered into an intermediary distribution agreement with Chongqing Pioneer Pharma Holdings Limited (“Chongqing Pioneer”), a related party, which was subsequently amended on June 29, 2020. The amended agreement provided that the Company would purchase all Test Kits from Chongqing Pioneer as an intermediary. This agreement also expired on December 31, 2021.

NOTE 11. RELATED PARTY NOTE PAYABLE

On February 27, 2019, the Company issued a $1.0 million promissory note payable to Pioneer Pharma (Hong Kong) Company Ltd. (“Pioneer Pharma”), which was amended on June 25, 2019 and May 14, 2020 (the “Promissory Note”). The Promissory Note provided for an interest payment of $0.2 million which was initially amended to a payment of $0.3 million and subsequently amended to the delivery of 65,178 units of NeutroPhase (40ml) to Pioneer Pharma. The second amendment to the Promissory Note also provided the Company with the right to repay the note at any time. On May 14, 2020, the Company repaid the $1.0 million principal balance of the Promissory Note using proceeds raised through the at-the-market offering and equity program (“ATM Program”) (see Note 14, “Stockholders’ Equity”). The Company settled the accrued interest through two separate shipments of NeutroPhase in 2020. Upon full repayment of principal and interest during the year ended December 31, 2020, the Company was released from the Promissory Note with Pioneer Pharma.

In connection with the Promissory Note, the Company paid China Kington a 2% fee for brokering the transaction and entered into a consulting agreement with China Kington for a term of one year, which expired on March 1, 2020. Bob Wu, acting in a dual role as a member of the Company’s Board of Directors and as principal of China Kington, was paid $0.1 million pursuant to such consulting agreement. Upon the expiration of the original consulting agreement, the parties entered into a new consulting agreement, in which no cash compensation will be paid. Debt issuance costs associated with the issuance of the Promissory Note of $20 thousand was recognized and recorded as an offset to the related party note payable in the consolidated balance sheets.

The interest expense recognized, including amortization of the issuance costs, was $75 thousand during the year ended December 31, 2020. There was no comparable expense for the year ended December 31, 2021.

NOTE 12. CONVERTIBLE NOTE

On March 26, 2019, the Company entered into a Securities Purchase Agreement with Iliad Research and Trading, L.P. (the “Lender”), pursuant to which the Company issued a Secured Convertible Promissory Note (the “Convertible Note”) to the Lender dated as of March 26, 2019. The Convertible Note had an original principal amount of $2.2 million, beared interest at a rate of 10% per annum and matured on September 26, 2020, unless earlier paid, redeemed or converted in accordance with its terms. The Company received net proceeds of $2.0 million after deducting an original issue discount of $0.2 million and debt issuance cost of Lender’s transaction fees of $15 thousand. The Company recognized an additional $0.2 million of debt issuance costs associated with the issuance of the Convertible Note. The Convertible Note was repaid in full during the third quarter of 2020. Upon full repayment, the Company was released from the Convertible Note.

51

Table of Contents

During the year ended December 31, 2020, the effective interest rate on the Convertible Note was 20%. Interest expense recognized, including amortization of the issuance costs and debt discount, was $0.2 million during the year ended December 31, 2020.

NOTE 13. WARRANT LIABILITY

July 2011 Warrants

The Company issued the July 2011 Warrants (as defined in Note 14, “Stockholders’ Equity”) in the third quarter of 2011. The terms of the July 2011 Warrants required registered shares to be delivered upon warrant exercise and potential cash-settlement in the event of a specified fundamental transaction. Under ASC 480, Distinguishing Liabilities from Equity, the warrants were classified as liabilities because the Company’s potential obligation to deliver registered shares and cash-settle the warrants were deemed to be beyond the Company’s control. The fair value of outstanding July 2011 Warrants was determined at each reporting date using a Lattice model with changes in fair value recorded in the consolidated statements of operations and comprehensive loss.

On March 6, 2020, the remaining 35,107 July 2011 Warrants expired unexercised. There were no July 2011 Warrants outstanding as of December 31, 2020 or December 31, 2021.

October 2015 Warrants

The Company issued the October 2015 Warrants (as defined in Note 14, “Stockholders’ Equity”) in the third quarter of 2015. The terms of the October 2015 Warrants required potential cash-settlement in the event of a specified fundamental transaction. Under ASC 480, Distinguishing Liabilities from Equity, the warrants were classified as liabilities because the Company’s potential obligation to cash-settle the warrants was deemed to be beyond the Company’s control. The fair value of outstanding October 2015 Warrants was determined at each reporting date using a Lattice model with changes in fair value recorded in the consolidated statements of operations and comprehensive loss.

During the fourth quarter of 2020, a total of 22,680 October 2015 Warrants were exercised, resulting in gross proceeds of $5 thousand. The liability associated with these warrants was adjusted to fair value of $12 thousand as of the date of exercise, with the change in fair value recorded in the consolidated statements of operations and comprehensive loss. The fair value was then transferred to equity.

On October 27, 2020, 15,320 October 2015 Warrants expired unexercised. There were no October 2015 Warrants outstanding as of December 31, 2020 or December 31, 2021.

2019 Domestic, Foreign & Ladenburg Warrants

As further described in Note 14, “Stockholders’ Equity”, the Company issued the 2019 Domestic Warrants, the 2019 Foreign Warrants and the 2019 Ladenburg Warrants in the third quarter of 2019. The terms of the 2019 Domestic Warrants, 2019 Foreign Warrants and 2019 Ladenburg Warrants all required potential cash-settlement in the event of a specified fundamental transaction. Under ASC 480, Distinguishing Liabilities from Equity, the warrants were classified as liabilities because the Company’s potential obligation to cash-settle the warrants was deemed to be beyond the Company’s control. The fair value of outstanding warrants was determined at each reporting date using a Black-Scholes option pricing model with the changes in fair value recorded in the consolidated statements of operations and comprehensive loss.

Upon issuance in the third quarter of 2019, the fair value of the 2019 Domestic Warrants, 2019 Foreign Warrants and 2019 Ladenburg Warrants was determined to be $3.1 million, $2.0 million and $0.1 million, respectively.

52

Table of Contents

In the third quarter of 2020, as further described in Note 14, “Stockholders’ Equity”, the 2019 Domestic Warrants and 2019 Foreign Warrants were exercised at reduced exercise prices. The warrant liabilities associated with these warrants was adjusted to their fair values as of the date of exercise, with the change in fair values recorded in the consolidated statements of operations and comprehensive loss. The fair values were then transferred to equity. As of the date of exercise, the fair value of the 2019 Domestic Warrants and 2019 Foreign Warrants was determined to be $4.9 million and $4.2 million, respectively, in accordance with the following key assumptions:

Assumptions |  | 2019 Domestic Warrants |  |  | 2019 Foreign Warrants |
Expected price volatility |  |  | 178 | % |  |  | 178 | %
Expected term (in years) |  |  | 4.57 |  |  |  | 4.57 |
Risk-free interest rate |  |  | 0.25 | % |  |  | 0.27 | %
Dividend yield |  |  | 0.00 | % |  |  | 0.00 | %
Weighted-average fair value of warrant |  | $ | 1.18 |  |  | $ | 1.54 |

There were no 2019 Domestic Warrants or 2019 Foreign Warrants outstanding as of December 31, 2020 or December 31, 2021.

In the third quarter of 2020, as further described in Note 14, “Stockholders’ Equity”, the Company amended the 2019 Ladenburg Warrants. The Company’s potential obligation to cash-settle the warrants if a specified fundamental transaction occurred was amended to apply only in situations within the Company’s control. Pursuant to this change, the 2019 Ladenburg Warrants were no longer classified as liabilities. The warrant liability associated with these warrants was adjusted to fair value as of the date of the amendment, with the change in fair value recorded in the consolidated statements of operations and comprehensive loss. The fair value was then transferred to equity. The fair value of the 2019 Ladenburg Warrants was determined to be $0.2 million on the date of amendment in accordance with the following key assumptions:

Expected price volatility |  |  | 186 | %
Expected term (in years) |  |  | 4.05 |
Risk-free interest rate |  |  | 0.22 | %
Dividend yield |  |  | 0.00 | %
Weighted-average fair value of warrants |  | $ | 1.17 |

The 2019 Ladenburg Warrants will no longer be adjusted to fair value in reporting periods after the amendment. All 2019 Ladenburg Warrants remained outstanding as of December 31, 2021.

November 2021 Warrants

As further described in Note 14, “Stockholders’ Equity”, the Company issued the 2021 Warrants in the fourth quarter of 2021. The terms of the 2021 Warrants required that the Company obtain shareholder approval for an increase in authorized shares before they became exercisable. Under ASC 480, Distinguishing Liabilities from Equity, the 2021 Warrants were classified as liabilities as of December 31, 2021 and until the 2021 Warrants became exercisable. The 2021 Warrants became exercisable subsequent to December 31, 2021, on January 31, 2022. The fair value was then transferred to equity.

Upon issuance, the fair value of the 2021 Warrants was determined to be $14.2 million in accordance with the following key assumptions as of November 2, 2021:

Expected price volatility |  |  | 84.9 | %
Expected term (in years) |  |  | 6.2 |
Risk-free interest rate |  |  | 1.29 | %
Dividend yield |  |  | 0.00 | %
Weighted-average fair value of warrants |  | $ | 0.38 |

As of December 31, 2021, the fair value of the 2021 Warrants was determined to be $9.6 million in accordance with the following key assumptions:

Expected price volatility |  |  | 87 | %
Expected term (in years) |  |  | 6.0 |
Risk-free interest rate |  |  | 1.31 | %
Dividend yield |  |  | 0.00 | %
Weighted-average fair value of warrants |  | $ | 0.25 |

53

Table of Contents

NOTE 14. STOCKHOLDERS' EQUITY

Preferred Stock

The Company is authorized to issue up to 5,000,000 shares of preferred stock with rights and preferences as may be approved by its Board of Directors under its Amended and Restated Certificate of Incorporation.

On October 29, 2021, the Company entered into a securities purchase agreement with various institutional investors to sell in a private placement offering (the “2021 Private Placement”) (i) an aggregate of 15,000 shares of our newly-created Series B Non-Voting Preferred Stock (the “Preferred Stock”) convertible into an aggregate of 37,500,000 shares of Common Stock, and (ii) warrants (the “2021 Warrants”) exercisable for 37,500,000 shares of Common Stock for net proceeds of $14.9 million. The 2021 Private Placement closed on November 2, 2021.

The 2021 Warrants are exercisable into 37,500,000 Warrant Shares at an exercise price of $0.53 per share, subject to adjustment. The Warrants were not immediately exercisable upon issuance. In order for the Warrants to become exercisable, the Company was required to hold a stockholder meeting to (i) obtain stockholder approval, in accordance with the NYSE American LLC Company Guide (the “Company Guide”) Section 713(a) and (b), for the issuance of the 37,500,000 shares of Common Stock upon the exercise of all of the Warrants, as well as the issuance of the 37,500,000 Conversion Shares upon conversion of the Preferred Stock (the “Share Issuance Proposal”) and (ii) obtain stockholder approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Common Stock from 100,000,000 shares to 150,000,000 shares (the “Authorized Share Increase Proposal”). The Company held a special meeting of stockholders on December 17, 2021 (the “Special Meeting”) at which the Share Issuance Approval was approved by stockholders and, at a subsequent adjournment of the Special Meeting on January 31, 2022, the stockholders approved the Authorized Share Increase Proposal. As a result of these approvals having been given by the stockholders at the Special Meeting, the Warrants became exercisable subsequent to December 31, 2021 and will continue to be exercisable for a period of six (6) years thereafter.

Each share of the Preferred Stock that we issued in the Private Placement had a purchase price of $1,000 per share and is initially convertible at a conversion price of $0.40 into 2,500 shares of Common Stock, or an aggregate of 37,500,000 shares of Common Stock. The conversion by the holders of the Preferred Stock was initially subject to approval of the Share Issuance Proposal. Until the Share Issuance Proposal was approved by stockholders at the Special Meeting, the holders of the Preferred Stock were limited in converting their shares to an aggregate of 19.99% of the outstanding shares of Common Stock immediately prior to the closing of the 2021 Private Placement, or 8,984,178 shares of Common Stock. As a result of the Company’s stockholders approving the Share Issuance Proposal at the Special Meeting, this limitation upon conversion of Preferred Stock was no longer applicable to the holders as of December 31, 2021. The Preferred Stock does not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of NovaBay. The Preferred Stock does, however, have anti-dilution protection in the event that we sell or grant any Common Stock or any other securities of our Company, subject to certain limited exceptions, that would entitle the holder thereof to acquire Common Stock at an effective price per share that is lower than the then applicable conversion price of the Preferred Stock.

The Company allocated the net proceeds between the Preferred Stock and the 2021 Warrants by applying the residual fair value methodology. The Company first allocated $14.2 million to the 2021 Warrants, with the residual amount allocated to the Preferred Stock. See Note 13, “Warrant Liability” for further discussion of the key assumptions used to value the 2021 Warrants.

In connection with the issuance of the Preferred Stock, the Company recorded a beneficial conversion feature of $0.7 million as a discount to Preferred Stock and an increase to additional paid in capital. The Company fully amortized the discount related to the beneficial conversion feature on the deemed dividend in the consolidated statements of operations and comprehensive loss upon approval of the Share Issuance Proposal in the fourth quarter of 2021.

The Company incurred total issuance costs of $1.7 million in conjunction with the 2021 Private placement. The Company allocated $1.6 million of the issuance costs to the warrant liability which was expensed in the Company’s consolidated statements of operations and comprehensive loss during the year ended December 31, 2021. The remaining $0.1 million was recorded as a reduction of Preferred Stock in the Company’s consolidated balance sheets.

There were 14 thousand shares of the Preferred Stock outstanding as of December 31, 2021.

Common Stock

April 2020 At the Market Offering

In the second quarter of 2020, the Company established the 2020 ATM Program with Ladenburg Thalmann & Co. Inc. (“Ladenburg”). For additional information regarding the offering and equity program, see the Company’s Current Reports on Form 8-K filed with the SEC on April 27, 2020 and September 15, 2020. During the second quarter of 2020, 5,836,792 shares of common stock were issued under the 2020 ATM Program for total net proceeds of $5.6 million, net of offering costs of $0.4 million.

May 2021 At the Market Offering

In the second quarter of 2021, the Company established the 2021 ATM Program with Ladenburg. For additional information regarding the offering and equity program, see the Company’s Current Report on Form 8-K filed with the SEC on May 14, 2021. During the second quarter of 2021, 2,672,000 shares of common stock were issued under the 2021 ATM Program for total net proceeds of $1.8 million, net of offering costs of $0.1 million.

Common Stock Warrants

July 2011 Warrants

In the third quarter of 2011, the Company issued 139,520 common stock purchase warrants exercisable for 139,520 shares of common stock in connection with a registered direct financing (the “July 2011 Warrants”). The July 2011 Warrants were issued with an exercise price of $33.25 and an expiration date of July 5, 2016. In October 2015, in connection with a separate financing event, the exercise price of outstanding July 2011 Warrants was reduced to $5.00 per share and the expiration date extended to March 6, 2020. In February 2016 and May 2019, the exercise price of outstanding July 2011 Warrants was reduced to $1.81 and $0.2061 per share, respectively, pursuant to price protection provisions of the warrants.

54

Table of Contents

In March 2020, a total of 35,107 July 2011 Warrants expired unexercised. As of December 31, 2021, there were no July 2011 Warrants outstanding.

March 2015 Warrants

In the first quarter of 2015, the Company issued 649,133 common stock purchase warrants exercisable for 649,133 shares of common stock in connection with a private placement offering (the “March 2015 Warrants”). The exercise price of individual March 2015 Warrants varied between $15.00 and $16.25 per share at the time of issuance. The Company issued 278,200 of the March 2015 Warrants with an expiration date of March 6, 2020 and the remaining 370,933 March 2015 Warrants with an expiration date of September 6, 2015. In October 2015, in connection with a separate financing event, the exercise price of all outstanding March 2015 Warrants was reduced to $5.00 per share and the expiration date of all outstanding warrants expiring on September 6, 2015 was extended to March 6, 2020. In February 2016 and May 2019, the exercise price of all outstanding July 2011 Warrants was reduced to $1.81 and $0.2061 per share, respectively, pursuant to price protection provisions of the warrants.

During the first quarter of 2020, a total of 70,000 March 2015 Warrants were exercised, resulting in gross proceeds of $14 thousand. Also in the first quarter of 2020, all remaining 7,419 March 2015 Warrants expired unexercised. As of December 31, 2021, there were no March 2015 Warrants outstanding.

October 2015 Warrants

In the fourth quarter of 2015, the Company issued 442,802 common stock purchase warrants exercisable for 442,802 shares of common stock in connection with a public offering (the “October 2015 Warrants”). The warrants were issued with an exercise price of $5.00 and an expiration date of October 27, 2020. In February 2016 and May 2019, the exercise price of outstanding October 2015 Warrants was reduced to $1.81 and $0.2061 per share, respectively, pursuant to price protection provisions of the warrants. Also during the fourth quarter of 2020, a total of 22,680 October 2015 Warrants were exercised, resulting in gross proceeds of $5 thousand.

During the fourth quarter of 2020, all remaining 15,320 October 2015 Warrants expired unexercised. As of December 31, 2021, there were no October 2015 Warrants outstanding.

June 2019 Private Placement and June 2019 Warrants

During the second quarter of 2019, the Company entered into a private placement agreement to sell 1,371,427 shares of common stock and 1,371,427 common stock purchase warrants exercisable for 1,371,427 shares of common stock (the “June 2019 Warrants”) for an aggregate subscription price of $2.4 million. Three accredited investors, Messrs. Xiao Rui Liu, Hai Dong Pang and Ping Huang, subscribed to the private placement for $1.0 million, $0.4 million and $1.0 million, respectively. China Kington served as placement agent in exchange for a commission equal to six percent (6%) of the gross proceeds, totaling $0.1 million. The Company also paid other offering costs of $27 thousand.

The June 2019 Warrants were issued with an exercise price of $0.87 and an expiration date of June 17, 2020. The June 2019 Warrants were callable by the Company if the closing price of the Company’s common stock, as reported on the NYSE American, was $1.00 or greater.

During the first quarter of 2020, a total of 228,571 June 2019 Warrants were exercised, resulting in gross proceeds of $199 thousand. The Company paid China Kington a fee of $12 thousand, or six percent (6%) of the gross proceeds, for brokering the exercise transaction.

During the second quarter of 2020, a total of 571,428 June 2019 Warrants were exercised, resulting in gross proceeds of $497 thousand. The Company paid China Kington a fee of $29 thousand, or six percent (6%) of the gross proceeds, for brokering the exercise transaction. Also during the second quarter of 2020, all remaining 571,428 June 2019 Warrants expired unexercised. As of December 31, 2021, there were no June 2019 Warrants outstanding.

55

Table of Contents

2019 Domestic Warrants, 2019 Ladenburg Warrants, 2019 Foreign Warrants, 2019 Ladenburg Warrants and July 2020 Warrants

In the third quarter of 2019, the Company entered into a purchase agreement (the “2019 Purchase Agreement”) for the sale of (i) 4,198,566 shares of common stock and (ii) 4,198,566 common stock purchase warrants exercisable for 4,198,566 shares of common stock (the “2019 Domestic Warrants”) for gross proceeds of $4.2 million. The 2019 Domestic Warrants were issued with an exercise price of $1.15 and an expiration date of February 13, 2025.

The Company allocated the proceeds between the common stock and 2019 Domestic Warrants by applying the relative fair value allocation methodology. The Company first allocated $3.1 million to the 2019 Domestic Warrants, with the residual amount allocated to the common stock. See Note 13, “Warrant Liability” for further discussion of the key assumptions used to value the 2019 Domestic Warrants.

Ladenburg served as the placement agent for the transaction in exchange for a commission representing six percent (6%) of the gross proceeds, totaling $0.3 million, and 167,942 common stock purchase warrants exercisable for 167,942 shares of common stock with an exercise price of $1.25 per share and an expiration date of August 8, 2024 (the “2019 Ladenburg Warrants”). In addition, the Company reimbursed the Placement Agent $60 thousand for certain expenses. The Company also incurred and paid other offering costs of $0.3 million.

The Company incurred total issuance costs of $0.5 million in conjunction with the 2019 Purchase Agreement. The Company allocated $0.2 million of the issuance costs to the warrant liability which was expensed in the Company’s consolidated statements of operations and comprehensive loss during the period. The remaining $0.3 million was recorded as a reduction of additional paid-in capital in the Company’s consolidated balance sheets. As the 2019 Ladenburg Warrants were accounted for as a stock issuance cost, $59 thousand was allocated to the warrant liability and expensed during the period and $65 thousand was recorded as a reduction to additional paid-in capital in the Company’s consolidated balance sheets. See Note 12, “Warrant Liability” for a discussion of the key assumptions used to value the 2019 Ladenburg Warrants.

During the third quarter of 2020, the Company and the holders of the 2019 Domestic Warrants and the 2019 Foreign Warrants entered into exercise agreements which resulted in the cash exercise of the warrants at a reduced exercise price of $0.99. The Company received aggregate gross proceeds of approximately $6.8 million from the exercises. The Company incurred and paid other offering costs of $0.2 million. The Company also incurred and paid a $0.2 million fee to China Kington for brokering the transaction, which equaled six percent (6%) of the gross proceeds from the 2019 Foreign Warrants.

During the third quarter of 2020, the Company and all holders of the 2019 Domestic Warrants and 2019 Foreign Warrants entered into warrant repricing letter agreements. Pursuant to the agreement, in consideration for the exercise in full of the 2019 Domestic Warrants and 2019 Foreign Warrants, the Company agreed to: (1) reduce the exercise price of the 2019 Domestic Warrants and the 2019 Foreign Warrants to $0.99 per share prior to exercise, and (2) in a private placement, issue new common stock purchase warrants (the “July 2020 Warrants”) to purchase up to a number of shares of common stock, equal to 100% of the number of 2019 Domestic Warrants and 2019 Foreign Warrants currently held by such holders upon the holders exercising their warrants.

The July 2020 Warrants became exercisable nine months after their issuance, for an aggregate of 6,898,566 shares of common stock. The July 2020 Warrants have an exercise price of $1.65 per share and will expire five and a half years after their issuance. The Company determined that the common stock issued from the exercise of the 2019 Domestic and 2019 Foreign Warrants, and the July 2020 Warrants to be one unit of account, and therefore did not allocate the proceeds between the common stock and the July 2020 Warrants as, the proceeds, even if allocated, would be both recognized in additional paid-in capital.

During the third quarter of 2020, the Company also entered into a reprice agreement with Ladenburg which reduced the exercise price to $0.99 per share and amended certain terms of the 2019 Ladenburg Warrants. The Company’s potential obligation to cash-settle the warrants if a specified fundamental transaction occurred was amended to apply only in situations within the Company’s control. As further described in Note 13 “Warrant Liability”, the 2019 Ladenburg Warrants were no longer classified as a liability as a result of this amendment.

TLF Bio Innovation 2021 Warrants

On January 15, 2021, TLF Bio Innovation was granted warrants exercisable for 15,000 shares of the Company’s common stock with an exercise price of $0.6718 (the “TLF Warrants”). The TLF Warrants will expire five years after their issuance. The TLF Warrants are classified as equity.

56

Table of Contents

The details of all outstanding warrants as of December 31, 2021 were as follows:

|  | Warrants (in thousands) |  |  | Weighted- Average Exercise Price |
Outstanding at December 31, 2020 |  |  | 7,067 |  |  | $ | 1.63 |
Warrants granted |  |  | 15 |  |  | $ | 0.67 |
Warrants expired |  |  | — |  |  | $ | — |
Outstanding at December 31, 2021 |  |  | 7,082 |  |  | $ | 1.63 |

NOTE 15. EQUITY-BASED COMPENSATION

Equity Compensation Plans

In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the “2007 Plan”) to provide for the granting of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2020.

In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the “2017 Plan”), which was approved by stockholders on June 2, 2017, to provide for the granting of equity awards, such as nonqualified stock options (“NQSOs”), incentive stock options (“ISOs”), restricted stock, performance shares, stock appreciation rights (“SARs”), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to 2,318,486 shares of the Company’s common stock, plus an automatic annual increase in the number of shares authorized for awards on the first day of each of the Company’s fiscal years beginning January 1, 2018 through January 1, 2027 equal to (i) 4% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year or (ii) such lesser number of shares of common stock than provided for in Section 4(a)(i) of the 2017 Plan as determined by the Board. On January 15, 2021, the number of shares available for future awards under the 2017 Plan was increased by 1,671,303 shares. As of December 31, 2021, there were 1,842,993 shares available for future awards under the 2017 Plan.

Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than 100% of the fair market value of the common stock on the date of grant and, if ISOs are granted to an owner of more than 10% of the Company’s stock, then not less than 110% of the fair market value of the common stock on the date of grant. The term of awards will not be longer than ten years, or in the case of ISOs, not longer than five years with respect to holders of more than 10% of the Company’s stock. Stock options granted to employees generally vest over four years, while options granted to directors and consultants typically vest over a shorter period, subject to continued service. The Company issues new shares to satisfy option exercises under the 2007 Plan and the 2017 Plan.

57

Table of Contents

Stock Option Summary

The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2021, 2020, and activity during the year ended December 31, 2021:

(in thousands, except years and per share data) |  | Options |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Life (years) |  |  | Aggregate Intrinsic Value |
Outstanding at December 31, 2020 |  |  | 3,165 |  |  | $ | 2.05 |  |  |  | 7.6 |  |  | $ | 189 |
Options granted |  |  | 516 |  |  | $ | 0.66 |  |  |  |  |  |  |  |  |
Restricted stock units granted |  |  | 1,528 |  |  | $ | — |  |  |  |  |  |  |  |  |
Restricted stock units vested |  |  | (488 | ) |  | $ | — |  |  |  |  |  |  |  |  |
Options forfeited/cancelled |  |  | (272 | ) |  | $ | 2.35 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2021 |  |  | 4,449 |  |  | $ | 1.39 |  |  |  | 7.6 |  |  | $ | 460 |
Vested and expected to vest at December 31, 2021 |  |  | 4,125 |  |  | $ | 1.46 |  |  |  | 7.5 |  |  | $ | 406 |
Vested at December 31, 2021 |  |  | 2,150 |  |  | $ | 2.42 |  |  |  | 5.4 |  |  | $ | 8 |
Exercisable at December 31, 2021 |  |  | 2,150 |  |  | $ | 2.42 |  |  |  | 5.9 |  |  | $ | 8 |

The aggregate intrinsic value in the table above is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of December 31, 2021 for options that have a quoted market price in excess of the exercise price. There were no stock option awards exercised during the year ended December 31, 2021. There were 20 thousand stock option awards exercised during the year ended December 31, 2020 for which the Company received cash payments of $7 thousand. There was no intrinsic value for stock option awards exercised for the year ended December 31, 2020. There were 83 thousand stock option awards exercised for the year ended December 31, 2019 for which the Company received cash payments of $0.2 million. There was no intrinsic value for stock option awards exercised for the year ended December 31, 2019.

As of December 31, 2021, total unrecognized compensation cost related to unvested stock options and restricted stock was approximately $1.2 million. This amount is expected to be recognized as stock-based compensation expense in the Company’s consolidated statements of operations and comprehensive loss over the remaining weighted average vesting period of 2.29 years.

Stock Option Awards to Employees and Directors

The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, “Summary of Significant Account Policies,” for a description of the accounting policies that the Company applied to value its stock-based awards.

During the years ended December 31, 2021, 2020, and 2019, the Company granted options to employees and directors to purchase an aggregate of 516,000, 1,158,000, and 145,000 shares of common stock, respectively.

58

Table of Contents

The weighted-average assumptions used in determining the value of options are as follows:

|  | Year Ended December 31, |
Assumptions |  | 2021 |  |  | 2020 |  |  | 2019 |
Expected price volatility |  |  | 164 | % |  |  | 161 | % |  |  | 112 | %
Expected term (in years) |  |  | 6.19 |  |  |  | 6.45 |  |  |  | 6.14 |
Risk-free interest rate |  |  | 1.05 | % |  |  | 0.45 | % |  |  | 1.99 | %
Dividend yield |  |  | 0.00 | % |  |  | 0.00 | % |  |  | 0.00 | %
Weighted-average fair value of options granted during the period |  | $ | 0.64 |  |  | $ | 0.94 |  |  | $ | 0.31 |

Expected Price Volatility—This is a measure of the amount by which the stock price has fluctuated or is expected to fluctuate. The computation of expected volatility was based on the historical volatility of our own stock.

Expected Term—This is the period of time over which the options granted are expected to remain outstanding. The expected life assumption is based on the Company’s historical data.

Risk-Free Interest Rate—This is the U.S. Treasury rate for the week of the grant having a term approximating the expected life of the option.

Dividend Yield—We have not made any dividend payments nor do we have plans to pay dividends in the foreseeable future.

Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate.

During the year ended December 31, 2021, the Company granted 1,200,000 RSUs to employees and directors. During the year December 31, 2020, the Company granted 160,000 RSU to one employee. No employees were granted RSUs during the year ended December 31, 2019.

For the years ended December 31, 2021, 2020, and 2019, the Company recognized stock-based compensation expense of $0.7 million, $0.5 million, and $0.4 million, respectively, for option awards to employees and directors.

The Company modified stock options held by Mr. Yonghao (Carl) Ma in April 2019, Mr. Yanbin (Lawrence) Liu in May 2019, Mr. Mark Sieczkarek in July 2019, Mr. Todd Zavodnick in September 2019, Ms. Gail Maderis in April 2020 and Mr. Xiaopei Wang in August 2020, who each resigned as a director of the Company. The option exercise period for each of the former directors listed was extended from three months to three years, calculated from each director’s date of resignation. Each director’s stock option awards became fully vested at the date of his or her resignation. In connection with the stock option modification for each of Messrs. Ma, Liu, Sieczkarek, Zavodnick, Ms. Maderis and Mr. Wang, the Company recognized stock-based compensation expense of $14 thousand, $7 thousand, $60 thousand, $24 thousand, $36 thousand and $17 thousand, respectively, which are included in the figure above.

Stock-Based Awards to Non-Employees

During the year December 31, 2021, the Company did not grant options to purchase shares of common stock to non-employees. During the year ended December 31, 2020, the Company granted options to purchase an aggregate of 400,000 shares of common stock to non-employees in exchange for advisory and consulting services. Out of the 400,000 shares, 300,000 shares were granted to a related party, Eric Wu, Partner and Senior Vice President of China Kington and the brother of Bob Wu, who serves on the Company’s Board of Directors. Please refer to Note 19, “Related Party Transactions”, for more details related to the consulting service agreement. During the year ended December 31, 2019, the Company did not grant options to purchase shares of common stock to non-employees.

Stock options granted to non-employees recorded at their fair value on the measurement date and recognized over the respective service or vesting period. The fair value of the stock options granted was calculated using the Black-Scholes-Merton option pricing model based upon the following assumptions:

|  | Year Ended December 31, |
Assumptions |  | 2021 |  |  | 2020 |
Expected price volatility |  |  | — |  |  |  | 162 | %
Expected term (in years) |  |  | — |  |  |  | 6.34 |
Risk-free interest rate |  |  | — |  |  |  | 0.50 | %
Dividend yield |  |  | — |  |  |  | 0.00 | %
Weighted-average fair value of options granted during the period |  | $ | — |  |  | $ | 0.73 |

59

Table of Contents

The Company did not grant restricted stock to non-employees during the year ended December 31, 2021.

In connection with Mr. Sieczkarek’s resignation, the Company granted 168 thousand shares of fully vested registered stock to Mr. Sieczkarek during the year ended December 31, 2019. The expense related to these shares was recorded in the Company’s consolidated statements of operations and comprehensive loss. At the time of his resignation, the Company also entered into a two-year consulting agreement with Mr. Sieczkarek under which he is entitled to receive additional shares of fully vested registered stock in exchange for consulting services. According to the terms of the agreement, the stock units are to be issued in two tranches of $0.2 million each for a total aggregate fair market value equal to $0.4 million. The number of shares issued for each tranche is calculated using the closing price on each respective grant date. In July 2020, the Company issued 192,983 shares to Mr. Sieczkarek to fulfill the first tranche. In July 2021, the Company issued 328,359 shares to Mr. Sieczkarek to fulfill the second tranche. The expense related to the shares issued under the consulting agreement is being recorded over the term of the Consulting Agreement.

During the fourth quarter of the year ended December 31, 2019, the Company paid two consultants, Ms. Moon and Ms. Xiao, via a combination of 36 thousand registered shares and cash for services rendered, based on the terms of their consulting agreements.

For the years ended December 31, 2021, 2020, and 2019, the Company recognized stock-based compensation expense of $240 thousand, $64 thousand, and $37 thousand, respectively, related to non-employee options and restricted stock grants.

Summary of Stock-Based Compensation Expense

A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Research and development |  | $ | 10 |  |  | $ | 23 |  |  | $ | 42 |
Sales and marketing |  |  | 129 |  |  |  | 85 |  |  |  | 93 |
General and administrative |  |  | 794 |  |  |  | 424 |  |  |  | 351 |
Total stock-based compensation expense |  | $ | 933 |  |  | $ | 532 |  |  | $ | 486 |

NOTE 16. LICENSE, COLLABORATION AND DISTRIBUTION AGREEMENTS

Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns.

The following table presents changes in the Company's contract assets and liabilities for the year ended December 31, 2021 (in thousands):

|  | Balance at Beginning of the Period |  |  | Additions |  |  | Deductions |  |  | Balance at the end of the Period |
Contract liabilities: deferred revenue |  | $ | 2 |  |  | $ | 176 |  |  | $ | (124 | ) |  | $ | 54 |
Contract liabilities: accrued liabilities (includes contract assets) |  |  | 573 |  |  |  | 1,851 |  |  |  | (1,154 | ) |  |  | 1,270 |
Total |  | $ | 575 |  |  | $ | 2,027 |  |  | $ | (1,278 | ) |  | $ | 1,324 |

The following table presents changes in the Company's contract assets and liabilities for the year ended December 31, 2020 (in thousands):

|  | Balance at Beginning of the Period |  |  | Additions |  |  | Deductions |  |  | Balance at the end of the Period |
Contract liabilities: deferred revenue |  | $ | — |  |  | $ | 2 |  |  | $ | — |  |  | $ | 2 |
Contract liabilities: accrued liabilities (includes contract assets) |  |  | 434 |  |  |  | 2,338 |  |  |  | (2,199 | ) |  |  | 573 |
Total |  | $ | 434 |  |  | $ | 2,340 |  |  | $ | (2,199 | ) |  | $ | 575 |

60

Table of Contents

For the years ended December 31, 2021, 2020 and 2019, the Company recognized the following revenue (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Revenue recognized in the period from: |  |  |  |  |  |  |  |  |  |  |  |
Amounts included in contract liabilities at the beginning of the period: |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied |  | $ | 573 |  |  | $ | 434 |  |  | $ | 1,473 |
New activities in the period: |  |  |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied |  |  | 7,848 |  |  |  | 9,500 |  |  |  | 5,126 |
|  | $ | 8,421 |  |  | $ | 9,934 |  |  | $ | 6,599 |

Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies

Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. We have also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the years ended December 31, 2021, 2020 and 2019, the Company earned $0.6 million, $1.7 million and $4.6 million, respectively, in sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements.

Under these product distribution arrangements, the Company had a contract liability balance of $0.9 million as of December 31, 2021 and $0.7 million as of December 31, 2020. The contract liability is included in accrued liabilities in the consolidated balance sheets. The Company also recorded a prepayment of $19 thousand and $144 thousand for rebates related to these distribution agreements as of December 31, 2021 and December 31, 2020, respectively, that is recorded in the prepaid expenses and other current assets in the consolidated balance sheets (see Note 5, “Prepaid Expenses and Other Current Assets”).

Over-the-Counter Sales of Avenova Spray

Avenova Spray was launched online on June 1, 2019 direct to U.S. customers. Avenova Spray is offered primarily for sale on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. Avenova Spray was launched at select CVS stores and online on CVS.com in February 2021. These channels provide the Company with more stable pricing and provide customers with easy access to our product. During the years ended December 31, 2021, 2020, and 2019 the revenue generated from Avenova Spray in these channels was $5.1 million, $3.3 million, and $1.0 million, respectively.

NOTE 17. EMPLOYEE BENEFIT PLAN

The Company has a 401(k) plan covering all eligible employees. The Company was not required to contribute to the plan and made no contributions during the year ended December 31, 2021 or 2020. The Company made an election to change the terms of the 401(k) plan such that, beginning on January 1, 2022, the Company will be required to make a matching contribution equal to 100% of the first 3% of compensation deferred, plus 50% of the next 2% of compensation deferred.

61

Table of Contents

NOTE 18. INCOME TAXES

For the years ended December 31, 2021, 2020 and 2019, loss before provision for income taxes consisted of the following (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
United States |  | $ | (5,824 | ) |  | $ | (11,034 | ) |  | $ | (9,652 | )
International |  |  | — |  |  |  | — |  |  |  | — |
|  | $ | (5,824 | ) |  | $ | (11,034 | ) |  | $ | (9,652 | )

For the years ended December 31, 2021, 2020 and 2019, the federal and state income tax provision is summarized as follows (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Current |  |  |  |  |  |  |  |  |  |  |  |
Federal |  | $ | — |  |  | $ | — |  |  | $ | — |
State |  |  | — |  |  |  | 5 |  |  |  | 6 |
Other |  |  | — |  |  |  | — |  |  |  | — |
Total current tax expense |  |  | — |  |  |  | 5 |  |  |  | 6 |
Deferred |  |  |  |  |  |  |  |  |  |  |  |
Federal |  |  | — |  |  |  | — |  |  |  | — |
State |  |  | — |  |  |  | — |  |  |  | — |
Other |  |  | — |  |  |  | — |  |  |  | — |
Total deferred tax expense |  |  | — |  |  |  | — |  |  |  | — |
Income tax provision |  | $ | — |  |  | $ | 5 |  |  | $ | 6 |

Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.

62

Table of Contents

The tax effects of significant items comprising the Company's deferred taxes as of December 31, 2021 and 2020 are as follows (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Deferred tax assets: |  |  |  |  |  |  |  |
Net operating losses |  | $ | 33,455 |  |  | $ | 31,115 |
Stock options |  |  | 884 |  |  |  | 790 |
Research and development credits |  |  | 641 |  |  |  | 641 |
Accruals |  |  | 306 |  |  |  | 267 |
Operating lease liabilities |  |  | 19 |  |  |  | 109 |
Property and equipment |  |  | 10 |  |  |  | 2 |
Other deferred tax assets |  |  | 376 |  |  |  | 81 |
Total deferred tax assets |  |  | 35,691 |  |  |  | 33,005 |
Deferred tax liabilities: |  |  |  |  |  |  |  |
Operating lease right-of-use assets |  |  | (19 | ) |  |  | (108 | )
Total deferred tax liabilities |  |  | (19 | ) |  |  | (108 | )
Valuation allowance |  |  | (35,672 | ) |  |  | (32,897 | )
Net deferred taxes |  | $ | — |  |  | $ | — |

ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act was enacted. The CARES Act changed net loss carryforward and back provisions and the business interest expenses limitation. The Company has evaluated the impact of the CARES Act and determined that none of the changes would result in a material cash benefit to the Company.

The valuation allowance increased by $2.8 million, $1.3 million and $2.2 million during the years ended December 31, 2021, 2020 and 2019, respectively.

Net operating loss and tax credit carryforwards as of December 31, 2021, are as follows (in thousands):

|  |  |  |  |  | Expiration |
|  | Amount |  |  | Years |
Net operating losses, federal (Post December 31, 2017) |  | $ | 30,989 |  |  | Does Not Expire |
Net operating losses, federal (Pre January 1, 2018) |  | $ | 94,886 |  |  | Beginning in 2024 |
Net operating losses, state |  | $ | 106,784 |  |  | Beginning in 2028 |
Tax credits, federal |  | $ | 1,321 |  |  | Beginning in 2026 |
Tax credits, state |  | $ | 325 |  |  | Indefinite |

A reconciliation of the beginning and ending balance of unrecognized income tax benefits follows (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |
Unrecognized benefit - beginning of period |  | $ | 974 |  |  | $ | 974 |
Change during the period |  |  | — |  |  |  | — |
Unrecognized benefit - end of period |  | $ | 974 |  |  | $ | 974 |

The entire amount of the unrecognized tax benefits would not impact our effective tax rate if recognized. The balance of unrecognized tax benefits increased as a result of a comprehensive analysis to substantiate the company's research credits. Accrued interest and penalties related to unrecognized tax benefits are classified as income tax expense and were immaterial. We do not anticipate that total unrecognized tax benefits will significantly change in the next 12 months. The Company files income tax returns in the United States and in California. Other jurisdictions are not significant. The tax years 2004 - 2021 remain open in the federal jurisdiction and 2006 - 2021 for California. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions.

63

Table of Contents

The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows:

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Statutory rate |  |  | 21.0 | % |  |  | 21.0 | % |  |  | 21.0 | %
State tax |  |  | 11.2 | % |  |  | 3.2 | % |  |  | 3.1 | %
Change in valuation allowance |  |  | (47.7 | %) |  |  | (11.7 | %) |  |  | (23.0 | %)
Warrant/equity expenses |  |  | 16.7 | % |  |  | (10.3 | %) |  |  | 1.7 | %
Stock-based compensation expense |  |  | (1.1 | %) |  |  | (4.0 | %) |  |  | (3.7 | %)
Other |  |  | (0.1 | %) |  |  | 1.7 | % |  |  | (0.3 | %)
Impact of 162m |  |  | — | % |  |  | — | % |  |  | 1.1 | %
Total |  |  | 0.0 | % |  |  | (0.1 | %) |  |  | (0.1 | %)

NOTE 19. RELATED PARTY TRANSACTIONS

Related Party Revenue

The following table summarizes information about the Company’s related party revenue and cost of goods sold during the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Related party revenue: |  |  |  |  |  |  |  |  |  |  |  |
NeutroPhase |  | $ | 368 |  |  | $ | 524 |  |  | $ | 209 |
Licensing |  |  | — |  |  |  | — |  |  |  | 41 |
Total related party revenue |  | $ | 368 |  |  | $ | 524 |  |  | $ | 250 |
Cost of goods sold |  |  |  |  |  |  |  |  |  |  |  |
NeutroPhase |  | $ | 325 |  |  | $ | 384 |  |  | $ | 176 |
Licensing |  |  | — |  |  |  | — |  |  |  | — |
Total related party expenses |  | $ | 325 |  |  | $ | 384 |  |  | $ | 176 |

Related party accounts receivable was $0.1 million and $0.2 million as of December 31, 2021 and December 31, 2020, respectively.

Other Related Party Expenses

During the year ended December 31, 2021, the Company purchased KN95 Masks through an affiliate of China Pioneer. As of December 31, 2021, there was no related party account payable as compared to related party accounts payable of $8 thousand as of December 31, 2020.

64

Table of Contents

The following table summarizes information about the Company’s other related party expenses excluding stock-based compensation during the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):

|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Commissions to China Kington related to: |  |  |  |  |  |  |  |  |  |  |  |
OP Private Placement |  | $ | — |  |  | $ | — |  |  | $ | — |
June 2019 Private Placement |  |  | — |  |  |  | — |  |  |  | 144 |
August 2019 Private Placement |  |  | — |  |  |  | — |  |  |  | 162 |
Exercise of June 2019 Warrants |  |  | — |  |  |  | 41 |  |  |  | — |
Exercise of 2019 Foreign Warrants |  |  | — |  |  |  | 160 |  |  |  | — |
Promissory Note to Pioneer Pharma (Hong Kong) Company Ltd. |  |  | — |  |  |  | — |  |  |  | 20 |
Total commissions to China Kington |  |  | — |  |  |  | 201 |  |  |  | 326 |
Board Director Bob Wu consulting fee |  |  | — |  |  |  | 50 |  |  |  | 83 |
Total related party expenses |  | $ | — |  |  | $ | 251 |  |  | $ | 409 |

On November 17, 2020, the Company entered into a consulting agreement with Eric Wu. Eric Wu is Partner and Senior Vice President of China Kington and the brother of Bob Wu, who serves on the Company’s Board of Directors. Pursuant to the Agreement, Eric Wu acted as a consultant to the Company in support of product expansion efforts as well as in potential financings and other transaction opportunities. The term of the Agreement was for twelve months. As consideration for his services, the Company granted Eric Wu options exercisable for 300,000 shares of the Company’s common stock under the Company’s 2017 Omnibus Incentive Plan with an exercise price equal to the Company’s closing stock price on the date of the grant and vesting on the one year anniversary of the grant date. Stock-based compensation expense of $152 thousand and $15 thousand was recorded for the year ended December 31, 2021 and 2020, respectively, related to Eric Wu’s options.

NOTE 20. PAYCHECK PROTECTION PROGRAM

On May 6, 2020, the Company received loan proceeds in the amount of $0.9 million from Wells Fargo Bank, N.A. (the “PPP Loan”) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020, or the PPP Flexibility Act, which was enacted on September 5, 2020. The PPP loan provided for an interest rate of 1.00% per year and maturity two years after the date of initial disbursement, with initial principal and interest payments coming due late in fiscal 2021. The PPP Loan could be prepaid by the Company at any time prior to the maturity with no prepayment penalties. Funds from the PPP Loan could only be used for payroll costs, costs used to continue group health care benefits, rent and utilities incurred during the 24-week period after receiving the PPP Loan (collectively, “Qualifying Expenses”) in order for the PPP Loan to be forgiven in whole or in part. The Company used the entire PPP Loan amount for Qualifying Expenses.

Since the Company determined that there was reasonable assurance that it would meet the conditions for forgiveness of the full loan amount, the Company accounted for the forgivable PPP Loan as a government income grant that we earned through the Company’s compliance with the loan forgiveness criteria. A deferred income liability was recognized upon receipt of the forgivable loan proceeds. The deferred income liability was recognized as other income as Qualifying Expenses were incurred. For the year ended December 31, 2020, $0.9 million, was recognized as other income and recorded in the consolidated statements of operations and comprehensive loss. No amount was recognized for the year ended December 31, 2021.

The Company received notice, dated May 24, 2021, from Wells Fargo Bank, N.A. confirming the full loan amount of $0.9 million was forgiven.

NOTE 21. SEGMENT REPORTING

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

Prior to the DERMAdoctor Acquisition in November 2021 (see Note 3, Business Combination), the Company was managed as a single segment focused on commercializing Avenova Spray in the United States. After the DERMAdoctor Acquisition, the Company began managing and aggregating its operational and financial information in accordance with two reportable segments: (1) Optical &Wound Care and (2) Skin Care. The Optical & Wound Care segment consists of products historically sold by NovaBay prior to the DERMAdoctor Acquisition. The Skin Care segment consists of products acquired in the DERMAdoctor Acquisition and skincare products subsequently sold under the DERMAdoctor brand.

Select financial information for each segment is as follows:

|  | Year Ended |  |  | Percentage |
|  | December 31, 2021 |  |  | of Total Revenue |
Optical & Wound Care |  | $ | 7,834 |  |  |  | 93 | %
Skincare |  |  | 587 |  |  |  | 7 | %
Total revenue |  | $ | 8,421 |  |  |  | 100 | %

65

Table of Contents

|  | Year Ended |  |  | Percentage |
|  | December 31, 2021 |  |  | of Total Gross Margin |
Optical &Wound Care |  | $ | 5,336 |  |  |  | 95 | %
Skincare |  |  | 309 |  |  |  | 5 | %
Total gross margin |  | $ | 5,645 |  |  |  | 100 | %

NOTE 22. SUBSEQUENT EVENTS

On January 19, 2022, the Company amended the lease for its corporate headquarters located in Emeryville, California to extend the term through July 31, 2027.

On January 31, 2022, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 100,000,000 to 150,000,000 (the “Amendment”). The Amendment became effective upon the Company’s filing of the Amendment with the Secretary of State of Delaware on January 31, 2022.

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these financial statements. Although the Company does not have significant customers, suppliers or operations within the affected geographies, the specific impact on the Company's financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.

66

Table of Contents

ITEM 9. | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

As previously reported on the Company’s Current Report on Form 8-K filed with the SEC on July 21, 2021, WithumSmith+Brown, PC, an independent registered public accounting firm (“Withum”), acquired certain assets of OUM & Co. LLP (“OUM”), the independent registered public accounting firm for NovaBay Pharmaceuticals, Inc. (the “Company”) (the “Transaction”). As a result of this Transaction, on July 15, 2021, OUM resigned as the Company’s independent registered public accounting firm. Concurrent with such resignation, the Company, with the approval of its Audit Committee, consented to the engagement of Withum as the Company’s new independent registered public accounting firm, effective July 15, 2021.

Prior to the Transaction, the Company did not consult with Withum regarding the application of accounting principles to any specific completed or contemplated transaction or regarding the type of audit opinion that might be rendered by Withum on the Company’s financial statements, and Withum did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue.

OUM’s Report of Independent Registered Public Accounting Firm (the “Audit Report”) on the Company’s financial statements for the fiscal years ended December 31, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.

During the years ended December 31, 2020 and 2019, and during the interim period from the end of the most recently completed fiscal year through July 15, 2021, the date of resignation, there were no “disagreements” (as such term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with OUM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of OUM would have caused it to make reference to such disagreement in its reports. During the fiscal years ended December 31, 2020 and 2019, and the subsequent interim period through July 15, 2021, there have been no “reportable events” (as such term is defined in Item 304 (a)(1)(v) of Regulation S-K).

ITEM 9A. | CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 and 15d-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Assessing the costs and benefits of such controls and procedures necessarily involves the exercise of judgment by management. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Based upon that evaluation at December 31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure, at the reasonable assurance level, that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management's Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021 for non-DERMAdoctor operations. Our management utilized the criteria set forth in "Internal Control-Integrated Framework (2013)" issued by the Committee of Sponsoring Organizations of the Treadway Commission to conduct an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2021 for non-DERMAdoctor operations. Our management has concluded that, as of December 31, 2021, our internal control over financial reporting was effective based on these criteria for non-DERMAdoctor operations.

The Company has one year to evaluate the Internal Control over Financial Reporting for the DERMAdoctor organization.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting which has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. | OTHER INFORMATION

On March 23, 2022, the Company’s Board authorized amendments to, and restatement of, the Company’s Bylaws (the “Amended and Restated Bylaws”). In addition to certain administrative updates, the Company’s Amended and Restated Bylaws include the following amendments:

| ● | Updates to Article XI (Indemnification) to indemnify directors to the fullest extent permitted by Delaware law.

| ● | Adding a new Section 48 (Exclusive Forums for Adjudication of Disputes) to provide that the Delaware Court of Chancery shall be the exclusive forum for derivative actions, actions for breach of fiduciary duty, actions pursuant to the Delaware General Corporation, the Company’s Certificate of Incorporation or the Amended and Restated Bylaws or actions under the internal affairs doctrine. This provision does not relate to suits under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction.

The directors believe that the above amendments will better assist the Company in attracting qualified directors and officers as well as prevent forum shopping. The above summary does not purport to be complete and is qualified in its entirety by reference to the Amended and Restated Bylaws, a copy of which is filed as Exhibit 3.7 to this Annual Report on Form 10-K and is incorporated herein by reference.

ITEM 9C. | DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

67

Table of Contents

PART III

ITEM 10. | DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item will be included in our Proxy Statement for the 2022 Annual Meeting of Stockholders (the “2022 Proxy Statement”) and is incorporated herein by reference.

ITEM 11. | EXECUTIVE COMPENSATION

The information required by this item will be included in the 2022 Proxy Statement and is incorporated herein by reference.

ITEM 12. | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The information required by this item will be included in the 2022 Proxy Statement and is incorporated herein by reference.

ITEM 13. | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this item will be included in the 2022 Proxy Statement and is incorporated herein by reference.

ITEM 14. | PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this item will be included in the 2022 Proxy Statement and is incorporated herein by reference.

68

Table of Contents

PART IV

ITEM 15. | EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) Documents filed as part of this report:

(1) Financial Statements. The financial statements listed in the Index for Item 8 hereof are filed as part of this report.

(2) Financial Statement Schedules. All schedules have been omitted because they are not required or the required information is included in our consolidated financial statements and notes thereto.

(3) Exhibits. The following exhibits are filed as part of this Report:

| Incorporation by Reference | Filed Herewith
Exhibit Number | Exhibit Description | Form | File Number | Exhibit/ Form 8-K Item Reference | Filing Date |
2.1 | Membership Unit Purchase Agreement dated September 27, 2021, by and among the Company, DERMAdoctor, the Founders and the Sellers (as defined therein) | 8-K | 001-3678 | 2.1 | 9/28/2021 |
3.1 | Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc. | 10-K | 001-33678 | 3.1 | 3/21/2018 |
3.2 | Amendment to the Amended and Restated Certificate of Incorporation | 8-K | 001-33678 | 3.1 | 6/04/2018 |
3.3 | Amendment to the Amended and Restated Certificate of Incorporation, as amended | 8-K | 001-33678 | 3.1 | 5/28/2020 |
3.4 | Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021 | 8-K | 001-33678 | 3.1 | 5/24/2021 |
3.5 | Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated January 31, 2022 | 8-K | 001-33678 | 3.1 | 2/1/2022 |
3.6 | Certificate of Designation for the Series B Preferred Stock | 8-K | 001-33678 | 3.1 | 11/1/2021 |
3.7 | Amended and Restated Bylaws |  |  |  |  | X
4.1 | Description of Securities |  |  |  |  | X
4.2 | Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020 | 8-K | 001-33678 | 4.1 | 5/18/2020 |
4.3 | Form of July 2020 Warrant | 8-K | 001-33678 | 4.1 | 7/21/2020 |
4.4 | Form of November 2021 Warrant | 8-K | 001-33678 | 4.1 | 11/01/2021 |
10.1+ | Director and Officer Indemnity Agreement |  |  |  |  | X
10.2+ | NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan (as amended and restated) | S-8 | 333-215680 | 99.1 | 1/24/2017 |
10.3+ | NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan | S-8 | 333-218469 | 99.1 | 6/02/2017 |
10.4+ | NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (Form Agreements to the 2017 Omnibus Incentive Plan) | S-8 | 333-218469 | 99.2 | 6/02/2017 |

69

Table of Contents

10.5+ | Executive Employment Agreement (Employment Agreement of Justin M. Hall) | 8-K | 001-33678 | 10.1 | 2/6/2020 |
10.6+ | First Amendment to the Executive Employment Agreement with Justin M. Hall, dated January 26, 2022 | 8-K | 001-33678 | 10.6 | 1/28/2022 |
10.7+* | Performance Restricted Stock Unit Award Agreement with Mr. Justin Hall | 10-Q | 001-33678 | 10.1 | 5/6/2021 |
10.8+ | Executive Employment Agreement (Employment Agreement of Andrew D. Jones) | 8-K | 001-33678 | 10.8 | 5/5/2020 |
10.9+* | Performance Restricted Stock Unit Award Agreement with Mr. Andrew Jones | 10-Q | 001-33678 | 10.2 | 5/6/2021 |
10.10+ | Executive Employment Agreement with Dr. Audrey Kunin, dated November 5, 2021 | 8-K | 001-33678 | 10.1 | 11/12/2021 |
10.11+ | Side Letter with Dr. Audrey Kunin, dated November 5, 2021 | 8-K | 001-33678 | 10.3 | 11/12/2021 |
10.12+* | Performance Restricted Stock Unit Award Agreement with Dr. Audrey Kunin | 8-K | 001-33678 | 10.4 | 11/12/2021 |
10.13+ | Executive Employment Agreement with Dr. Jeff Kunin, dated November 5, 2021 | 8-K | 001-33678 | 10.2 | 11/12/2021 |
10.14+ | Consulting Agreement between the Company and Eric Wu, dated November 17, 2020 | 8-K | 001-33678 | 10.1 | 11/18/2020 |
10.15+ | 2022 Non-Employee Director Compensation Plan |  |  |  |  | X
10.16 | Office Lease (between the Company and KBSIII Towers at Emeryville, LLC) | 8-K | 001-33678 | 10.1 | 8/26/2016 |
10.17 | First Amendment to Office Lease by and between the Company and KBSIII Towers at Emeryville, LLC, dated January 24, 2022 | 8-K | 001-33678 | 10.2 | 1/28/2022 |
10.18† | International Distribution Agreement (by and between the Company and Pioneer Pharma Co. Ltd.) | 10-K | 001-33678 | 10.18 | 3/27/2012 |
10.19 | At the Market Offering Agreement between the Company and Ladenburg Thalmann & Co. Inc., dated April 27, 2020 | 8-K | 001-33678 | 1.1 | 4/27/2020 |
10.20 | At the Market Offering Agreement between the Company and Ladenburg Thalmann & Co. Inc., dated May 14, 2021 | 8-K | 001-33678 | 1.1 | 5/14/2021 |
10.21 | Paycheck Protection Program Promissory Note and Agreement, dated May 3, 2020, between the Company and Wells Fargo Bank, N.A. | 10-Q | 001-33678 | 10.28 | 5/7/2020 |
10.22 | Form of Exercise Agreement with Holders of 2019 Domestic Warrants | 8-K | 001-33678 | 10.1 | 7/21/2020 |
10.23 | Form of Exercise Agreement with Holders of 2019 Foreign Warrants | 8-K | 001-33678 | 10.2 | 7/21/2020 |
10.24 | Form of Reprice Agreement with Ladenburg | 8-K | 001-33678 | 10.3 | 7/21/2020 |

70

Table of Contents

10.25 | Form of Securities Purchase Agreement, dated October 29, 2021 | 8-K | 001-33678 | 1.1 | 11/01/2021 |
10.26 | Form of Registration Rights Agreement, dated October 29, 2021 | 8-K | 001-33678 | 10.1 | 11/01/2021 |
21 | Subsidiaries of the Company |  |  |  |  | X
23.1 | Consent of WithumSmith+Brown PC |  |  |  |  | X
23.2 | Consent of OUM & Co. LLP |  |  |  |  | X
31.1 | Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) |  |  |  |  | X
31.2 | Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) |  |  |  |  | X
32.1 | Certification by the Chief Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) |  |  |  |  | X
32.2 | Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) |  |  |  |  | X
101.INS | Inline XBRL Instance Document |  |  |  |  | X
101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | X
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  | X
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase |  |  |  |  | X
101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document |  |  |  |  | X
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  | X
104 | The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments) |  |  |  |  | X

+ | Indicates a management contract or compensatory plan or arrangement
† | NovaBay Pharmaceuticals, Inc. has been granted confidential treatment with respect to certain portions of this exhibit (indicated by asterisks), which have been separately filed with the Securities and Exchange Commission.
* | Certain confidential portions of this exhibit were omitted by means of marking such portions with brackets because the confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

71

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 29, 2022 |
| By: | /s/ Justin Hall
|  | Justin Hall Chief Executive Officer, General Counsel and Director (principal executive officer)

Date: March 29, 2022 |
| By: | /s/ Andrew Jones
|  | Andrew Jones Chief Financial Officer (principal financial officer)

POWER OF ATTORNEY

We, the undersigned officers and directors of NovaBay Pharmaceuticals, Inc., do hereby constitute and appoint Justin Hall and Andrew Jones, and each of them, our true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby, ratifying and confirming all that each of said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated:

Signature |  | Title | Date
/s/ JUSTIN HALL |  | Chief Executive Officer, General Counsel and Director | March 29, 2022
Justin Hall |  | (principal executive officer) |
/s/ ANDREW JONES |  | Chief Financial Officer | March 29, 2022
Andrew Jones |  | (principal financial officer) |
/s/ PAUL E. FREIMAN |  | Chairman of the Board | March 29, 2022
Paul E. Freiman |  |  |
/s/ JULIE GARLIKOV |  | Director | March 29, 2022
Julie Garlikov |  |  |
/s/ AUDREY KUNIN |  | Director | March 29, 2022
Audrey Kunin |  |  |
/s/ XINZHOU LI |  | Director | March 29, 2022
Xinzhou Li (Paul Li) |  |  |
/s/ SWAN SIT |  | Director | March 29, 2022
Swan Sit |  |  |
/s/ MIJIA WU |  | Director | March 29, 2022
Mijia Wu, M.B.A. (Bob Wu) |  |  |
/s/ YENYOU ZHENG |  | Director | March 29, 2022
Yenyou (Jeff) Zheng |  |  |

72